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Abstract 
Mitochondria are organelles present in all nucleated cells and are the only location of 
extra-chromosomal DNA within mammalian cells. They are responsible for the generation 
of ATP by oxidative phosphorylation (OXPHOS). An extensive range of molecular defects 
have been identified in the human mitochondrial genome, many associated with well-
characterised, progressive neurological syndromes. Diseases due to mutations in the 
mitochondrial genome (mtDNA) are clinically, genetically and biochemically diverse. 
I have investigated the molecular genetic basis of mitochondrial disease in a cohort of 
patients with biochemical deficiencies, using a range of histochemical, biochemical, 
molecular genetic and cell biological techniques. Whole genome sequencing results 
revealed the identification of novel and recurrent pathogenic mutations in different 
subunits of complex I (m.11453G>A, m.11777C>A, m 13051G>A, m.13513G>A and 
m.14453G>A). To assign pathogenicity of these identified mutations, several approaches 
were carried out to distinguish between pathogenic and neutral mtDNA changes. 
Investigation of different tissues from patients and their relatives explored mtDNA 
heteroplasmy, and determined whether mutations had a risen sporadically or been 
maternally-inherited. Transmitochondrial cybrids were established as an in vitro model to 
assess the functional consequences of the m.11777C>A mutation, revealing significant 
defects in these cells supporting the role of this mutation in causing disease in patient. The 
m.11777C>A and m.13051G>A mutations were associated with increased reactive oxygen 
species (ROS) production as a consequence of the effect of these mutations on complex I 
function. Moreover, the expression of several mitochondrial complex I subunits was 
differentially affected in fibroblasts from patients based on western blotting analysis. 
In addition, 3 novel, pathogenic mt-tRNA mutations were identified; m.618T>G MTTF 
gene mutation, a m.12261T>C MTTS2 gene mutation and a m.12283G>A MTTL2 gene 
mutation. These mutations were shown to be pathogenic as they segregated with the 
biochemical defect within individual cytochrome c oxidase (COX)-deficient fibres. 
Interestingly, the m.12283G>A mutation was present at very low levels in mature muscle 
as compared to other mt-tRNA mutations, and exhibited an unusual pattern of segregation 
in single muscle fibres.  
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The MitoChip (V2.0) is an oligonucleotide tiling array for the resequencing of the human 
mitochondrial genome, which has been proposed as an alternative diagnostic screening tool 
given it is rapid and relatively cheap. A comparative study between conventional dideoxy 
Sanger sequencing and MitoChip (V2.0) analysis revealed an inability of this technology 
to detect single nucleotide insertion and deletion mtDNA mutations.  
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Chapter 1 : Introduction and review of the literature 
This chapter will present an introduction and review of the literature for mammalian 
mitochondria unless otherwise stated. 
1.1 Origin of mitochondria 
Mitochondria are ubiquitous cellular organelles present in all nucleated human cells and 
they are the only location of extra-chromosomal DNA within mammalian cells [1]. The 
prokaryotic character of the mitochondria suggests that they evolved from bacteria long 
time ago [2]. According to the endosymbiont hypothesis, eukaryotic cells started out as 
anaerobic organisms without mitochondria or chloroplasts and then established a stable 
endosymbiotic relationship with bacteria, which have their own oxidative phosphorylation 
system [3-5]. Sequence similarity suggests that mitochondria may have descended from a 
particular type of purple photosynthetic bacterium that had previously lost its ability to 
perform photosynthesis but had a respiratory chain [2, 3]. 
Hydrogenosomes and mitosomes are mitochondria-like organelles of eukaryotic organisms 
originated through endosymbiotic relationship with bacteria [6-8] long time ago [9]. They 
have some features similar to mitochondria such as the double membrane and pathway of 
proteins import [10]. However, they lacked mitochondrial DNA [11-14]. 
1.2 Mitochondrial morphology and structure  
Human mitochondria have no fixed size, but typically in hepatocytes and fibroblasts they 
have a sausage-like shape with dimensions of 3-4μm in length and ~1μm in diameter. The 
number of mitochondria is different in each cell type and tissues according to the metabolic 
requirements, so it may range from a single large mitochondrion to thousands of organelles 
[15]. For example, there are ~800 mitochondria per hepatocyte [16], >100,000 
mitochondria in oocytes [17], but only a few in spermatozoa [18]. 
Mitochondria are found in the cytoplasm of all nucleated mammalian cells [19]. Each 
mitochondrion contains an inner membrane, outer membrane and matrix (Figure 1-1). The 
two membranes separate the mitochondrion into two parts: the internal matrix and the 
intermembrane space [20]. The outer membrane contains many copies of a transport 
protein named porin, which forms channels through the lipid bilayer [21]. This membrane 
 functions as a sieve that allows entrance and exit of molecules of 5000 Daltons or less 
22, 23]. The inner membrane, which surrounds the matrix, is highly specialized 
composed of a lipid bilayer with a high proportion of the phospholipid cardiolipin 
which contains four fatty acids 
especially impermeable to ions 
transport proteins, which make it selectively permeable to small molecules 
metabolised or required by the matrix enzymes. These enzymes include enzymes that 
metabolize pyruvate and fatty acids to produce acetyl CoA as well as enzyme that oxidise 
acetyl CoA in the Krebs’ cycle. In addition, all enzym
reactions are embedded in this membrane 
Figure 
Electron microscope image (A) and schematic representation (B) showing the general structure of 
mitochondria: outer membrane, intermembrane space, inner membrane, cristae, and matrix (t
http://academic.brooklyn.cuny.edu/biology/bio4fv/page/mito.gif
In addition to the above, the inner membrane is usually found in a highly convoluted form 
creating a series of infoldings known as cristae which project into the matrix to increase 
the surface area of the inner membrane 
mitochondrion to another and may depend on the cellular demand for ATP. For example, 
the number of cristae is high in the mitochondrion of heart muscle cell 
is a large internal space that contains a mixture of hundreds of enzymes required for 
oxidation of pyruvate and fatty acids and for the citric acid cycle 
3 
[26] instead of two and may help to make the membrane 
[27]. In addition, this membrane contains d
es required for respiratory chain 
[22, 29-32]. 
 
1-1 The general organisation of a mitochondrion. 
). 
[33]. The number of cristae differs from one 
[15, 34]
[35]. It also contains the 
[20, 
[23]. It is 
[24, 25], 
ifferent 
[23, 28] that are 
aken from 
. The matrix 
 mitochondrial DNA, mitochondrial ribosomes, mitochondrial tRNAs, and further proteins 
required for the expression of mitochondrial genes such as
Moreover, mitochondria are dynamic organelles 
38]. The balance between 
proteins [39, 40], controls the shape of mitochondria 
Figure 
A 2D image of JC1-stained NIH 3T3 cell (mice fibroblasts)
Argon laser, shows the mitochondrial network organisation a complex in contact with other cell 
compartments such as nucleus (black circle in the centre). 
emission from green to red as mitochondrial membrane potential increases
emissions were separately recorded and merged 
1.3 Functions of mitochondria
Mitochondria are the main site for ATP generation within most tissues by oxidative 
phosphorylation (OXPHOS).
anaerobic glycolysis for all of their adenosine triphosphate (ATP)
mitochondria participate in 
thermogenesis and control of apopto
oxygen species (ROS) production 
4 
 polymerase γ
with dynamic network 
fusion and fission events, which are mediated by specific 
[41] (more details in section 1.16)
 
1-2 The dynamic mitochondrial network. 
, that was excited with the 488 nm line of an 
JC1 undergoes a reversible change in fluorescence 
. Red and green fluorescence 
(taken from http://www.med.unipg.it/imagelab/mitoch.html).
 
 Without mitochondria, cells would be 
 [1, 38]
other cellular activities including intracellular Ca
sis. Mitochondria are also the primary site of 
[42]. Functions will be discussed more below.
 [36]. 
(Figure 1-2) [37, 
. 
  
dependent on 
. In addition, 
2+
 regulation, 
reactive 
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1.3.1 Mitochondria and thermogenesis 
Newborn, cold adapted and hibernating mammals may have the ability to maintain their 
body temperature in a manner independent of shivering, but secondary to an adrenergic 
stimulated increase in respiration [43]. This promotes an increase in blood flow  to brown 
adipose tissue which is responsible for non-shivering thermogenesis [44]. Mitochondria 
within brown adipose tissue behave differently than those in other tissues in terms of 
limited ATP synthesis, reduced membrane potential and increased rates of respiration [45, 
46]. This suggests that inner membranes in these mitochondria have a higher rate of proton 
permeability. The increase in permeability to protons allows part of the energy stored as 
membrane potential, generated by the mitochondrial respiratory chain, to be released in the 
form of heat when protons return to the mitochondrial matrix. 
1.3.2 Mitochondria and Ca2+ homeostasis 
Cytosolic Ca2+ levels are maintained at concentrations approximately 10,000 times lower 
than the Ca2+ concentrations in the extracellular medium [47, 48]. This process is 
controlled mainly by the plasma membrane, endoplasmic reticulum Ca2+ ATPases, and by 
Ca2+ exchanges in a process that requires energy. Mitochondria themselves are responsible 
for providing such energy. They provide cations through the membrane potential to drive 
the force for Ca2+ uptake. For Ca2+ efflux, they have a Ca2+ release system composed of 
two transporters: the Ca2+/2H+ exchange and the Ca2+/2Na+ exchange [42]. 
1.3.3 Mitochondria and generation of ROS 
Under normal conditions, the mitochondrial respiratory chain produces reactive oxygen 
species as by-products of electron transport [49] . These radicals in the form of either 
superoxide or hydroxyl radicals are thought to be produced by interaction of molecular 
oxygen with semi-quinone or -flavone species resulting from transient one electron transfer 
reactions with the respiratory chain complexes [50, 51]. Because of the antioxidant systems 
within mitochondria, ROS are removed [52] and do not cause any permanent damage to 
mitochondria. However, under non-physiological conditions or due to vicious cycles, 
mitochondrial ROS may lead to both mitochondrial and cellular damage [42]. Both 
respiratory complexes I and III in mitochondria are the major sources of superoxide and 
H2O2 in mitochondria [53-55]. However, it has been reported that complex I produces most 
of the ROS generated in intact mammalian mitochondria in vitro [56-58] suggesting that 
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ROS generation by complex III is of limited physiological importance [59, 60]. However, 
the exact sites for ROS production within complex I in vivo or in intact cells are still not 
fully determined [61]. In vitro studies from isolated complex I suggested that the reduced 
flavin is the source of ROS production [62]. In addition, both NADH and quinone-binding 
sites are thought to be sites for ROS production within complex I in Thermus thermophilus 
[62]. 
1.3.4 Mitochondria and apoptosis 
Mitochondria play an important role in the regulation of cell death. Two mitochondrial 
intermembrane-space proteins, cytochrome c and the apoptosis inducing factor (AIF), have 
been shown to migrate from a mitochondrial to a cytosolic location shortly before 
apoptosis [63, 64]. In addition, mitochondria contain pro-caspase 9, pro-caspase 3 and pro-
caspase 2 [65, 66], which initiate the apoptotic cascade. The Bcl-2 family proteins are 
known to be involved in both anti- and pro-apoptotic activities [42]. Also Smac/DIABLO 
was identified as a mitochondria-derived pro-apoptotic factor [67]. In addition, other 
mitochondrial proteins were identified to be involved in apoptosis regulation such as 
Omi/HtrA2 and EndoG [68]. 
1.4 Mitochondrial oxidative phosphorylation and respiratory 
chain 
Oxidative phosphorylation (OXPHOS) is so named because this process donates the 
removal of hydrogen ions from one molecule and gives phosphate molecules to another 
molecule. Embedded in the inner membranes of the mitochondria are proteins and 
complexes of molecules that are involved in this process (Figure 1-3). Hydrogen ions or 
electrons are donated to the two carriers nicotine adenine dinucleotide (NAD) and flavin 
adenine dinucleotide (FAD) in the Kreb`s cycle. Reduced NAD, NADH, carries energy to 
complex I and reduced FAD, FADH, carries energy to complex II. As these hydrogens are 
transferred from one complex to another, the hydrogen protons separate from their 
electrons and protons are pumped out. NADH binds to complex I through a prosthetic 
group called flavin mononucleotide (FMN) and is immediately reduced to NAD, which 
can be recycled, thereby acting as an energy carrier. Upon binding, FMN receives the 
hydrogen from the NADH and two electrons and also picks up a proton from the matrix. 
FMN passes the electrons to iron-sulphur clusters, which are part of complex I and also 
 pumps two protons into the intermembrane space. Elec
without concomitant proton translocation
all. Electrons pass from comple
complex III, which is associated with ano
III, electrons are passed to complex IV through cytochrome 
translocated into the intermembrane space. Finally, complex IV passes two electrons to an 
oxygen molecule the last electron acce
Figure 
The electron transport chain in the 
FADH2, which are generated from 
respiratory chain complexes (I-IV). NADH
pass from complex I to complex III 
cytochrome c. Complex IV passes two electrons to 
respiratory chain. During electrons transport 
generating an electrochemical gradient across the inner membrane
matrix through the ATP synthase
phosphorylating ADP molecules to become ATP. 
Proton translocation during electron transfer along the respiratory chain generates an 
electrochemical gradient across the inner membrane which becomes polarized and has 
~180mV with negative polarity on the matrix side. As a result, this drives the pumping of 
protons in the intermembrane space through the ATP synthase 
the energy production by phosphorylating ADP molecules to become ATP. Finally, the 
electrons reunite with protons to form hydrogen and the chemical union of the hydrogen 
and oxygen produces water. The energy carried by ATP is then used for all cellular
functions like movement, transport, entry and exit of molecules out of the cytoplasm, and 
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trons cannot travel from complex I 
, the two events, must happen together or not at 
x I to a carrier, Coenzyme Q, which passes the electrons to 
ther proton translocation event. From complex 
c and more protons are 
ptor within the respiratory chain. 
1-3 Electron transport and oxidative phosphorylation.
mitochondrion is the site of oxidative phosphorylation. The NADH and 
citric acid cycle, are oxidized to initiate electron transport through 
 binds to complex I and FADH2 binds to complex II. 
through Coenzyme Q and from complex III to complex IV through 
oxygen, which is the last electron accepto
more protons are translocated into the intermembrane 
. This drives pumping of protons in the 
 complex (complex V) and initiates the energy production by 
 
(FoF1 complex)
 
 
 
Electrons 
r within the 
space 
 and initiates 
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cell division. Thus, oxygen is the final acceptor in the electron transport system which 
explains why organisms which respire aerobically. In the absence of oxygen four 
molecules of ATP energy are produced for each glucose molecule, however, the presence 
of oxygen makes the Kreb’s cycle running to produce many more hydrogen ions which 
drive the ATP pump and eventually produces 24-28 ATP molecules. In addition, absence 
of oxygen,which accepts electrons, results in the accumulation of electrons in the 
respiratory chain complexes therefore blocking ATP production [69].Furthermore, a defect 
in one or more of these complexes changes the oxidation rate of NADH to NAD (or 
FADH2 to FAD), which results in an increase in NADH and a decrease in NAD levels. 
The increased NADH/NAD levels inhibit the conversion of pyruvate to acetyl-CoA 
leading to an increase in pyruvate levels in both mitochondria and the cytosol. The 
accumulated pyruvate in the cytosol is metabolized into lactate or converted to alanine. 
The final result of a complex I deficiency is an intracellular increase of lactate, pyruvate, 
and alanine as well in the body fluids: blood, urine and in cerebrospinal fluid (CSF) [70]. 
1.5 Respiratory chain complexes  
Mitochondria are the main site for energy production in eukaryotic cells [71]. Within the 
inner mitochondrial membrane there are five complexes are essential for electron transport 
and energy transduction. These complexes are: NADH–ubiquinone oxidoreductase 
(complex I), succinate–ubiquinone oxidoreductase (complex II), ubiquinol–cytochrome c 
oxidoreductase (cytochrome bc1 complex or complex III), cytochrome c oxidoreductase 
(complex IV), and F1F0–ATP synthase (complex V) [71]. Some of these complexes were 
found to interact with each other to form supercomplexes [71, 72] (more details in section 
1.7). 
1.5.1 Complex I (NADH: ubiquinone oxidoreductase) 
The mammalian complex I is the largest and least understood component of the respiratory 
chain. It consists of at least 45 different subunits (Figure 1.4) that assemble together into a 
structure of ~1 MDa [72, 73]. Seven subunits out of the 45 are encoded by the 
mitochondrial DNA and the other 38 subunits are encoded by nuclear genes, which are 
imported into the mitochondria after translation. In addition, it initiates the first step in the 
mitochondrial respiratory chain through the oxidation of NADH as described above. 
 Despite the availability of the
low resolution 3D structures of complex I are available 
revealed that the 45 subunits within complex I assemble together to form 
structure with a hydrophilic peripheral arm and a hydrophobic membrane
(Figure 1-4). Studies from 
bilayer as an active enzyme 
of the hydrophilic peripheral arm of complex I from the thermophilic bacterium 
thermophilus using X-ray crystallography provided the best current model for 
mitochondrial complex I structure 
Figure 1-4 Schematic structure showin
The mammalian complex I has an
membrane-embedded arm. The highlighted boxes are the 
(ND1-6 and ND4L) and the rest are the nuclear encoded subunits (taken and modified from 
The seven mitochondrially encoded subunits of complex I are ND1
all hydrophobic and in association with ~ 20 other integral membrane proteins they 
the membrane arm of the enzyme
proposed to be involved in ubiquinone binding 
between ND2, ND4, ND5 and other antiporters subunits such as K
these subunits may be part of the proton translocation machinery 
and ND5 may also have ubiquinone binding sites 
to be involved in proton translocation 
9 
 crystal structures for the other OXPHOS complexes, only 
[74-76]. Electron microscopy 
E. coli showed that complex I is maintained 
[78]. However, the recent identification of the atomic structure 
[79, 80]. 
g subunit composition of human complex I.
 L-shaped structure with two arms, a peripheral arm towards the matrix and 
seven mitochondrial encoded subunits of complex I 
-6 and ND4L. They are 
 [81]. Because ND1 has a quinine binding site, it is 
[82] as well ND6 [83]. Sequence similarity 
+ or Na
[84]
[85]. Finally, the ND3 subunit is thought 
[83]. 
an L-shaped [77] 
-embedded arm 
in a native lipid 
Thermus 
 
 
[82]). 
form 
+/H+ suggests 
. In addition, ND4 
 1.5.1.1 Assembly of complex I
Although complex I is composed of ~ 45 subunits, which assemble together to form the 
whole complex. It was reported that 
into complex I while mtDNA
that require significant time for
model for the assembly in mammalian mitochondria 
[72] (Figure 1-5). This model 
intermediates and fully assembled complex I
integration is still not fully understood.
The first step in assembly starts with the subassembly of subunits NDUFS2 and NDUFS7 
which is one of the first complex I assembly intermediates formed and additionally
contains subunits NDUFS3 and NDUFS8
Figure 
Step 1 of complex I assembly involves subassembly of NDU
membrane by ND1 and other subunits forming ~ 400 kDa. In step 
assembled forming a ~460 kDa subcomplex. Step 
~400 kDa and ~460 kDa intermediates to form a stable~830 kDa intermediate that is associated with B17.2L, 
C6ORF66, complexes III and IV, and other nuclear
nuclear-encoded subunits, ND4 and ND5. In the last step (
complex I results in the release of CIA30/Ecsit and B17.2L forming the holoenzyme. (Taken from 
Then, the mtDNA-encoded subunit ND1, possibly in conjunction with other subunits, may 
anchor the subassembly to the inner membrane forming an ~400 kDa intermediate 
10 
  
nuclear DNA-encoded subunits can
-encoded subunits first assemble into intermediate complexes 
 their integration into the holoenzyme [86, 87]
is best described by Lazarou 
shows the assembly via dynamic cycling b
; however, the exact order of subassembly 
 
 [88-90]. 
1-5 Model of human complex I assembly.  
FS2 and NDUFS7 which anchored to the 
2, CIA30, Ecsit, ND2, ND3 and ND6 are 
3 involves the combination between the previously formed 
-encoded subunits. Step 4 involves the addition of other 
5), assembly of subunits into the matrix arm of 
 integrate rapidly 
. The current 
et al. 
etween 
 
 
[72]). 
[86]. 
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Secondly, a membrane subcomplex, which contains ND2, ND3 and ND6 (as well as other 
subunits), is assembled to form a separate ~460 kDa subcomplex via CIA30 [91] in 
conjunction with Ecsit. Third, the membrane arm intermediates come together to form an 
~830 kDa intermediate that is associated with B17.2L and perhaps C6ORF66 then 
complexes III and IV combine with a complex I intermediate to form a supercomplex. 
Additionally, subunits such as NDUFA9, NDUFA10 and NDUFB8 are added to the ~830 
kDa [86, 92]. Subsequently, the ‘cap’, which consists of subunits NDUFV1, NDUFV2, 
NDUFV3, NDUFS1, NDUFS4, NDUFS6 and other subunits, is added to the complex in 
addition to ND4 and ND5 subunits [86, 91]. Finally, the assembly of subunits into the 
matrix arm of complex I is associated with the release of CIA30/Ecsit and B17.2L forming 
the holoenzyme. 
1.5.2 Complex II (succinate-ubiquinone oxidoreductase) 
Complex II is the simplest complex of all electron transport chain (ETC) complexes since 
in vertebrates and many bacteria it contains only four subunits [93]: a matrix-exposed 
FAD-containing subunit that oxidizes succinate to fumarate and an iron-sulfur-containing 
subunit that is also largely exposed to the matrix, also two integral membrane subunits 
which provide the binding site, a b-type cytochrome and the quinone-reducing site of the 
enzyme [94]. This complex is known to be entirely encoded by the nuclear genome and 
functions to link the Kreb’s cycle with the respiratory chain [95-97]. However, this 
complex does not pump protons across the inner membrane [98]. 
1.5.3 Complex III (cytochrome c reductase) 
Complex III is composed of 11 subunits in mammals: 10 subunits are encoded by the 
nuclear genome, and only one subunit is encoded by the mitochondrial genome which is 
cytochrome b. The most important subunits of this complex are: cytochrome b, cytochrome 
c1 and the Rieske iron-sulfur protein since they are all involved in electron transport. In 
addition, this complex contains two reaction centers for ubiquinone, QN and QP, which are 
required for proton pumping through Q cycle mechanism to generate a proton gradient and 
membrane potential for ATP synthesis (Figure 1-6). The QN or quinone reduction centre, 
located on the matrix side of the inner membrane, is involved in the recycling of half of the 
electrons back into the quinine pool and the uptake of proton from the matrix. The QP  
center, which is located near the outer face of the inner membrane, accepts electrons from 
 reduced ubiquinone and half of them are recycled and the others are transferred through the 
iron-sulfur center and cyt 
intermembrane space [93]. 
Figure 1-6 The structure of complex III and electrons transfer through the Q cycle
Complex III is composed of cytochrome 
membrane. Cvtochrome b, with the
membrane. The ubiquinol (QH2) oxidation site, ce
b. Q-n at centre N is  a stable semiqumone radical where cytochrome 
and ubisemiquinone to utnqumol. Proton uptake and release takes place at centres N and P and electron 
transfer from cytochrome c1 to cytochrome
1.5.4 Complex IV (cytochrome 
Complex IV is the final enzyme of the electron transport chain and belongs to the family of 
heme copper enzymes [100]
[101]. Mammalian cytochrome 
subunits are encoded by the mitochondrial genome, Cox1, Cox2 and Cox3, and all other 
subunits are encoded by the nuclear genome 
coordinates heme α and a fused b
ion by a site that also possesses affinity for Ca
important subunit both for assembly and 
pumping [100]. Cox2 is the smallest subunit with two tr
function is to dock cytochrome 
binding of heme α3 in association with Cox1p in humans 
12 
c1 to cytochrome c. Thereby, protons are released in the 
c1 and iron-sulpuur protein, which are located on one side of the 
 b-566 heme and the b-560 heme, is located on the othe
nter P, is between the iron-sulphur protein and cytochrome 
b reduces ubiquinone to ub
 c (taken and modified from [99]). 
c oxidase) 
. It catalyses the four-electron reduction of oxygen to water 
c oxidase (COX) is composed of 13 subunits:  three large 
[102, 103] (Figure 1-7). The Cox1 subunit 
inuclear heme α3-CuB redox center and ligates a sodium 
2+
 ions [104-106]. In addition, it is the most 
function of COX and is involved in proton 
ansmembrane domains and its 
c via the CuA center [102]. Cox2 is also involved in the 
[107]. The Cox3 subunit is 
 
. 
r side of the 
isemiquinone 
 involved in the folding, action and/or stability of COX 
translocation [102, 110, 111]
function of COX in addition to formation of the enzyme 
Figure 
This figure shows only the three largest
and other nuclear- encoded subunits
membrane space (taken from [100]
 
1.5.6 Complex V (ATP synthase)
Mammalian complex V is composed of 16 different subunits, two of which are encoded by 
the mitochondrial genome (subunits 6 and 8) while the rest are encoded by the nuclear 
genome [112]. Together these subunits form two opposing rotary mo
motor is composed of the subunits (
a rotary mechanism. The F0 motor catalyses ion tran
coupled to rotation of the c ring versus the stator subunits 
connected by two stalks, a central one containing the 
involving the δ- and b-subunits (Figur
the transmembrane proton motive force generated by the electron transport chain to drive 
the synthesis of ATP from ADP and inorganic phosphate. This is achieved by the flow of 
protons through the peripheral and central stalks which initiates the c
rotate and the energy produced by this rotation is used by F1 to drive ATP synthesis. Each 
molecule of ATP requires three protons to initiate ATP production, one proton for each 
active site [114]. In addition, the rotation of the central stalk, which proceeds through 120°, 
changes the through cycles of ‘open’, ‘loose’ and ‘tight’ states. Three 120° steps in a 360° 
13 
[108, 109] 
. The nuclear encoded subunits are involved in the catalytic 
[100]. 
 
1-7 A schematic representation of mammalian COX. 
 mitochondrial-encoded subunits of COX (Cox1p, Cox2p and Cox3p) 
, which are involved in early assembly steps of the enzyme
). 
 
α3β3γδε) and catalyses ATP synthesis or hydrolysis by 
slocation across the membrane that is 
α and b2. Both motors are 
γ- and ε-subunits and a peripheral one 
e 1-8) [113]. The function of this complex is to use 
but not in proton 
. IMS: inner 
tors [113]. The F1 
-subunit of F0 to 
 cycle take each subunit through all three states, and three molecules of ATP are produced 
[115, 116]. 
Figure 1-8
The mammalian complex V is composed of 16 subunits, which assemble together to form the F1F0 ATPase 
complex. The F1 motor, which catalyses ATP synthesis or hydrolysis, is composed of t
and located in the matrix side. The F0 motor, which catalyses ion translocation across the membrane, is 
composed of c subunits embedded in the inner membrane. Both motors are connected by two stalks, a central 
one containing the γ- and ε-subunits and a peripheral one involving the 
pumping intiates the rotation of the two motors in an opposing direction resulting in the production of ATP 
from ADP and inorganic phosphate (taken from 
1.6 Control of the OXPHOS 
The permeability of the outer mitochondrial membrane 
membrane allows entrance of 
translocase (ANT) has been reported to be involved in the
the inner mitochondrial membrane
events, the state III and state IV respiration. When concentrations of ADP in the matrix are 
high and oxygen is consumed by the electron transport chain, ATP is synthesised to restore 
the electrochemical gradients, this is known as sta
synthesised ATP from the matrix to cytoplasm is coupled with the import of ADP and 
inorganic phosphate from the cytoplasm into the matrix. However, when the matrix ADP 
concentrations are low, oxygen consumption is re
gradients; this is known as state IV respiration. The ratio of state III respiration (maximum 
14 
 Schematic representation of the structure of complex V.
δ- and b-
http://www.atpsynthase.info/images/ATP_synthesis1.jpg
 
and the inner
metabolites, such as ADP and ATP. Adenine nucleotide 
 exchange of ADP and ATP on 
 [117]. Generally, the OXPHOS is controlled by two 
te III respiration. Export of the newly 
duced to maintain electrochemical 
 
 
he subunits (α3β3γδε) 
subunits. Protons (H+) 
). 
 mitochondrial 
15 
 
respiration) to state IV respiration (lower respiration) is known as the respiratory control 
ratio, which indicates the tightness of the coupling between respiration and 
phosphorylation [15, 118, 119]. 
1.7 Supercomplexes structure 
The respiratory chain complexes as described (section 1.4) were initially identified as 
random complexes within the inner mitochondrial membrane, with electrons moving 
between them via the electrons carriers. This model is known as the fluid model [120]. 
However, other studies have since described another model known as solid model, in 
which complexes were found to interact and organize into supercomplexes or respirasomes 
[71, 120-122]. The respirasomes in mammals are found in two forms: the complete 
respirasome containing complexes I, II and IV in a ratio of 1:2:4 and a second form 
containing complex III and complex IV
 
in a  2:4 ratio [72]. Complex II was found as a 
monomer and complex V as a dimer [31, 122]. More recently, the existence of such 
supercomplexes is thought to have important functional consequences [72]. The use  of 
electron shuttling molecules, such as ubiquinol and cytochrome c may not be required [72]. 
Also, catalytic activity may be enhanced due to reduced diffusion times of substrates [72]. 
Moreover, the production of damaging molecules such as superoxides [123, 124] may be 
limited. In addition, the presence of such supercomplexes has shown to be essential for 
complex I assembly and stability [72, 124].  
1.8 Mitochondrial genetics 
Each nucleated mammalian cell contains several hundreds to more than a thousand 
mitochondria and each mitochondrion harbors 2-10 copies of mtDNA. Mitochondrial size, 
shape and abundance is different in different cell types and may change due to the degree 
of energy demand and different physiological or environmental conditions [125]. The 
number of mitochondria within a cell is determined by the biogenesis and division of the 
mitochondria through the activation of specific transcription factors and signaling 
pathways [126, 127]. Mitochondria are genetically controlled by both nuclear DNA and the 
mitochondrial genome [1]. 
The mitochondrial genome is a multicopy, double-stranded circular DNA molecule, which 
is 16.6 kb in human. This genome encodes 13 essential proteins for the OXPHOS system 
 and 24 components of the RNA machinery: 2 rRNAs and 22 tRNAs. MtDNA is intronless 
and the only non-coding region is the displacement region (D
contains both the replication origins and the transcriptional promoters (Figure 1
128]. The 13 proteins include seven subunits of NADH d
ND2, ND3, ND4, ND4L, ND5and ND6), cytochrome 
subunits of cytochrome c oxidase or complex IV (COI, COII and COIII) and two subunits 
of F0F1 ATPase (ATPase 6 and ATPase 8); all are encoded by mt
the organelle [125, 126]. Complex II or succinate dehydrogenase is entirely encoded by the 
nuclear genome, as are the remaining subunits of complexes I, III, IV and V. The
encoded proteins are synthesized on cytosolic ribosomes and subsequently transported into 
the mitochondria [102, 129]
The 37 genes entirely encoded by the mitochondrial genome 
ND4L), cytochrome b of complex III, the 3 subunits of complex IV (COXI
ATPases (6 and 8), and the tRNA genes, which are denoted by the single letter code of the amino acid they 
encode. D-loop is the displacement loop or non
replication and OL is the origin of light
the heavy-strand promoters (taken from 
16 
-Loop), a region of 1.1 kb. It 
ehydrogenase (complex I: ND1, 
b (subunit of complex III), three 
DNA and synthesized in 
. 
Figure 1-9 The human mitochondrial genome. 
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Mitochondrial genetics differ from Mendelian genetics in almost every aspect: genome 
size, number of DNA molecules per cell, number of encoded genes, gene density, lack of 
introns, mode of inheritance, replication, transcription, and recombination as compared and 
summarized in Table 1-1. 
Table 1-1 Differences between the human mtDNA and nuclear DNA. 
 
Characteristic 
 
Nuclear genome 
 
Mitochondrial genome 
 
 
Size 
 
 
~3.3 x 109 bp 
 
16.569 bp 
 
Number of DNA 
molecules 
per cell 
 
23 in haploid cells, 46 in diploid cells 
 
Multicopy 
 
Number of 
encoded genes 
 
 
~20,000-30,000 
 
37 (13 polypeptides, 22 tRNAs and 2 rRNAs) 
 
Gene density 
 
 
~1 per 40,000 bp 
 
1 per 450 bp 
 
Introns 
 
 
In most genes 
 
Absent 
 
Percentage of 
coding DNA 
 
 
~3% 
 
~93% 
 
Codon usage 
 
The universal genetic code 
 
    AUA codes for methionine, UGA codes for 
          tryptophan instead of termination. 
AGA and AGG contribute to a −1 frameshift 
but are not stop codons [130]. 
 
 
Associated 
proteins 
 
Nucleosome-associated histone proteins 
and non-histone proteins 
 
No histones; but associated with several 
proteins (e.g.TFAM) which form nucleoids 
 
 
Mode of 
inheritance 
 
Mendelian inheritance for autosomes and 
the X chromosome; paternal inheritance 
for the Y chromosome 
 
 
Only maternal 
 
Replication 
 
Strand-coupled mechanism that uses 
DNA polymerases α and δ 
 
Strand-coupled and strand-displacement 
models; only uses DNA polymerase γ 
 
Transcription 
 
 
Most genes are transcribed individually 
 
All genes on both strands are transcribed as 
large polycistrons 
 
Recombination 
 
Each pair of homologues recombines 
during the prophase of meiosis 
 
There is evidence that recombination occurs 
at a cellular level but little evidence that it 
occurs at a molecular level 
(Modified from Taylor & Turnbull 2005). 
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1.9 Mitochondrial DNA Replication 
The mechanism of mtDNA replication is still not clearly determined since four models of 
replication have been described. In the first model, mtDNA is replicated from two origins 
the H-strand (OH) and the L-strand (OL). DNA replication is initiated at OH using an RNA 
primer generated from the L-strand transcript. Then the H-strand synthesis proceeds two-
third of the way around the mt-DNA and displaces the parental H-strand until it reaches the 
L-strand origin (OL). This displacement exposes the OL to allow the accumulation of the 
transcription machinery to initiate synthesis of the L-strand which proceeds in the opposite 
direction along the H-strand template (Figure 1-9). Thus, mtDNA replication is 
bidirectional but asynchronous [131-133]. 
The second model indicates that the bidirectional replication is initiated at multiple sites 
across the D-Loop region, which includes the genes for cytochrome b, ND5, and ND6. This 
bidirectional replication initiation is followed by a subsequent fork arrest near the OH then 
replication is restricted to one direction only [134, 135]. 
The third model contradicts the previous models, which described bidirectional and 
asymmetric mechanisms. In this conventional model, mtDNA replication is initiated at a 
specific position in the D-Loop (OH) and the nascent chains starting at this origin do not 
terminate prematurely at the terminus of the D-Loop but continue along the mtDNA 
template. This origin is thought to be responsible for mtDNA maintenance under steady-
state conditions [136]. 
Recently, the RITOLS replication model was described which is similar to the strand-
asynchronous model of replication but initiation is unidirectional and occurs in the non-
coding region (NCR). This model involves the recruitment of RNA on the displaced H-
strand rather than the mitochondrial single stranded DNA-binding protein (mt-SSB) thus 
forming Ribonucleotide Incorporation ThroughOut the Lagging Strand (RITOLS) 
intermediates [137, 138]. 
Regardless of the exact mechanism involved in mt-DNA replication, mtDNA replication is 
achieved by nuclear-encoded factors [139] such as polymerase γ, which consists of a 
catalytic subunit that has proof reading ability (POLG1) and another processing subunit 
(POLG2) [36], Twinkle [140] and the mitochondrial single stranded DNA-binding protein 
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(mt-SSB) [139, 141]. All these proteins are associated together with the mtDNA to form 
mtDNA-protein complexes known as nucleoids, which are believed to be involved in 
mtDNA transmission, inheritance [1, 142], replication/translation, maintenance, repair, and 
recombination [143]. 
1.10 Mitochondrial DNA transcription 
MtDNA transcription is initiated from three promoters in the D-Loop, the heavy strand 
promoter (HSP) and the light strand promoter (LSP) (Figure 1-9) [144].The heavy strand 
transcript begins first from the HSP and then the light strand transcript begins later from 
the LSP. Alternatively, transcription of the heavy strand may be initiated either from 
HSP1, generating a short transcript which terminates at the 16SrRNA, or from HSP2, 
generating a polycistronic transcript [145]. However, transcription from the mitochondrial 
promoters produces a polycistronic precursor RNA that is then processed to produce 
individual tRNA and mature mRNA molecules [1, 132, 146].  
The exact mechanisms involved in mtDNA transcription are still not fully understood, 
however; the understanding of the machinery has improved due to the identification of 
specific proteins and the availability of  in vivo experimental system [147]. It is known that 
mtDNA transcription is different from that of nuclear DNA in some aspects. In mtDNA 
transcription, the polymerase γ is the only DNA polymerase involved in the process and 
genes on both strands are transcribed polycistronically, unlike nuclear gene transcription in 
which most genes are transcribed individually [146]. Interestingly, a recent study showed 
that the mitochondrial transcription termination factor 3 (MTERF3), which is located in the 
mitochondria, acts as a negative regulator of mammalian mtDNA transcription. MTERF3 
binds at or near the mtDNA promoter regions, HSP1, HSP2 or LSP, to repress 
transcription, which may be important in regulating oxidative phosphorylation in response 
to different physiological demands. It may also provide a mechanism to avoid collision 
between transcription complexes generated by the opposing promoters [148]. More 
recently, the mitochondrial transcription factor B2 (TFB2M) was reported as a 
mitochondrial DNA transcriptional activator in a complex with the mitochondrial 
transcription factor (TFAM) and the RNA polymerase (POLRMT). In addition, the TFBM 
factors are thought to couple mitochondrial transcription and translation [149]. 
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1.11 Mitochondrial RNA translation 
Translation of mt-mRNAs for the 13 mitochondrial-encoded proteins takes place on 
mitochondrial ribosomes [150, 151] However, initiation and termination of mitochondrial 
proteins synthesis is not widely understood [152]. The mitochondrial mRNAs were 
described to lack the 5'-untranslated region, which interacts with 16S rRNA during the 
initiation of protein synthesis [153], however, 4 RNA species (MTCO1, MTND4, MTATP8, 
and MTATP6) do have the 5'-untranslated region [154]. In addition, the 5` termini of the 
mtRNAs lack the 7-methylguanylate cap structure that is present in the majority of 
eukaryotic mRNAs and is essential for recruiting translation initiation factors, which 
interact with poly(A) binding protein [155]. Although mitochondrial mRNAs harbour 
initiation codons, the mechanism that guides mitochondrial ribosomal subunits to this 
region is currently unclear, however, it is possible that the structure of the mRNA alone 
guides the ribosome to the proper start codon [156]. Many nuclear-encoded factors have 
been involved in the translation of mtDNA. These include, for example, ribosomal 
proteins, aminoacyl tRNA synthetases, mt-tRNA modification proteins, mitochondrial 
initiation factors [157, 158], mitochondrial elongation factors [159, 160], in addition to 
Pentatricopeptide repeat domain 3 (PTCD3) [161], the ribosome recycling factor mtRRF 
[162, 163], methionine aminopeptidase (MAP1D) [164], and at least one termination 
release factor, mtRF1a [165]. 
 
The disruption of mitochondrial translation due to mutations in mitochondrial tRNA or 
ribosomal RNA genes leads to mitochondrial translation defects therefore causing 
pathology. Mutations in nuclear genes essential for mitochondrial translation, such as the 
mitochondrial ribosomal protein S16 (MRPS16) [166] and the mitochondrial elongation 
factor G1 (EFG1) [167], resulted in mitochondrial translation defects [1]. Mutations in the 
elongation factors Tu (EFTu) [168] and the mitochondrial translation elongation factor Ts 
(EFTs) were associated with mitochondrial translation defects as well [169]. Recently, a 
point mutation in the mitochondrial tRNAMet caused a mitochondrial myopathy due to 
tRNA misfolding leading to defects in translational initiation and elongation [170]. 
1.12 Mitochondrial protein import 
Although mitochondria have their own genome, only 1% of mitochondrial proteins are 
encoded by the mitochondrial genome. The majority of the mitochondrial proteins are 
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encoded by nuclear genes and then synthesized as precursors on cytosolic ribosomes. 
Translocases on the mitochondrial membranes and chaperones direct the import of these 
proteins into the mitochondria. There are two kinds of mitochondrial precursor proteins. 
The first are preproteins with positively charged and cleavable targeting signals, termed 
presequence, at the the N-terminus which interact with mitochondrial import receptors on 
both outer and inner membranes. These include matrix proteins, some of the 
intermembrane space proteins, and inner membrane proteins. The second preproteins with 
various internal targeting signals; these include all outer membrane proteins and other 
intermembrane and inner membrane proteins [171-173]. 
There are two translocases involved in mitochondrial protein import.  One of these is the 
translocase of the outer mitochondrial membrane (TOM) complex, which consists of seven 
different subunits. Only precursors for mitochondrial proteins pass through this complex. 
The other translocase is located in the inner mitochondrial membrane and includes the 
TIM22 and TIM23 complexes. The TIM22 complex consists of several subunits including 
TIM9 and TIM10 involved in precursor transfer to the complex [174]. TIM23 consists of 
three different subunits [173] in association with TIM50 which transfers precursors from 
the TOM complex to the TIM complexes [175]. 
Upon mitochondrial precursor or preprotein synthesis, precursors are directed to receptors 
on the mitochondrial surface by the help of cytosolic heat shock proteins. The TOM 
complex is the main gate for import; precursors are then shuttled down one of three 
different pathways according to their final destination in the mitochondria [171] (Figure 1-
10). 
Precursors of outer membrane proteins are imported first through the TOM complex and to 
the intermembrane space. Small TIM proteins within the intermembrane space participate 
in the transport of these precursors to the sorting and assembly machinery (SAM complex) 
in the outer membrane [171, 176, 177]. 
After passing the TOM complex, precursors of many hydrophobic proteins, including 
metabolite carriers, pass through the carrier translocase (TIM22 complex) and are directed 
to the inner membrane with the help of chaperone-like components from the 
intermembrane space [171]. 
 Precursors with a cleavable signal peptide are transferred to 
mitochondrial outer membrane, which forms
associates with both the matrix heat shock protein
(PAM) to complete protein transport into the matrix 
cleaved by an endometallopeptidase.
Figure 
Precursors of mitochondrial proteins are synthesised in the cytosol then imported through the TOM complex 
with the help of cytosolic chaperones. Precursor proteins are then directed to their destinations according to 
the targeting signal. Precursors with i
proteins, are directed to the outer membrane through the SAM complex and precursors of the inner 
membrane, such as carrier proteins, are directed to the inner membrane (IM) through the TI
chaperone-like proteins within the inner membrane space (IMS). Precursors with N
are directed to the matrix through the TIM23 and PAM complexes (taken from 
1.13 Mitochondrial DNA damage
The human mtDNA is a compact DNA molecule without protection by histones, but 
instead it is packaged with other proteins such as: 
polymerase γ [143, 178]. 
observed in nuclear DNA [132]
the inner mitochondrial membrane 
target for attack by reactive oxygen species (ROS) and free radicals generated as a result of 
electron leakage from the mitochondrial respiratory chain 
22 
the TIM23 complex 
 a channel across the outer membrane and 
70 (mtHsp70) and the import motor 
[171]. The signal peptide is then 
 
1-10 Pathways of mitochondrial protein import.  
nternal targeting signals, such as precursors of outer membrane (OM) 
-terminal signal peptides 
[171]).
 
mtTFA, mtSSB, Twinkle, and 
It replicates rapidly with high mutation rate 
. In addition to the site of the mtDNA, which is attached to 
[179, 180], all these factors render the mtDNA an easy 
[181]. 
on the 
 
M22 complex and 
 
higher than that 
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The free radical theory suggested that ROS, which are constantly generated through 
normal mitochondrial metabolism, cause ageing and age-associated degenerative diseases 
by introducing damage to membranes, proteins and DNA [182]. The mitochondrial theory 
of aging, which supports the free radical theory, suggests that the accumulation of somatic 
mutations in mtDNA during an organism`s lifetime results in mitochondrial dysfunction 
[182-184]. The ROS vicious cycles are believed to account for an exponential increase in 
oxidative damage during aging, which eventually results in loss of cellular and tissue 
functions through a combination of energy insufficiency, signaling defects, apoptosis and 
replicative senescence. This was proved by the presence of pathogenic mutations 
associated with increased levels of ROS [185]. More recently, some somatic mutations in 
the mtDNA, which inhibited electron transport, led to increased production of ROS [186-
189]. 
As mentioned above, the mitochondrial DNA has high rate of mutations. T o cope with this 
high rate if mutations, a DNA repair system is required to maintain the integrity of the 
mtDNA. However, mtDNA repair may occasionally fail or become limited due to excess 
of mtDNA damage caused by ROS production  resulting in the accumulation of  damaged 
mt DNA leading to diseases [190, 191]. 
Unlike nuclear DNA, mtDNA repair in mammalian cells is not widely investigated as early 
studies suggested absence of DNA repair in mitochondria [192]. Several DNA repair 
pathways have been described in the nucleus including: direct reversal (DR), nucleotide 
excision repair (NER), base excision repair (BER), mismatch repair (MMR), 
recombinational repair (RER), and translesion synthesis (TLS) [193]. While the damaged 
mtDNA can be repaired by the base excision repair pathway, which is well described in 
mitochondria [194-196], mismatch repair [19], and direct repair [197]. However, the 
presence of other mtDNA repair pathways is still unclear [191]. 
1.14 Mitochondrial DNA inheritance 
The mammalian egg contains about 100,000 molecules of mtDNA and the sperm contains 
100-1500 mtDNAs [17, 198]. When the sperm fertilizes the egg, the sperm mtDNA is 
actively degraded [199] by an ubiquitin system-driven process [200]. Therefore, the 
mtDNA is only maternally inherited. However, this model of inheritance has been 
challenged because the transmission of paternal mtDNA was observed after interspecific 
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crosses between mouse, but not within species [201]. Further studies showed that the 
paternal mtDNA was only transmitted after several generations [202]. In humans, only one 
case was reported of paternal inheritance of an mtDNA mutation, a patient with 
mitochondrial myopathy due to a novel 2-bp mtDNA deletion in the MTND2 gene [203, 
204]. This case is more likely to be rare because family members were not affected and no 
trace of mutation was detected in their blood or muscle, which suggest that this mutation 
arose spontaneously in early embryogenesis or in the paternal germ line [204]. Recent 
reproduction studies were carried out to further investigate mtDNA paternal inheritance 
using intracytoplasmic sperm injection (ICSI), which is widely used in cases of severe 
male infertility. The theory behind these studies was that the mutant mtDNA in the sperm 
may bypass direct degradation after fertilization thereby increasing the risk of transmitting 
mtDNA disease to children born by this technique. However, results showed no evidence 
of paternal mtDNA transmission to offspring or extra-embryonic tissues [205, 206]. 
1.15 Heteroplasmy and the threshold effect 
In contrast to nuclear genes, with one maternal and one paternal allele, mtDNA molecules 
are present in hundreds or thousands of copies in each cell [199], thus the mitochondrial 
genome has a polyploid nature which means the mitochondrial genome copies can exist in 
two forms, homoplasmy or heteroplasmy [1]. Homoplasmy is when all the mitochondrial 
genome copies are identical and heteroplasmy is when there is a mixture of two or more 
mitochondrial genotypes.  
Deleterious mutations of mtDNA typically affect some but not all genomes. Thus, cells, 
tissues and individuals may harbor two populations of mtDNA: wild type and mutant 
(heteroplasmy). In normal subjects, all mtDNAs are identical wild-type copy known as 
homoplasmy. Non-deleterious mutations of mtDNA (neutral polymorphisms) are typically 
homoplasmic and the pathogenic mutations are usually but not invariably heteroplasmic 
[199]. 
In the presence of heteroplasmy, there is a threshold level of mutation which is important 
for both the clinical expression of the disease as well as the biochemical defects [1].The 
phenotypic threshold effect can be observed when the wild-type mtDNA in a single cell 
can no longer complement the effects of the mutant mtDNAs and eventually leading to 
mitochondrial dysfunction [207]. The mitochondrial threshold varies according to the 
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mtDNA mutation type, ranging from 60% for mtDNA deletion mutations to 90% for some 
tRNA mutations or could be less [133, 208]. For example, high levels of mtDNA deletions 
were found in Parkinson disease [209]. The threshold levels were 50% in the m.3243A>G 
mutation [210], 60% in the m.5650G>A mutation [211], and more than 90% in the 
m.3302A>G mutation [212]. 
1.16 Mitochondrial division and segregation 
Mitochondria are dynamic organelles that actively divide and fuse to mix metabolites and 
mtDNA copies according to the energy demands of the cell [213]. The copy number and 
shape of mitochondria are different in different cell types. They can change in the same 
cell type under different physiological conditions ranging from multiple spherical 
organelles to a single organelle with a branched structure or reticulum. The number of the 
mitochondrial genomes inside mitochondrion depends on the degree of fragmentation. In 
most cells, mtDNA replication is not limited to the S phase of the cell cycle when the 
nuclear DNA replicates, but occurs independently of the cell cycle. However, during the 
cell cycle the numbers of mitochondria and their mtDNA have to double and the newly 
formed organelles have to be segregated to the daughter cells. Mitochondrial fission and 
fusion (Figure 1-11) events are involved in this complex process because mitochondria are 
enclosed by a double membrane structure [214]. 
Large dynamin-related GTPases have been reported to be involved in the balance between 
mitochondrial fission and fusion. Although the exact mechanism of mitochondrial fission 
in mammals is not understood, Fis1 and DRP1 have been described to be involved in 
mitochondrial fission [215-217], by assembling into rings surrounding the mitochondrial 
outer membrane, in addition to hFIS1 and other unknown cofactors and regulators [40, 
218]. hFIS1 is located throughout the outer mitochondrial membrane and it recruits DRP1 
from the cytosol to the outer mitochondrial membrane [219]. GTP hydrolysis is thought to 
cause a conformational change in DRP1 that drives the mitochondrial outer membrane 
fission event [213]. 
The fusion event involves both the outer and inner membranes through Mitofusins 1, 2 
(Mfn1, 2), which facilitate outer membrane fusion in mammals through trans interactions 
that promote membrane curvature and fusion [37, 220, 221]. Regardless of the exact 
mechanism, studies showed that the two distinct isoforms of the GTPase OPA1 (optic 
 atrophy), which is the main mediator of membra
mammals [222-224], are necessary for suc
Figure 1-11
(A) In mitochondrial fission, FIS1 recruits the large GTPase and DRP1 
membrane (OMM). (B) Mitochondrial fusion involves both 
mitochondrial membrane (OMM)
(taken from [40]). 
1.17 Mitochondrial DNA transmission and the genetic 
bottleneck 
Maternal mutant mtDNA is transmitted to offspring with different degrees since the risk 
depends on the type of mutation and the segre
Therefore, a mother carrying a mtDNA mutation may pass it to all her children, but only 
her daughters will transmit it to their progeny 
transmitted to all maternal offspring. However, not all offspring will develop the disease 
since nuclear genetics and environmental factors play major roles in the expression of the 
disease. 
The transmission of heteroplasmic mtDNA muta
controlled by different factors. Not only do nuclear genetic and environmental factors 
affect the expression of the disease, but also the genetic bottleneck (Figure1
the number of mutant mtDNA molecules are 
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 Mitochondrial fission and fusion in mammalian cells. 
throughout the outer mitochondrial 
mitofusins 1/2 which are located on the outer 
 and OPA1 which is located partially on the inner mitochondrial membrane 
gation of mutation in the mother`s tissues. 
[199]. Homoplasmic mtDNA mutations are 
tions is more complex since it is 
reduced during oogenesis thereby decrease 
DNA in 
. 
 
 
-12). In which, 
 the number of the mutant mtDNA when they are passed from a mother to her offspring 
[228].  
During cell division, the mitochondria and their genomes are randomly distributed to the 
daughter cells, a process known as replicative segregation. Mitochondria have the ability to 
fuse, which results in the accumulation of their genomes 
result in the random distribution of their genomes. These processes can change the 
proportion of mutant mtDNA in daughter cells and when the
in a specific tissue, the phenotype can also change. Mitotic segregation explains the 
differences in the mutation load in different tissues from different members carrying the 
same pathogenic mutation and the time
in mtDNA-related disorders 
non-diving cells such as skeletal muscle and neurons which can be attr
replication of mtDNA [230]
 
Selected number of mtDNA molecules is transferred into each oocyte during the production of primary 
oocytes. Oocyte maturation is associated with the r
mutation load of the mtDNA between generations is responsible for the variable levels of mutated mtDNA 
observed in affected offspring from mothers with pathogenic mtDNA mutations
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[229], mitochondria division will  
 pathogenic threshold changes 
-related phenotypic differences frequently observed 
[199]. However, mitotic segregation cannot explain changes in 
. 
Figure 1-12 The genetic bottleneck. 
apid replication of this mtDNA population. Difference in 
 (taken from 
ibuted to relaxed 
 
[1]). 
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1.18 Mitochondrial DNA and mutations 
Mitochondrial diseases are estimated to affect 1 in 5000 of the population, although the 
exact number could be much higher [231]. A study in 2008, in the North East of England, 
revealed that the prevalence of mitochondrial DNA disease in adults is 9.2 in 100,000 of 
population [232]. Other studies based on patients with the most common mtDNA mutation, 
the m.3243A>G mutation, revealed a prevalence of 1 in 200 [233] ;  and the m.1555A→G 
mutation gave a prevalence of 1 in 520 [234]. The mitochondrial diseases are multisystem 
diseases that mainly affect skeletal muscle, cardiac muscle and the central nervous system 
[235]. Symptoms range from mild disturbances of eye movement in late adulthood to 
neonatal death associated with profound lactic acidosis [236]. Several factors increase the 
rate of mtDNA mutations as mentioned above, such as the lack of a DNA repair system 
[237], the lack of protective proteins such as histones and the association  with the inner 
mitochondrial membrane which makes the mtDNA a close target for ROS during 
OXHPHOS [238]. 
To date, more than 250 pathogenic mtDNA mutations have been reported [190]. Mutations 
affecting mtDNA can be divided into two groups; mtDNA mutations affecting protein 
synthesis and mtDNA mutations affecting protein-coding  genes [199]. These mutations 
can also be grouped into base substitution mutations and rearrangement mutations 
(deletion or duplication). The first group of mutations can change the amino acid thereby 
the proteins (missense mutation) or rRNAs and tRNAs (protein synthesis mutations). 
Rearrangement mutations generally involve the deletion of at least one tRNA thereby 
causing protein synthesis defects [199]. 
Missense mutations have been linked with different mitochondrial diseases associated with 
myopathy, optic atrophy, dystonia, Leigh syndrome, ragged-red fibres and subsarcolemmal 
aggregates of abnormal mitochondria [239]. Diseases resulting from mtDNA 
rearrangements are invariably heteroplasmic and give rise to phenotypes ranging from 
adult-onset type II diabetes and deafness, through ophthalmoplegia and mitochondrial 
myopathy to lethal pediatric pancytopenia [239]. 
Not every mtDNA mutation leads to the development of mitochondrial disease since some 
mutations are silent and have no physiological effect. In addition, the mitochondrial 
genome contains a large number of neutral base changes and insertions or deletions that 
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have no pathogenic significance, known as neutral polymorphisms [199]. In order to assign 
pathogenicity to a novel mtDNA mutation, six canonical criteria have been proposed 
which should be met [199, 240-242]. 
1.19 Defining pathogenicity of a mtDNA point mutation  
Not all sequence changes in the mitochondrial genome are pathogenic since it contains a 
large number of neutral changes. These changes can be beneficial to anthropological 
studies and forensic medicine [243, 244]. Defining pathogenicity of mt-tRNA mutations is 
further complicated because of the clinical and biochemical heterogeneity associated with 
these mutations. For example there is often little correlation between which mt-tRNA is 
mutated and the resulting phenotype if we consider the common consequence to be 
reduction in protein synthesis [118]. To assign pathogenicity of a mtDNA mutation, six 
canonical criteria were suggested by DiMauro and Schon [199]. 
1. The mutation must be heteroplasmic (i.e. co-existent wild-type and mutated 
mitochondrial genomes in the same tissue). However, not only heteroplamic 
mutations are pathogenic; homoplasmic mtDNA mutations have also been 
identified to be pathogenic [245-247]. 
2. The proportion of mutated mtDNA should be higher in tissue from affected 
individuals than in the same tissue from their unaffected relatives. This is only 
applicable to heteroplasmic mutations and it is difficult to determine mutation 
segregation in small families [118]. 
3. The proportion of mutated mtDNA should be higher in clinically affected tissues. 
This only applies to heteroplasmic mutations because mutation loads in 
homoplasmic mutations are 100%. 
4. The proportion of mutated mtDNA should segregate with a biochemical defect. 
This can be clearly seen if the mutation load in the COX-deficient fibres is higher 
than in the COX-positive fibres to have a direct correlation [248]. However, 
homoplasmic mutations do not segregate with biochemical defect because mutation 
load in all fibres will be the same [245, 247, 249, 250]. 
5. The mutation should occur at an evolutionary conserved site in the mitochondrial 
genome. However, some pathogenic mutations may not be considered pathogenic 
because of poor evolutionary conservation in the region [118] such as the 
pathogenic m.8344A>G in mt-tRNALys  [248, 251]. 
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6. The mutation should be absent from healthy controls and not reported in the two 
mitochondrial DNA databases [69, 252]. 
1.20 Clinical syndromes and features of the human 
mitochondrial diseases 
Syndromes due to mtDNA mutations were widely investigated following the discovery in 
1988 of the first two syndromes Kearns-Sayre (KSS) and LHON [253, 254], which were 
due to pathogenic mtDNA mutations. This led to further investigations for other mtDNA 
mutations resulting in the identification of hundreds of other mutations. Some classical 
syndromes, along with the most common clinical phenotypes in patients are summarized in 
Table 1-2.  
The existence of mitochondria in all nucleated cells mean mtDNA associated diseases 
affect many tissues with different phenotypes [1]. The biochemical and genetic complexity 
of the respiratory chain system can explain the wide range of clinical phenotypes of 
mitochondrial disease. It is clear that organs with a high requirement for aerobic 
respiration, such as brain, heart and skeletal muscle, are more likely to be severely affected 
by pathogenic mtDNA mutations. Other organs that can be affected include the 
gastrointestinal tract [255], the liver [256], the kidneys [257] and the endocrine systems 
[257]. Mitochondrial diseases often show a delayed onset and a progressive course. This is 
thought to be the result of an age-related decline in OXPHOS function in postmitotic 
tissues [258] associated with the progressive accumulation of somatic mtDNA 
rearrangement mutations [259]. The two main features in most mitochondrial disease are 
respiratory chain deficiency and lactic acidosis. Furthermore, patients with mitochondrial 
disease often have abnormal subsarcolemmal mitochondria in their muscle shown as 
ragged-red fibres [260]. 
Genetically, mitochondrial diseases can be divided into three groups: diseases due to 
sporadic or maternally inherited mtDNA mutations, diseases due to mutations in nuclear 
genes, which control mitochondrial and diseases that do not result from mtDNA mutations 
but are thought on the basis of biochemical findings to be caused by nuclear DNA 
mutations [261]. 
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Table 1-2 Clinical disorders which are caused by mutations in mtDNA
Mitochondrial DNA disorder Clinical phenotype MtDNA genotype Gene Status Inheritance 
Kearns-Sayre syndrome Progressive myopathy, 
ophthalmoplegia, cardiomyopathy 
Single, large scale mtDNA 
deletion Several deleted genes Heteroplasmic Usually sporadic 
Chronic progressive external 
ophthalmoplegia (CPEO) Ophthalmoplegia, 
Single, large scale mtDNA 
deletion Several deleted genes Heteroplasmic Usually sporadic 
Pearson syndrome Pancytopoenia, lactic acidosis Single, large scale mtDNA 
 deletion Several deleted genes Heteroplasmic Usually sporadic 
Mitochondrial myopathy, 
encephalopathy, lactic 
acidosis& stroke-like episodes 
(MELAS) 
Myopathy, encephalopathy, lactic 
acidosis & stroke-like episodes 
m.3243A>G, m.3271T>C ; 
 
individual mutations 
MTTL1 
 
MTND1&MTND5 
Heteroplasmic Maternal 
Myoclonic epilepsy & ragged-
red fibres (MERRF) Myoclonic epilepsy, myopathy m.8344A>G, m.8356T>C MTTK Heteroplasmic Maternal 
Neurogenic weakness, ataxia 
and retinitis pigmentosa 
(NARP) 
Neuropathy, ataxia, retinitis 
pigmentosa m.8993T>G MTATP6 Heteroplasmic Maternal 
Maternally-inherited Leigh 
syndrome (MILS) 
 
Progressive brain-stem disorder m.8993T>C MTATP6 Heteroplasmic Maternal 
Maternally-inherited diabetes 
and deafness (MIDD) Diabetes, deafness m.3243A>G MTTL1 Heteroplasmic Maternal 
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             MTATP6: ATPase 6; MTCYB: cytochrome b; MTND1, 3–6: NADH dehydrogenase subunits 1, 3–6; MTRNR1: 12S ribosomal RNA; MTTE, MTTK, MTTL1, and MTTS1 
             are  mitochondrial tRNAs (modified from [1]).
Mitochondrial DNA 
disorder Clinical phenotype MtDNA genotype Gene Status Inheritance 
Leber’s hereditary optic 
neuropathy (LHON) Optic neuropathy 
m.3460G>A, 
m.11778G>A, 
m.14484T>C 
MTND1 
MTND4 
MTND6 
Hetero-or homoplasmic Maternal 
Myopathy and diabetes Myopathy, weakness, diabetes m.14709T>C MTTE Hetero-or homoplasmic Maternal 
Sensorineural hearing loss Deafness 
m.1555A>G 
 
Individual mutations 
MTRNR1 
 
MTTS1 
Homoplasmic 
 
Hetero-or homoplasmic 
Maternal 
Exercise intolerance Fatigue , muscle 
weakness Individual mutations MTCYB Heteroplasmicc Sporadic 
Fatal, infantile 
encephalopathy, 
Leigh/Leigh-like syndrome 
Encephalopathy, lactic 
acidosis 
m.10158T>C, 
m.10191T>C MTND3 Heteroplasmic Sporadic 
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1.21 Diagnosis of mitochondrial disorders 
Diagnosis of a mitochondrial disease is not straightforward. The principal difficulty for 
clinicians is that patients with mitochondrial disease rarely have a classic phenotype and 
mtDNA is involved in the differential diagnosis of many common clinical syndromes [1]. For 
example, mtDNA mutations have been linked to some common metabolic syndromes as 
reviewed in [262] and [263]. Furthermore, some symptoms of mitochondrial diseases are age-
related, while others can present at any age [70], and they often present in specific 
combination with other clinical symptoms, e.g. mitochondrial diabetes is often accompanied 
by deafness [264], and stroke-like-episodes usually are associated with migraine-like 
symptoms [1]. 
1.22 Investigations of a mitochondrial disorder 
1.22.1 Preliminary investigations  
Patients suspected to have a mitochondrial disease initially undergo biochemical 
investigations which include: creatine kinase assay, full blood count, tests of thyroid and liver 
function and bone chemistry, measurements of resting blood lactate, random blood glucose, 
and glycated haemoglobin. In addition, investigation should include electrocardiography to 
determine possible conduction defects or cardiac hypertrophy [265].  
1.22.2 Investigation of relevant tissues  
Following clinical and laboratory investigations, patients are further investigated by 
histochemical, biochemical and molecular genetics techniques which provide correct and 
accurate diagnosis for the majority of patients [265]. These techniques involve the 
examination of blood or muscle DNA samples, fibroblasts and muscle biopsies. 
The biochemical investigations of fibroblasts are necessary for diagnostic purposes if no 
muscle sample is available, if prenatal diagnosis is required, or to confirm results obtained 
from muscle investigation. In addition, fibroblasts are suitable for molecular genetic 
investigations. However, they are less preferred than fresh muscle for investigating respiratory 
chain disorders since a defect that is present in muscle is not always expressed in fibroblasts 
[70]. 
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Muscle biopsies are mainly preferred because they are the most diagnostically accessible 
source of clinically affected tissue [265] and most of the defects are expressed in these tissues 
[70], however, it is still with some limitations. The biopsy is taken with needle biopsy using 
local anaesthesia. The size and quality of the investigated muscle biopsy are important. So, it 
must be free of connective tissue and fatty tissue. Conditions of specimen collection and 
transport are critical. Also, investigation of a muscle biopsy for diagnostic purposes should be 
avoided in the first month of life if possible and medication should be avoided before taking 
the biopsy to avoid false positive diagnosis due to secondary inhibitory effects of medication 
[70]. 
Prenatal diagnosis is required, to confirm results obtained in muscle tissues, and if further 
molecular genetic investigations are required. It can be performed reliably in families if a 
defect has been confirmed in at least two different tissues. Currently, prenatal diagnosis is 
performed both in chorionic villi and in amniocytes. However, chorionic villi are preferred 
because they allow the prenatal diagnosis at earlier stage of the pregnancy (around the 10th 
week) as compared with amniocytes. Moreover, chorionic villi can be investigated without 
cultivation, in contrast to amniocytes reducing the time of investigation [70]. 
1.22.3 Histochemical investigations  
The histochemical analysis of muscle biopsy is the most commonly used technique to 
investigate mitochondrial abnormalities [266]. Gomori trichrome stain is a method used to 
detect subsarcolemmal mitochondrial accumulation, called ragged-red fibres (RRF) (Figure 1-
13-A). However, this method is not fully accurate because it does not evaluate mitochondrial 
enzyme involvement. The combined succinate dehydrogenase (SDH) and cytochrome c 
oxidase (COX) are widely used to measure activities. The COX reaction (Figure 1-13-B and 
C) evaluates the mitochondrial myopathies because COX contains subunits encoded by both 
the mitochondrial and nuclear genomes [240], while the SDH, is only nuclear encoded and the 
reaction can reveal the subsarcolemmal mitochondrial accumulation (Figure 1-13-D). 
 Figure 
(A) Classical ragged-red fibres after Gomori trichrome staining
accumulation. (B) Normal muscle fibres after COX staining
COX staining alone. (D) COX-
(taken and modified from [240]).
1.22.4 Biochemical investigations 
Measurement of individual respiratory chain enzyme activities for the mitochondrial 
complexes is the ultimate investigation in the diagnosis of a patient suspected to have a 
mitochondrial disease because these diseases are caused b
respiratory chain complexes. This analysis can be performed on both muscle biopsies and 
fibroblasts. In general, fresh muscle samples are preferred to frozen samples as they contain 
functionally intact mitochondria, whi
phosphorylation and the activity of the respiratory chain enzymes to be measured. A frozen 
sample can be used for measuring only the individual enzyme activities instead of the 
complete chain. In addition, other 
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1-13 Histochemical analysis of muscle fibres. 
 showing the subsarcolemmal mitochondrial 
 (brown). (C) COX-deficient muscle fibres after 
deficient fibres stain blue after the combined SDH (blue) and COX staining 
 
 
y deficiencies in one or more of the 
ch allows the overall capacity of oxidative 
factors have to be considered when dealing with muscle 
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biopsies to ensure reliable results such as: sample size, quality of the sample, transport 
conditions, age of the patient at date of biopsy and use of medications [70]. 
1.22.5 Molecular genetic investigations  
The molecular genetic investigations of patients suspected of a mitochondrial disease can be 
complex. These investigations are normally performed in all patients with abnormal 
histochemistry or biochemistry and in patients suspected to have a mitochondrial disease but 
with normal muscle biopsy results [265]. The molecular genetic investigations involve 
searching for novel and pathogenic mutations through sequencing of the entire mitochondrial 
genome of patients, or in some cases excluding mtDNA involvement in the disease. Also they 
involve searching for mitochondrial genome rearrangements which include single deletions, 
duplications and multiple mtDNA deletions which can be detected by Southern blot [240] or 
long-range PCR [267].  
Furthermore, restriction fragment length polymorphism (RFLP) is one of the molecular 
genetic techniques often performed to search for common mtDNA point mutations and 
quantify the mutation load which is clinically significant to correlate genotype with the 
resulted phenotype in patients [268, 269]. 
1.23 Animal models of mitochondrial diseases 
The inability to transfect mitochondria with exogenous DNAs in vitro or in vivo is one of the 
factors that has prevented progress in the study of the relationship between mtDNA genotype 
and phenotype. However, several trials have been carried out to create animal models carrying 
heteroplasmic and pathogenic mtDNA mutations to further investigate the pathogenicity of 
mtDNA mutations.  
The first trial involved the microinjection of cytoplasm containing mtDNA into oocytes which 
resulted in chimeric embryos, but the mutant mtDNA was lost by segregation in early 
development [270].  Another study involved the introduction of mtDNA mutations into the 
mouse female germ line by electrofusing cytoplasts derived from NZB or BALB mice zygotes 
carrying one mtDNA genotype to recipient one-cell embryos of the other type [271-273]. 
Transmitochondrial chimeric mice with chlorampenicol-resistant mitochondria (CARR), 
resistant to the mitochondrial ribosome inhibitor (CAR), were generated by fusing a 
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chlorampenicol-resistant cell line with female ES cells. These were then injected into donor 
blastocysts [273, 274]. Mice with mitochondrial dysfunction were produced by introducing 
mouse mtDNA carrying a deletion into zygotes [275]. Another group generated mice with 
pathogenic mtDNA mutations that were transmitted through the germ lines [208]. 
Advanced studies have moved to create mouse models through the targeting of genes involved 
in the maintenance or replication of the mtDNA by disrupting the mitochondrial transcription 
factor A (Tfam), which resulted in mitochondria-associated disease phenotypes in different 
tissues [276-279]. A recent study performed by Trifunovic and colleagues showed that knock-
in mice, harboring a mtDNA mutation in the polymerase-γ gene (PolgA), resulted in short 
lifespan and premature ageing phenotypes: weight loss, reduced fat, hair loss, curvation of the 
spine, osteoporosis, anemia, reduced fertility, and heart enlargement [280, 281].  
Although, these trials were successful in generating mice with mtDNA diseases due to 
mutations in the mitochondrial genome and also showed the involvement of mtDNA 
mutations in the development of new diseases that were not seen in humans as they died due 
to renal failure [275], phenotypes and inheritance patterns for some mutations were different 
from those seen in humans [282]. However, doubts were raised after the premature ageing 
phenotypes lacked both increased oxidative stress and exponential accumulation of mtDNA 
mutations. These findings argued against the direct involvement of oxidative stress in the 
ageing process, contradicting the oxidative stress theory of ageing, and favored the accelerated 
aging phenotypes to the respiratory chain defect as a primary inducer of premature ageing in 
those mice [283-285]. 
To further investigate the relationship between mitochondrial mutations and aging, a 
quantitative PCR-based approach that relies on PCR amplification of single molecules for 
mutation detection was carried out. Results showed that mutator mice had increased levels of 
point mutations in tissues compared to wild-type, which had no obvious features of rapidly 
accelerated aging. Therefore, results strongly suggest that mitochondrial point mutations do 
not limit the lifespan of wild-type mice [286]. 
Despite some doubts raised by previous animal models with mitochondrial mutations, 
subsequent trials have been performed to further increase our knowledge of the role of 
mitochondria in diseases. More recently, a mouse model carrying a mutation in the 
mitochondrial Thymidine Kinase 2 (TK2), which is essential for the mitochondrial nucleoside 
38 
 
salvage pathway, was created [287, 288]. Results showed rapid and progressive mtDNA 
depletion in all studied tissues, which is similar to patients with mtDNA-depletion syndromes 
(MDS). In addition, a mouse model with two mutations in the mtDNA mutations, in the 
MTND6 and MTCOI genes, was created [289]. Results showed that the severe MTND6 
mutation was selectively eliminated during oogenesis within four generations, whereas the 
milder MTCOI mutation was retained throughout multiple generations [289]. This is 
consistent with results from mutator mice which showed strong purifying selection against 
mutations within mtDNA protein-coding genes [290]. 
1.24 Cell culture model of mtDNA disease 
In order to understand the functional consequences of a point mutation in a specific gene, it is 
necessary to determine the expression level of this gene, the assembly of the respiratory 
complexes, and the enzyme activities [207]. Transmitochondrial cytoplasmic hybrids or 
cybrids are the most widely used approach for these investigations of mtDNA mutations; 
especially after doubts have been raised against the mtDNA-mutator mice. Cybrids are 
generated by fusion of enucleated cytoplasts from patient’s cells, which harbor a mtDNA 
mutation, with a human cell line lacking mtDNA (p0) (Figure 1-12) and growing under 
specific selection conditions [291]. The p0 cells are either osteosarcoma or lung carcinoma 
cells [38], which had been completely depleted of mtDNA by long-term exposure to ethidium 
bromide and post-fusion are repopulated with the exogenous patient mitochondria [292]. As 
these Rho0 cells have no functional respiratory chain and are dependent on pyruvate and 
uridine for growth, loss of one or both of these metabolic requirements can be used to select 
for cybrids that have mtDNA [292].  
Generally, this system has proved to be useful for the study of the functional and 
physiological consequence of different levels of heteroplasmy of certain mtDNA mutations 
[208], for determining the effect of nuclear background on the segregation of pathogenic 
mtDNA mutations [293], for developing genetic therapies and for investigating heterologous 
mtDNA recombination in human cells [294]. 
Although, most cybrid models are established using aneuploid tumour cells (with abnormal 
number of chromosomes), however, this may affect the stoichiometry of nuclear- and 
mitochondrial-encoded RC subunits, therefore affecting expression of phenotype [190] . Also, 
tumour cells are dependent on glycolysis for energy production instead of OXPHOS, while 
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mtDNA disorders take place in highly aerobic cells. So, this may have an effect on the 
phenotypic expression of an mtDNA mutation [295]. In addition, both the p0 cells and 
cybridisation processes can cause significant and stable up-regulation of many nuclear 
transcripts involved in OXHOS which can explain why in vivo phenotypes are not always 
expressed in an in vitro cybridsystem [296, 297]. 
1.25 Approaches to manage and treat mtDNA diseases 
Although it has been more than two decades since the identification of the first mtDNA 
mutation and the subsequent identifications of several others, there is currently no effective 
treatment for mitochondrial diseases. Only symptom alleviating treatments are available 
[298]. The increased identification of mtDNA mutations and their involvement in diseases has 
encouraged researchers to develop several methods to manage mitochondrial diseases. One of 
the issues, which has hindered the progress to cure these diseases, is the complicated 
mitochondrial genetics and the varied expressed clinical phenotypes associated with these 
disorders.  
Treatment for the relief of specific symptoms of mitochondrial disorders include drugs, blood 
transfusions, hemodialysis, invasive measures, surgery, dietary measures and physiotherapy 
[298]. The administration of different pharmmacological and biochemical agents has shown to 
be helpful. Those agents include antioxidants such as : co-enzyme Q10, idebenone, vitamin C, 
and vitamin E. Some agents were used to improve lactic acidosis such as: dichloroacetate and 
dimethylglycine. Carnitine and creatine were used to correct secondary biochemical defects. 
Nicotinamide, riboflavin, succinate, and co-enzymeQ10 were used as respiratory chain co-
factors in addition to hormones [299]. However, whilst helpful, these approaches are not 
curative. 
The best approach would be to provide a safe and effective treatment to improve patients` 
lives if cures for the diseases are impossible. Exercise therapy is one of the approaches which 
has shown great promise for improving physical capacity and quality of life in patients with 
heteroplasmic mtDNA mutations. This includes endurance training and resistance training. 
Endurance training means the ability to exert yourself for a long period of time, while 
resistance training or strength training means training against a specific opposing force. 
Patients, who undertook 14 weeks endurance training, have shown improved OXPHOS 
functions but no change in muscle mtDNA mutations levels were detected [300-302]. 
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Resistance training utilizes musculoskeletal loading, such as weight lifting, that is increased in 
intensity or volume incrementally over time to improve strength and increase muscle mass . It 
is believed to stimulate muscle regeneration via the satellite cells in response to fibre injury, 
gave similar results with great improvement in the proportion of heteroplasmic mtDNA 
mutations. Studies from 12 weeks resistance training in patients with single, large-scale 
mtDNA deletions have shown increased satellite cell proportion with improvements in 
muscular strength and oxidative capacity suggesting a change of the mtDNA mutation levels 
to more wild-type in patients` muscles [303]. 
Moreover, an in vitro trial has been undertaken to manage mitochondrial diseases via gene 
therapy by shifting the levels of mtDNA mutations to wild-type. This approach was based on 
the inhibition of mutated mtDNA replication thereby increasing the number of wild-type 
copies of the mtDNA. This was carried out using selectively targeted sequence-specific 
nucleic acid derivatives such as peptide nucleic acids (PNAs), which are complementary to 
human mtDNA templates. The antigenomic PNAs specifically inhibited replication of the 
mutated mtDNA but not the wild-type mtDNA confirming the success of this approach in 
vitro but the question remains, is it applicable in vivo? [304]. 
Restriction endonucleases approach is another approach capable of distinguishing between the 
mutated and wild-type mtDNA, however, it is limited to mutations which create a novel 
cleavage site that is not present in the wild-type mtDNA [190, 305]. Results from mouse 
models carrying mtDNA mutations, which were injected with transgenes, showed the 
possibility of manipulating heteroplasmy levels of mtDNA in liver and muscle tissues [305]. 
A modified approach that targets and the mtDNA in a sequence-specific manner using a 
chimeric zinc finger methylase was achieved. Results from targeting the m.8993T>G (NARP) 
revealed the selective methylation of cytosines adjacent to the mutation site confirming the 
ability to disrupt the mutant mtDNA and maintain the wild-type mtDNA [306]. 
The recent discovery of the import system of tRNAs, rather than protein import, is another 
approach to manipulate defective mitochondria by restoring the function of the mutant gene 
[307]. This can be done by modifying or overexpressing the cognate aminoacyl synthetase of 
the pathogenic mt-tRNA mutations [190]. Results from overexpressing of the cognate 
aminoacyl synthetase of the mt-tRNAPhe causing the m.611G>A significantly improved the 
aminoacylation state of this mutation [308]. Also overexpression of mitochondrial leucyl-
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tRNA synthetase [309] and human mitochondrial valyl tRNA synthetase rescued 
mitochondrial dysfunctions due to mutations in the cognate mt-tRNAs [310]. 
Another alternative strategy is to prevent the transmission of mtDNA disease. The 
investigation of prenatal samples such as chorionic villus biopsy or amniocentesis is widely 
used to detect the presence or absence of mtDNA mutations in such tissues [190]. In addition, 
preimplantation genetic diagnosis (PGD), which involves screening for mtDNA mutations in 
unfertilised oocytes or single cells removed from early embryos prior to implantation, is 
another alternative approach. 
Very recently, Craven et al. showed that pronuclear transfer from one fertilised human zygote 
to another enucleated human zygote, with a different mitochondrial genotype, was compatible 
with development to the blastocyst stage after in vitro culturing [311]. Given that maternally 
inherited mtDNA mutations require high mutation loads to be reached before causing 
biochemical defects [312] , this approach successfully showed the ability to manipulate human 
embryos with very low levels of mutation loads, which can not be detected by standard 
techniques, below the disease threshold. This favours pronuclear transfer with great promise 
to prevent the transmission of mtDNA disease in humans.  
However, some limitations or side effects might arise from such approaches. For example, 
mtDNA depletion was described to happen during manipulating heteroplasmy levels [305] 
which may affect results as mtDNA copy numbers known to play a role in defining the 
expression levels of phenotypes [207, 313]. Also, a very low percentage of carry-over of 
mutant mtDNA associated with the pronuclear transfer [311]. 
Despite previously mentioned limitations or side effects; these findings show great promise in 
preventing the transmission of diseases due to mtDNA defects. 
1.26 Aims 
This thesis introduces the reader to mitochondria, mitochondrial genetics, basic organellar 
functions, and biology. I also describe mitochondrial diseases with reference to the variability 
observed in their clinical phenotypes, and the importance of both mitochondrial DNA 
(mtDNA)-encoded and nuclear-encoded genes in regulating mitochondrial respiratory chain 
function. This provides the reader with the necessary information to understand mechanisms 
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involved in mitochondrial disease pathology, in addition to understanding the functional 
consequences due to specific defects in mtDNA.  
The overall aims of this thesis are several fold:  
1] to investigate a cohort of patients either confirmed as having, or suspected to have, a 
biochemical defect in complex I using a variety of biochemical, histochemical, and molecular 
genetic approaches to confirm the involvement of mtDNA mutations and prove pathogenicity 
by assessing several cellular properties;  
2] to investigate patients with mitochondrial disease phenotypes with suspected mt-tRNA 
gene mutations, and demonstrate the pathogenic nature of these novel mtDNA variants;  
3] to evaluate whether the MitoChip (V2.0) is a reproducible tool for detecting heteroplasmic, 
pathogenic human mtDNA mutations which have previously been identified using 
conventional ABI sequencing protocols.  
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Chapter 2 : Materials and methods 
2.1 Materials 
2.1.1 Equipment 
AlphaImage series 2200 Software for gel imaging     Flowgen 
ABI 3130xI Genetic Analyser (SeqScape software) Applied Biosystems 
ABI GeneAMP 9700 Thermal cycler Applied Biosystems 
Autoclave  Astell 
Automated Plate reader E1x800  Bio-Tech 
AxioCam MR3 digital black and white camera Zeiss 
AxioVision image capture software (Version. 4.6.3.0) Zeiss 
Axiovert 200M fluorescence microscope Zeiss 
Balance: Sartorius Basic Sartorius 
Bench-top centrifuge Sigma 
Bench-top refrigerated centrifuge 5417R Eppendorf 
Binder general purpose incubator Philip Harris 
Cerenkov counter type 6-20 Mini instruments 
Cryostat (Cryo-star HM 560M) Microm International 
Dry heat block Techne 
Electrophoresis power supply model 250EX Life technologies 
EPSON Expression 1680 pro (EPSON Scan software) EPSON 
Freezing container Nalgene 
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Geiger counter series-900 Mini Instruments 
Gel Dryer vacuum system model 543 BioRad 
GeneChip CustomSeq® Array 2.0 Affymetrix 
GeneChip scanner Affymetrix 
Gradient maker SG series Hoefer® Inc   
Gradient mixer Hoefer ® Inc 
Horizontal agarose gel electrophoresis systems Amersham 
InCu saFeTM CO2 incubator Sanyo 
Leica laser-microdissection system Leica 
Magnetic stirrer  Fisher 
Microflow biological safety cabinet Bioquell 
Mighty Small II SE250 GEHealthcare Life Sciences 
NanoDrop ND-1000 spectrophotometer (ND-1000 software) Labtech International 
Partec PAS for flow cytometry Partec 
Peristaltic pump P-1 Pharmacia 
PhosphorImager, Storm 860 (Image Quant software) Molecular Dynamics 
Teflon-glass homogeniser (2ml) Wheaton 
UV gel documentation system  Flowgen 
Varian cary 300 bio spectrophotometer (WinUV software) Cary 
Zeiss imaging system Zeiss 
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2.1.2 Consumables 
0.2ml 96 well PCR plates StarLabs 
0.2ml Eppendorf tubes Biogene   
0.5ml Eppendorf tubes Biogene 
1.5ml Eppendorf tubes Biogene  
2.0ml Eppendorf tubes Biogene 
96 well optical bottom plates Starlabs 
Coverslips 22x50mm Merck 
Cellstar disposable Pipettes (5ml, 10ml, and 25ml) Greiner 
Cellstar tissue culture flasks (25cm2, 75cm2, and 225cm2) Greiner  
Cryo tubes (1.8ml) Nunc  
Falcon tubes (15ml and 50ml) Costar 
Gilson Pipetteman (P2, P10, P20, P200, and P1000) Anachem 
Microscope slides (76x26x1.0-1.2mm) Merck 
Polyethylenenaphthalate (PEN) membrane slide Leica 
SlideRite MailerTM  CellPath 
Tissue culture plates (6-well, 12-well, and 24-well) Cell Star 
Whatman paper  Merck 
Whatman grade 1 filter paper Merck 
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2.1.3 Chemicals and reagents 
2.1.3.1 Tissue culture and mitochondrial protein preparations 
25% Trypsin /EDTA Invitrogen 
Bromodeoxyuridine (BrdU) Sigma 
Cytochalasin B Sigma 
Dialyzed fetal calf serum Gibco  
Dimethyl sulfoxide (DMSO) Sigma 
Dulbecco`s modified Eagle Medium (DMEM) Invitrogen 
Ethanol Analar Merck 
Fetal Bovine Serum Invitrogen 
Iso-Pentane Merck 
Liquid nitrogen BOC 
MycoAlert® Mycoplasma detection kit Lonza 
Nonidet P-40           BDH 
O.C.T. compound VWR  
PEG 1500 Roche  
Penicillin and Streptomycin solution (Pen-Strep) Gibco 
Percoll Amersham 
Phosphate Buffered Saline tablets OXOID 
Protease inhibitors Roche 
Polyethylene glycol  Roche 
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Uridine Sigma 
2.1.3.2 Histological and histochemical reagents 
3.3’Diaminobenzidine tetrahydrochloride (DAB) Sigma 
Calcium Chloride Sigma 
Catalase Sigma 
Cytochrome c Sigma 
Di-Sodium Hydrogen Phosphate Sigma 
DPX mountant Sigma 
Eosin solution Merck 
Ethanol Analar Fisher Scientific 
Formaldehyde Merck 
Haematoxylin solution Merck 
HistoclearTM National Diagnostics 
HRP-Polymer MenaPath 
Liquid stable DAB chromogen MenaPath 
Liquid stable DAB substrate buffer MenaPath 
Nitro Blue Tetrazolium Sigma 
Paraformaldehyde (PFA) Sigma 
Phenazine methosulphate (PMS)  Sigma 
Sodium Azide Sigma 
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Sodium Dihydrogen Phosphate  BDH 
Sodium Succinate  Sigma 
Universal probe MenaPath 
2.1.3.3 Extraction, precipitation and purification reagents 
3M Sodium acetate pH5.2 Sigma 
EZ1 Blood DNA Extraction kit   QIAGEN 
Chloroform Sigma 
Ethylenediaminetetracetic acid (EDTA) Sigma 
Hydrochloric acid (HCl) BDH 
Isoamyl alcohol Sigma 
Isopropanol Sigma 
Magnesium Chloride (MgCl2) Sigma 
Phenol Sigma 
Potassium Chloride (KCl) Sigma 
Proteinase K Invitrogen 
Sodium Chloride (NaCl) BDH 
Sodium Hydroxide (NaOH) BDH 
Trizma base Sigma 
2.1.3.4 Gel electrophoresis reagents 
1 Kb DNA ladder Gibco BRL 
Agarose MP Roche  
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Ammonium Persulphate (AMPS) Sigma 
Bromophenol Blue Sigma 
Butanol AnalaR 
Ethidium Bromide Merck 
Glycerol Sigma 
Hyperladder IV Bioline 
Kaleidoscope Pre-stained standards BioRad 
N,N,N`N`-tetramethylenediamine (TEMED) Sigma 
Sodium dodecyl sulphate (SDS) BDH 
Sodium hydroxide (NaOH) BDH 
Tris-acetate EDTA (10xTAE) Sigma 
Tris-borate EDTA (10xTBE) Sigma 
Trizma base Sigma 
Xylene cyanol Sigma 
2.1.3.5 Polymerase chain reaction and sequencing reagents 
10x PCR Buffer Applied Biosystems 
AmpliTaq Gold DNA polymerase Applied Biosystems 
BigDye terminator v3.1 cycle sequencing kit Applied Biosystems 
Dexoynucleotide triphosphates Roche 
DNA oligonucleotide synthesis primers MWG Biotech UK Ltd 
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ExoSAP-IT GE Healthcare 
Expand long range Roche 
HiDi  Applied Biosystems 
Taq DNA polymerase New England Biolabs 
TaqMan master universal PCR master mix Applied Biosystems 
2.1.3.6 PCR-RFLP reagents 
[α-32P]-dCTP (3,000 Ci/mmol) Amersham Pharmacia 
Acrylamide:bisacrylamide 29:1 40% Amresco 
Ammonium Acetate BDH 
AgeI  New England Biolabs 
AluI  New England Biolabs 
BbsI  New England Biolabs 
DraI  New England Biolabs  
Fun4HI New England Biolabs 
HaeIII New England Biolabs 
HinfI  New England Biolabs  
MaeIII New England Biolabs 
Mn1I New England Biolabs 
Pellet Paint® Co-Precipitant Novagen 
52 
 
2.1.3.7 Western blot reagents  
3-[cyclohexylamino]-1-propanesulphonic acid (CAPS) Sigma 
Acrylamide:bisacrylamide (29:1)  30% Amresco 
Bradford assay kit Biorad 
Dried skimmed milk Premier Int. Foods Ltd. 
ECL-Plus Western detection kit Amersham 
Expand long template PCR system Roche 
Glycine Sigma 
Immobilon transfer membrane Millipore  
Methanol Fisher Scientific 
Mouse anti beta actin antibody Dako 
Mouse anti Complex I subunit GRIM-19 MitoSciences 
Mouse anti-OXPHOS complex I -20 MitoSciences    
Mouse anti-OXPHOS complex I -30 MitoSciences    
Mouse anti-OXPHOS complex II-70 Invitrogen 
Poloxyethylenesorbitan monolaurate (Tween 20) Sigma 
β-mercaptoethanol Sigma  
Rabbit anti-mouse horse radish peroxidase Dako  
Rabbit IgG secondary antibody-HRP Abcam  
Rabbit polyclonal IgG Anti-MnSOD Upstate  
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2.1.3.8 Blue-Native PAGE reagents 
AminoCaporic acid Sigma 
Bis-Tris Sigma 
Digitonin Fluka 
Hydrochloric Acid (HCL) BDH 
Laurylmaltoside (n-Dodecyl β–D-maltoside) Sigma 
Nitro tetrazolium Blue (NBT) Sigma 
Reduced nicotine amide adenine dinucleotide (NADH) Sigma 
Serva Blue G-250 AMS Biotechnology 
Tricine Sigma 
2.1.3.9 Respiratory chain complex measurement reagents 
Acetyl Coenzyme Sigma 
Albumin bovine serum (BSA) Sigma 
Antimycin A Sigma 
Digitonin Fluka 
2, 6-dichlorophenolindophenol (DCPIP) Sigma 
5, 5`-dithio-bis-(2-nitobenzoic acid) (DTNB) Sigma 
Ethylenediaminetetracetic acid (EDTA) USB Corp. 
Ethyleneglycolbis (β-aminoethyl ether)-N, N, N`, N`-  
tetraacetic acid (EGTA) Sigma 
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4-(2-hydroxyethyl) piperazine-1-(2-ethanesulfonic acid)  
(HEPES)  Sigma 
Oxaloacetic acid Sigma 
Potassium Bicarbonate (KHCO3) Sigma 
Potassium Cyanide (KCN) Sigma 
Potassium Chloride (KCL) Sigma 
Potassium phosphate (KH2PO4) Sigma 
Rotenone Sigma 
Sodium succinate Triton X-100 Sigma 
Sucrose BDH 
Ubiquinone-1 Sigma 
2.1.3.10 Flow cytometry reagents 
Dihydrorhodamine123 (DHR) Molecular Probes 
(5,5', 6,6’-tetrachloro-1,1', 3,3’- tetraethylbenzimidazolylcarbocyanine- 
iodide (JC1) Molecular Probes  
MitoSOX Molecular Probes 
10-n-nonyl-acridine (NAO) Molecular Probes 
2.1.3.11 The GeneChip human resequencing array 2.0 reagents 
GeneChip® Resequencing Assay Kit Affymetrix 
GeneChip® Resequencing Reagent Kit Affymetrix 
LA PCR Kit Ver. 2.1 kit TaKaRa Bio Inc. 
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DNA Amplification Clean-Up Kit Clontech 
2.1.4 Solutions 
Nanopure (18 MegaOhms activity) water was used to prepare the solutions listed below. In 
some cases, distilled water was used as specified. 
Medium B: 
120mM KCl,20mM HEPES,5mM MgCl2,1mM EGTA,5mg/ml BSA 
DNA loading buffer:   
0.25% (w/v) Bromophenol Blue, 0.25% (w/v) Xylene Cyanol, 30% (v/v) Glycerol 
Electrophoresis buffer: 
100ml 10x TAE, 900ml water, 80µl ethidium bromide 
Separating gel (Western blot): 
3.75ml of 30% acrylamide (acrylamide:bisacrylamide (29:1))  , 2.81 ml 1M separating buffer, 
0.82ml d.H2O, 37.5µl 20% SDS,75µl 10% AMPS,7.5 µl TEMED 
Western blot stacking gel  
0.67ml of 30% acrylamide (acrylamide:bisacrylamide (29:1)), 0.25ml 0.5M stacking buffer, 
4.05ml d.H2O, 25 µl 20% SDS, 25 µl 10% AMPS,5 µl TEMED  
Lysis buffer: 
(170µl of l50mM Tris/HCl, 150mM NaCl, 2mM MgCl2), 28µl of 7x Roche protease inhibitors 
(1tablet in 1.5ml of d.H2O), 2µl Nonidet P-40 
5% Milk solution in TTBS: 
5g skimmed milk powder, 100ml TTBS 
1M Phosphate buffer: 
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Buffer A: 3.12g of Sodium dihydrogen phosphate (NaH2PO4.2 (H2O)) in 50ml d.H2O 
Buffer B: 14.15g of Disodium hydrogen phosphate (Na2HPO4) in 250ml d.H2O 
1M Phosphate buffer: 47.5µl of buffer A + 202.5µl of buffer B up to 500ml with d.H2O. 
4% Paraformaldehyde (pH 7.4):  
500ml of d.H2O (65oC), 40g of Paraformaldehyde, drops of 1M NaOH, 500ml of 1M 
phosphate buffer 
1X Phosphate buffered saline:  
1 tablet of Phosphate Buffered Saline in 100ml water 
Western blot Running buffer (pH 8.8 with 5M HCl):  
3g Trizma base, 14.4g Glycine, 1g SDS, Water up to 1L 
Western Blot transfer buffer: 
6g Trizma base, 28.8g Glycine, 0.02% SDS, 15% Methanol, Water up to 1L 
Western Blot sample buffer: 
10ml Stacking buffer, 4ml Glycerol, 4ml 20% SDS, 0.02g Bromophenol blue, 2ml water 
Western blot separating buffer (1M Tris-HCl pH, 8.8 with 5M HCl): 
60.55g Trizma base in 500ml water  
Western blot stacking buffer (0.5M Tris-HCl, pH 6.8 with 5M HCl): 
30.275g trizma base in 500ml water 
TTBS pH 7.6: 
2.42g Trizma base in 1l water, 8g NaCl, 0.1% Tween 20, drops of 1M NaOH 
BN-PAGE anode buffer (50 mM Bis-Tris; pH 7.0 with 5M HCl): 
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19.68g AminoCaproic Acid, 3.1386g Bis-Tris, 100ml water  
BN-PAGE cathode buffer A (15mM Bis-Tris; 50mM Tricine; 0.02% Serva Blue G-250; pH 
7.0 with 5M HCl ): 
1.57g Bis-Tris, 4.48g Tricine, 0.1g Serva Blue G-250, 1L water 
BN-PAGE cathode buffer B (15 mM Bis-Tris; 50 mM Tricine; pH 7.0 with 5M HCl):  
1.57g Bis-Tris, 4.48g Tricine, 1L water 
BN-PAGE transfer buffer (25mM Tris, 192mM Glycine, 20% methanol, 0.02% SDS, pH 8.2 
with 5M HCl ): 
5.24g Tris, 14.44g Glycine, 200ml methanol, 1ml 20% SDS, 799ml water 
BN-PAGE sample buffer (750mM AminoCaproic acid, 50mM Tricine, 0.5mM EDTA, 0.02% 
Serva blue G-250, pH 7.0 with 5M HCl): 
3.75ml of 2M AminoCaproic acid, 1.0ml of 500mM Bis-Tris, 0.05ml 100mM EDTA, 0.5g 
Serva Blue G-250, 10ml water 
BN-PAGE dissociation solution (1% SDS and 1% β-mercaptoethanol): 
0.5ml 20% SDS, 0.1ml β-mercaptoethanol, 10ml water 
2.2 Methods 
2.2.1 DNA Extraction 
Often patient blood, buccal, muscle, and urine DNA samples arrived at the lab already 
extracted; if not, DNA was extracted. When fibroblasts from patients were provided, DNA 
was extracted from fibroblasts cultured in 25cm2 flasks.  
2.2.1.1 Total DNA extraction from fibroblasts 
Harvested cell pellets were washed twice with 1XPBS and, following the last wash, cells were 
resuspended in 2ml of 1XPBS and centrifuged at full speed (13000 rpm for 10 minutes). The 
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resulting pellets were resuspended in 400µl TE/H2O (25:75) before 50µl of 10% SDS and 
50µl of proteinase K (20mg/ml) were added. Samples were then incubated overnight at 37oC.  
The following day one volume (500µl) of Phenol was added to the cell lysate to remove 
proteins. Samples were vortexed briefly, centrifuged at full speed for 5 minutes at room 
temperature, and the upper aqueous layer was removed to a clean 1.5 ml eppendorf tube. A 
mix of 250µl of phenol and 250µl of chloroform: isoamyl alcohol (24:1) was added, vortexed, 
and the samples centrifuged at full speed again for 5 minutes. Samples were again washed 
with 500µl chloroform: isoamyl alcohol and centrifuged at full speed for 10 minutes. The 
aqueous layer, 500µl, was moved to a clean 2ml eppendorf tube and 50µl of 3M NaAc, pH 5.2 
and 1ml of absolute ethanol were added, then samples were frozen at -80oC for more than an 
hour. Samples were centrifuged at 20817g for 10 minutes and the resulting pellets were 
washed with 70% ethanol. Samples were spun down again for 5 minutes at full speed, the 
supernatants were removed, and the pellets were allowed to air-dry for 10 minutes. Finally, 
DNA was resuspended in an appropriate volume of 25:75 TE/H2O to give a final 
concentration of ~ 100ng/ml. DNA concentration was quantified by ND-1000 
spectrophotometer. 
2.2.1.2 Total DNA extraction from blood 
EZ1 Blood DNA extraction Kit was used to extract DNA from 5ml blood sample according to 
the manufacturer’s protocol. Extracted DNA was resuspended in an appropriate amount of 
TE/dH2O (25:75) according to the pellet size to give a final concentration of 100ng/ml. 
Samples were stored at -20oC. 
2.2.1.3 Total DNA extraction from hair 
Hair follicles were carefully dissected into 1.5ml eppendorf tubes and then 30µl of Tris-EDTA 
buffer pH 7.4 were added. Samples were centrifuged at 14000rpm for 10 minutes at room 
temperature. Supernatants were removed and 10µl of DNA extraction buffer (50mM Tris-HCl 
pH8.5, 1mMEDTA, 0.5% Tween 20 (containing 200µg/ml proteinase K) were added to the 
pellets. Samples were incubated at 55oC for 2 hours, during which time samples were 
centrifuged every 15 minutes. After 2 hours, tubes were centrifuged at 14000rpm for 1 minute 
at room temperature and incubated at 95oC to inactivate the proteinase K. 
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2.2.1.4 Total DNA extraction from single muscle fibres 
COX/SDH stained PEN membrane slides were allowed to air dry for 1 hour prior dissecting 
single-muscle fibres for analysis. Fibres with normal histochemical COX activity (COX 
positive) and abnormal COX activity (COX deficient) were randomly selected and dissected 
from the sections using the Leica laser micro-dissection system. To isolate total DNA from 
single muscle fibres, single cells were cut into separate sterile 0.5ml tubes and centrifuged at 
full speed for 10 minutes. 10-30µl of cell lysis buffer (0.5M Tris-HCL, pH8.5, 1mM EDTA, 
0.5% Tween-20, and 200ng/ml proteinase K) were added to cells, incubated at 55oC for 2 
hours followed by 10 minute incubation at 95oC to facilitate proteinase K inactivation. 
2.2.1.5 Total DNA extraction from homogenate tissue 
A DNAeasy tissue extraction kit was used to extract DNA from ~25mg of homogenate tissue 
according to the manufacturer’s protocol. Extracted DNA was resuspended in an appropriate 
amount of TE/dH2O (25:75) according to the pellet size to give a final concentration of ~ 
100ng/ µl and stored at -20oC. 
2.2.1.6 Total DNA extraction from urine sediment 
Phenol/Chloroform extraction was used to extract DNA from urine sediment. Urine samples 
were centrifuged at 6000rpm for 10 minutes and the supernatant removed. The pellet cells 
were incubated overnight at 37oC in Proteinase K (0.5mg/ml) diluted in TNES buffer (0.5M 
Tris-HCl pH 7.4, 1mM EDTA, 0.1M NaCl, 1%SDS). 
The following day, one volume (500µl) of Phenol was added to the samples to remove 
proteins. Samples were vortexed briefly and centrifuged at full speed for 5 minutes at room 
temperature. The upper aqueous layer was removed to a clean 1.5 ml eppendorf tube and a 
mix of 250µl of phenol and 250µl of chloroform: isoamyl alcohol (24:1) was added prior to 
vortexing and centrifugation at full speed for 5 minutes. Samples were again washed with 
500µl chloroform: isoamyl alcohol and centrifuged at full speed for 10 minutes. The aqueous 
layer (500µl) was moved to a clean 2 ml eppendorf tube and 50µl of 3M NaAc, pH 5.2 and 
1ml of absolute ethanol were added. Samples were then frozen at -80oC for more than an hour. 
Samples were centrifuged at 20817g for 10 minutes and pellets were washed with 70% 
ethanol then spun down for 5minutes at full speed. Supernatants were removed and pellets 
were allowed to air-dry for 10 minutes. Finally, the DNA was resuspended in an appropriate 
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volume of 25:75 TE/H2O to give a final concentration of 100ng/ml. DNA concentration was 
quantified as previously described (section 2.2.1.1). 
2.2.2 DNA quantification 
A NanoDrop ND-1000 spectrophotometer and ND-1000 software was used to quantify 1µl of 
the extracted DNA.This software calculates and displays A260/A280 ratios to determine both 
DNA concentration and quality. 
2.2.3 Preparation of human muscle tissue  
Iso-pentane was pre-cooled to -160oC
 
in liquid nitrogen
 
and muscle tissue was placed on 
Whatman grade 1 filter paper using OCT as an adhesive. This was then rapidly frozen by 
immersion in pre-cooled iso-pentane for 15 seconds. Frozen tissue was transported in a liquid 
nitrogen container and stored at -80oC. To cut sections for histological and histochemical 
staining, a Cryo-star HM 560M cryostat was used; the internal temperature was set at -19oC 
and the knife at -21oC. 
2.2.4 Tissue culture  
A humidified incubator was used to incubate all cells at 37oC with 5% CO2. All procedures 
were performed using aseptic techniques, sterile equipment and reagents in a Class II 
biological cabinet. Periodically, cells were tested for possible Mycoplasma contamination 
using a MycoAlert® mycoplasma detection kit according to the manufacturer’s instructions. 
2.2.4.1 Cell manipulations 
Patients` cultured skin fibroblasts, either frozen in liquid nitrogen or referred for investigation, 
were grown in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal calf serum, 
25mg/ml uridine and 1% penicillin-streptomycin. 
2.2.4.2 Cell passaging and harvesting  
Both medium and trypsin were pre-warmed at 37oC in the incubator prior to use. Cells were 
washed with 1xPBS. Depending on the size of flask, sufficient trypsin was added to cover the 
surface of the flask, which was then incubated in 37oC incubator for 1-2 minutes to dislodge 
the cells from the flask. Complete growth medium was added to prevent further proteolysis by 
quenching the trypsin.  
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To continue growing the cells, they were split into new flasks, supplemented with complete 
medium, according to the density of cells. Medium was changed every 3-4 days depending on 
the speed of cell growth. 
Alternatively, cells were harvested at this stage for analysis after washing twice with 1XPBS. 
Following each wash, cells were pelleted by centrifugation at 1200 rpm for 3 minutes at room 
temperature and supernatant was aspirated off. 
2.2.4.3 Freezing cells 
To freeze cells down, they were harvested as previously described and pellets were 
resuspended in freezing media containing fetal calf serum and 10% DMSO. 1ml of freezing 
media was added to 90% confluent cells from 75cm2 flask in 1.8ml Cryo tubes. Aliquots were 
frozen at -80oC and then transferred to liquid nitrogen for long-term storage the following day. 
2.2.5 Generation of cybrids 
Transmitochondrial cytoplasmic hybrids (cybrids) were generated by fusing the enucleated 
patents’ fibroblasts (cytoplasts) with the osteosarcoma cell line 143BTK (po ) which was 
entirely depleted of mtDNA following long-term exposure to low concentrations of ethidium 
bromide [292].  
One day before starting the fusion, 20ml of a 1:1 mix of DMEM (10%FCS, 1% Pen-Strep, 
25mg/ml uridine) and Percoll was prepared and allowed to equilibrate at 37oC overnight. 
Confluent fibroblasts were harvested as previously described (section 2.2.4.2) and enucleated 
using Percoll isopycnic gradient as described in [314]. Harvested cells were washed in 1xPBS 
and resuspended in the DMEM/Percoll mix. 80µl of cytochalasin B (5mg/ml in DMSO) were 
added and samples were centrifuged at 25oC for 70 minutes at 16500 rpm for enucleation. The 
cytoplast layer was collected, washed with DMEM, centrifuged at 650g for 10 minutes and 
the resulting pellet was resuspended in10ml of DMEM. Confluent po cells were harvested and 
resuspended in 5ml DMEM. Then both cytoplasts and po cells were mixed thoroughly, 
aliquoted evenly in two 25cm2 flasks and allowed to attach for 4-5 hours at 37oC. Cells were 
washed with serum free DMEM twice, 1.5ml of Polyethylene Glycol (PEG) 1500 was added 
to each flask, agitated for 1 minute, and cells washed again with serum free DMEM three 
times. 10ml of DMEM were added to each flask and cells were then incubated at 37oC 
overnight.  
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The following day, cells were harvested, resuspended in 100ml of DMEM, and evenly 
aliquoted into four 24-well cell culture plates (1ml/well). The following day, DMEM was 
removed and replaced with uridine-free selection DMEM containing 10% dialyzed FCS, 
100µg/ml BrdU and 1% Pen-Strep to select cybrids (Figure 2-1).  
After the appearance of colonies, these were harvested, resuspended in selection medium and 
aliquoted into 6-well cell culture plates. Finally, the colonies were selected and expanded in 
12-well and then 24-well plates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 2-1 The establishment of 
 This diagram illustrates the procedure for the isolation of 
cells, which are thymidine kinase positive (TK
and mixed with the recipient 143B TK
cells in the presence of Polyethylene Glycol (PEG) 1500.
resulting populations by their ability to grow in the absence of uridine (to select for mitochondrial function) and 
in the presence of bromodeoxyuridine (BrdU,
 
63 
transmitochondrial cytoplasmic hybrids (Cybrids).
transmitochondrial cell lines. The mitochondrial donor 
+) and are able to synthesize uridylic acid (UR
- Rho0 cells, which are TK- and UR-. The cytoplasts are fused with Rho
 The transmitochondrial cells are then selected from the 
 to select against cell hybrids and donor cells).
 
 
+), are enucleated 
0
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2.2.6 Mitochondrial genome sequencing 
DNA from extracted samples was used to amplify the entire mitochondrial genome by PCR. 
Samples with a DNA concentration lower than 100ng/ul were amplified using two rounds of 
PCR, while samples with a DNA concentration equal to 100ng/ul or higher were amplified 
using a second round of PCR amplification. 
2.2.6.1 The first round PCR amplification 
This PCR was carried out using nine fragments of overlapping primer pairs (Table 2-1), which 
have an identical annealing temperature (60oC) to avoid any variation in PCR program. Primer 
sequences were based on the revised Cambridge Reference Sequence (rCRS) [252]. 
The PCR reactions were performed in total volume of 50µl, containing 2µl DNA as a 
template, 5µl of 10X dNTPs, 5µl of 10X PCR buffer, 2µl of 25mM MgCl2 solution, 1.5µl of 
20µM forward primer, 1.5µl of 20µM reverse primer, and 0.35 of AmpliTaq Gold DNA 
polymerase. PCR-graded dH2O was added to make a final reaction volume of 50µl.  
The PCR cycling conditions for the amplification included an initial denaturation at 95oC for 
10 minutes to activate the polymerase followed by 38 cycles at 94oC denaturation for 45 
seconds, 60oC primer annealing for 45 seconds, and 72oC primer extension for 2 minutes. 
Lastly, final extension at 72oC for 8 minutes was included. In all cases a positive control and a 
negative control (no DNA) were included. The first round PCR products were diluted 1/3 in 
sterile water prior to being used as DNA template for the second round PCR amplification. 
2.2.6.2 The second round PCR amplification  
Amplification was carried out using 36 overlapping pairs of primers with a similar annealing 
temperature (60oC). In addition, they were engineered to be tagged with universal M13-tails to 
facilitate sequencing of the PCR products (Table 2-2). The M13 forward primer sequence was 
5’-TGTAAAACGACGGCCAGT-3’ and the reverse primer M13-tag sequence was 5’-
CAGGAAACAGCTATGACC-3’. The PCR products from the first round PCR and other 
DNA samples for PCR were used as DNA templates for second round PCR.  
 
 
 
 
65 
 
Table 2-1 First round PCR primer sequences. 
 
 
Mitochondrial First Round Primer Sequences 
Fragment  Sequence Position 
A 
Forward 5’-GCTCACATCACCCCATAAAC-3’ 627 - 646 
Reverse 5’-GATTACTCCGGTCTGAACTC-3’ 3087 - 3068 
B 
Forward 5’-ACCAACAAGTCATTATTACCC-3’ 2395 - 2415 
Reverse 5’-TGAGGAAATACTTGATGGCAG-3’ 4653 - 4633 
C 
Forward 5’-CCGTCATCTACTCTACCATC-3’ 4489 - 4508 
Reverse 5’-GGACGGATCAGACGAAGAG-3’ 6468 - 6450 
D 
Forward 5’-AATACCCATCATAATCGGAGG-3’ 6113 - 6133 
Reverse 5’-GGTGATGAGGAATAGTGTAAG-3’ 8437 - 8417 
E 
Forward 5’-TCAATGCTCTGAAATCTGTGG –3’ 8167 - 8187 
Reverse 5’-TCGAAGCCGCACTCGTAAG-3’ 10103 - 10165 
F 
Forward 5’-ACTTCACGTCATTATTGGCTC-3’ 9821 - 9841 
Reverse 5’-ATAGGAGGAGAATGGGGGATAG-3’ 12101 - 12080 
G 
Forward 5’-ACTGTGCTAGTAACCACGTTC-3’ 11866 - 11887 
Reverse 5’-GGTAGAATCCGAGTATGTTGG-3’ 13924 - 13904 
H 
Forward 5’-TATTCGCAGGATTTCTCATTAC-3’ 13721 - 13742 
Reverse 5’-GTGCTAATGGTGGAGTTAAAG-3’ 15989 - 15969 
I 
Forward 5’-CCCATCCTCCATATATCCAAAC -3’ 15695 - 15680 
Reverse 5’-GGTTAGTATAGCTTAGTTAAAC-3’ 868 - 847 
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Table 2-2 Sequence of the second round PCR primers. 
Mitochondrial Second Round primer sequences 
Fragment   Sequence Base pairs 
1 
Forward  5`-TGTAAAACGACGGCCAGTTCACCCTCTAAATCACCAG-3` 721 - 740 
Reverse 5`-CAGGAAACAGCTATGACCGATGGCGGTATATAGGCTGAG-3` 1268 - 1248 
2 
Forward  5`-TGTAAAACGACGGCCAGTTTAAAACTCAAAGGACCTGGC-3` 1157 - 1177 
Reverse 5`-CAGGAAACAGCTATGACCCTGGTAGTAAGGTGGAGTGGG-3` 1709 - 1689 
3 
Forward  5`-TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG-3` 1650 - 1671 
Reverse 5`-CAGGAAACAGCTATGACCATTGGTGGCTGCTTTTAGG-3` 2193 - 2175 
4 
Forward  5`-TGTAAAACGACGGCCAGTACTGTTAGTCCAAAGAGGAAC-3` 2091 - 2111 
Reverse 5`-CAGGAAACAGCTATGACCTCGTGGAGCCATTCATACAG-3` 2644 - 2625 
5 
Forward  5`-TGTAAAACGACGGCCAGTCAGTGACACATGTTTAACGGC-3` 2549 - 2569 
Reverse 5`-CAGGAAACAGCTATGACCGATTACTCCGGTCTGAACTC-3` 3087 - 3068 
6 
Forward  5`-TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG-3` 3017 - 3036 
Reverse 5`-CAGGAAACAGCTATGACCGGAGGGGGGTTCATAGTAG-3` 3574 - 3556 
7 
Forward  5`-TGTAAAACGACGGCCAGTACCATCACCCTCTACATCAC-3` 3505 - 3524 
Reverse 5`-CAGGAAACAGCTATGACCAGAGTGCGTCATATGTTGTTC-3` 4057 - 4037 
8 
Forward  5`-TGTAAAACGACGGCCAGTTCGCCCTATTCTTCATAGCC-3` 3965 - 3984 
Reverse 5`-CAGGAAACAGCTATGACCGTTTATTTCTAGGCCTACTCAG-3` 4577 - 4556 
9 
Forward  5`-TGTAAAACGACGGCCAGTACACTCATCACAGCGCTAAG-3` 4518 - 4537 
Reverse 5`-CAGGAAACAGCTATGACCGATTTTGCGTAGCTGGGTTTG-3` 5003 - 4983 
10 
Forward  5`-TGTAAAACGACGGCCAGTCTCACTCTCTCAATCTTATCC-3` 4932 - 4952 
Reverse 5`-CAGGAAACAGCTATGACCTGTAGGAGTAGCGTGGTAAGG-3` 5481 - 5462 
11 
Forward  5`-TGTAAAACGACGGCCAGTACCTCAATCACACTACTCCC-3` 5367 - 5386 
Reverse 5`-CAGGAAACAGCTATGACCTAGTCAACGGTCGGCGAAC-3` 5924 - 5906 
12 
Forward  5`-TGTAAAACGACGGCCAGTAGATTTACAGTCCAATGCTTC-3` 5855 - 5875  
Reverse 5`-CAGGAAACAGCTATGACCATGGCAGGGGGTTTTATATTG-3` 6430 - 6410 
13 
Forward  5`-TGTAAAACGACGGCCAGTTAGCAGGTGTCTCCTCTATC-3` 6358 - 6377 
Reverse 5`-CAGGAAACAGCTATGACCAAGAAAGATGAATCCTAGGGC-3` 6944 - 6924 
14 
Forward  5`-TGTAAAACGACGGCCAGTATTTAGCTGACTCGCCACAC-3` 6863 - 6882 
Reverse 5`-CAGGAAACAGCTATGACCCATCCATATAGTCACTCCAGG-3` 7396 - 7376 
15 
Forward  5`-TGTAAAACGACGGCCAGTGGCTCATTCATTTCTCTAACAG-3` 7272 - 7293 
Reverse 5`-CAGGAAACAGCTATGACCGGCAGGATAGTTCAGACGG-3` 7791 - 7773 
16 
Forward  5`-TGTAAAACGACGGCCAGTTCCTAACACTCACAACAAAAC-3` 7713 - 7723 
Reverse 5`-CAGGAAACAGCTATGACCTACAGTGGGCTCTAGAGGG-3` 8301 - 8283 
17 
Forward  5`-TGTAAAACGACGGCCAGTACAGTTTCATGCCCATCGTC-3` 8196 - 8215 
Reverse 5`-CAGGAAACAGCTATGACCGTATAAGAGATCAGGTTCGTC-3` 8740 - 8720 
18 
Forward  5`-TGTAAAACGACGGCCAGTACCACCCAACAATGACTAATC-3` 8656 - 8676 
Reverse 5`-CAGGAAACAGCTATGACCGTTGTCGTGCAGGTAGAGG-3` 9201 - 9183 
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The bold sequence in each primer highlights the relevant M13-tag. 
Mitochondrial Second Round primer sequences 
Fragment   Sequence Base pairs 
19 
Forward  5`-TGTAAAACGACGGCCAGTATCCTAGAAATCGCTGTCGC-3` 9127 - 9146 
Reverse 5`-CAGGAAACAGCTATGACCATTAGACTATGGTGAGCTCAG-3` 9661 - 9641 
20 
Forward  5`-TGTAAAACGACGGCCAGTCATCCGTATTACTCGCATCAG-3` 9607 - 9627 
Reverse 5`-CAGGAAACAGCTATGACCTAGCCGTTGAGTTGTGGTAG-3` 10147 - 10128 
21 
Forward  5`-TGTAAAACGACGGCCAGTCAACACCCTCCTAGCCTTAC-3` 10085 -10104 
Reverse 5`-CAGGAAACAGCTATGACCAGGCACAATATTGGCTAAGAG-3` 10649 - 10629 
22 
Forward  5`-TGTAAAACGACGGCCAGTATCGCTCACACCTCATATCC-3` 10534 - 10553 
Reverse 5`-CAGGAAACAGCTATGACCATGATTAGTTCTGTGGCTGTG-3` 11109 - 11089 
23 
Forward  5`-TGTAAAACGACGGCCAGTTATCCAGTGAACCACTATCAC-3` 11010 - 11030 
Reverse 5`CAGGAAACAGCTATGACCTAGGTCTGTTTGTCGTAGGC-3` 11605 - 11586 
24 
Forward  5`-TGTAAAACGACGGCCAGTTCCTTGTACTATCCCTATGAG-3` 11541 - 11561 
Reverse 5`-CAGGAAACAGCTATGACCCGTGTGAATGAGGGTTTTATG-3` 12054 - 12034 
25 
Forward  5`-TGTAAAACGACGGCCAGTCTCCCTCTACATATTTACCAC-3` 11977 - 11997 
Reverse 5`-CAGGAAACAGCTATGACCGTGGCTCAGTGTCAGTTCG-3` 12545 - 12527 
26 
Forward  5`-TGTAAAACGACGGCCAGTCTCTTCCCCACAACAATATTC-3` 12478 - 12498 
Reverse 5`-CAGGAAACAGCTATGACCCTGATTTGCCTGCTGCTGC-3` 13009 - 12991 
27 
Forward  5`-TGTAAAACGACGGCCAGTGCCCTTCTAAACGCTAATCC-3` 12940 - 12959 
Reverse 5`-CAGGAAACAGCTATGACCGGGAGGTTGAAGTGAGAGG-3` 13453 - 13435 
28 
Forward  5`-TGTAAAACGACGGCCAGTCGGGTCCATCATCCACAAC-3` 13365 - 13383 
Reverse 5`-CAGGAAACAGCTATGACCGTTAGGTAGTTGAGGTCTAGG-3` 13859 - 13839 
29 
Forward  5`-TGTAAAACGACGGCCAGTACCTAAAACTCACAGCCCTC-3` 13790 - 13809 
Reverse 5`-CAGGAAACAGCTATGACCAGGATTGGTGCTGTGGGTG-3` 14374 - 14356 
30 
Forward  5`-TGTAAAACGACGGCCAGTATTAAAGTTTACCACAACCACC-3` 14317 - 14341 
Reverse 5`-CAGGAAACAGCTATGACCAAGGAGTGAGCCGAAGTTTC-3` 14857 - 14838 
31 
Forward  5`-TGTAAAACGACGGCCAGTATTCATCGACCTCCCCACC-3` 14797 - 14815 
Reverse 5`-CAGGAAACAGCTATGACCGGTTGTTTGATCCCGTTTCG-3` 15368 - 15349 
32 
Forward  5`-TGTAAAACGACGGCCAGTCATCTTGCCCTTCATTATTGC-3` 15295 - 15315 
Reverse 5`-CAGGAAACAGCTATGACCTACAAGGACAGGCCCATTTG-3` 15896 - 15877 
D1 
Forward  5`-TGTAAAACGACGGCCAGTATCGGAGGACAACCAGTAAG-3` 15758 - 15777 
Reverse 5`-CAGGAAACAGCTATGACCAGGGTGATAGACCTGTGATC-3` 019 - 001 
D2 
Forward  5`-TGTAAAACGACGGCCAGTCTCAACTATCACACATCAACTG-3` 16223 - 16244 
Reverse 5`CAGGAAACAGCTATGACCAGATACTGCGACATAGGGTG-3` 129 - 110 
D3 
Forward  5`-TGTAAAACGACGGCCAGTCCTTAAATAAGACATCACGATG-3` 16548 - 16569 
Reverse 5`-CAGGAAACAGCTATGACCCTGGTTAGGCTGGTGTTAGG-3` 389 - 370 
D4 
Forward  5`-TGTAAAACGACGGCCAGTGCCACAGCACTTAAACACATC-3` 323-343 
Reverse 5`-CAGGAAACAGCTATGACCTGCTGCGTGCTTGATGCTTG-3` 771 - 752 
68 
 
The PCR reactions were performed in total volume of 25µl containing 1µl DNA as template at 
~100ng/µl concentration, 2.5µl of 10X dNTPs, 2.5µl of 10X PCR buffer, 1µl of 20µM 
forward primer, 1µl of 20µM reverse primer, and 0.13µl of AmpliTaq Gold DNA polymerase. 
PCR-graded dH2O was added to make a final reaction volume of 25µl. 
PCR cycling conditions for the amplification included an initial denaturation at 95oC for 10 
minutes to activate the polymerase followed by 30 cycles at 94oC denaturation for 45 seconds, 
58oC primer annealing for 45 seconds, and 72oC primer extension for 1 minute. Lastly, 
amplification was allowed for final extension at 72oC for 8 minutes. In all cases a positive and 
negative control, which had no DNA, were included in the PCR amplification set up. 
2.2.7 Agarose gel electrophoresis 
Upon amplification, 5µl of PCR products were investigated by running samples on 1.5% 
agarose gels together with Hyperladder IV to confirm amplification and product size. The 
1.5% agarose gel was prepared by mixing 1.5g of agarose and 100ml of 1XTAE buffer 
containing 5µg/ml ethidium bromide; this was microwaved for around 2 minutes. Agarose 
was allowed to cool to 60oC, poured into a sealed casting tray into which well-forming combs 
were inserted. 1XTAE buffer was added to the tank then 5µl of PCR product and 5µl of 
Hyperladder IV were individually mixed with 0.5-1µl of 10X loading buffer and loaded into 
the wells. Gels were electrophoresed at 65-80 Volts, depending on the tank size to allow 
separation of PCR products. Gels were subsequently examined under a UV light source to 
visualize bands.  
2.2.8 Cycle sequencing 
In the cycle sequence stage, 5µl of PCR products were added to the wells of a 96 well-plate 
and a 2µl of ExoSAP-IT were added while the plate was kept on ice. The plate was covered 
with a rubber mat, briefly mixed and pulse spun. The plate was incubated in the thermal cycler 
for 15 minutes at 37oC followed by 80oC for 15 minutes. The ExoSAP-IT enzyme functions to 
remove free dNTPs and any non-specific products such as single stranded DNA molecules to 
give pure double-stranded PCR products. 
To cycle sequence, the following volumes of reagents were added to each sample: 7µl of 
water, 3µl of 5X sequencing buffer, 1µl of the universal forward primer, and 2µl of Big-Dye 
v3.1. Then samples were cycle sequenced on the thermal cycler with initial denaturation at 
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96oC for 1 minute followed by 25 cycles at 96oC for 10 seconds denaturation, 50oC for 5 
seconds annealing, 60oC for 4 minutes extension. Finally, samples were precipitated prior to 
sequencing on an ABI 3130xI genetic analyser. 
To precipitate PCR products, 2µl of 125mM EDTA, 2µl of 3M sodium acetate, and 50µl of 
100% Ethanol were added to each of the cycle sequenced samples in the 96-well plate. The 
plate was capped, inverted 4 times to mix the samples and incubated at room temperature for 
15 minutes. The plate was centrifuged at 2090g for 30 minutes and supernatants were 
removed by inverting the plate onto a pad of white paper towels and pulse spun at 100g. Then 
70µl of 70% Ethanol were added to the samples, the plate was spun down at 1650g for 15 
minutes and supernatants were removed as previous described. The plate was left to air dry at 
room temperature for 15-20 minutes before adding 10µl of HiDi. Finally, before loading the 
plate into the machine, the plate was covered and heated to 95oC for 2 minutes in a 9700 PCR 
block. 
2.2.9 Sequence analysis 
Sequenced samples were analyzed using Applied Biosystems SeqScape analysis software. The 
recorded changes were compared to two, web-based human mtDNA sequence databases [69, 
252] to see if they were neutral, recurrent or novel changes. 
2.2.10 Restriction fragment length polymorphism (RFLP) analysis 
Putative pathogenic mtDNA mutations in tissues and/or cells from patients were further 
investigated to quantify the relative proportion of the wild-type and mutant mtDNA by RFLP 
as described in [315-318]. 
PCR reactions were performed as previously described (section 2.2.5.2). The PCR reaction 
contained 1µl DNA, 5µl 10X PCR buffer, 5µl dNTPs, 1.5µl forward primer, 1.5µl reverse 
primer, 0.35µl Taq DNA polymerase, and d.H2O to make a final volume of 50µl. Samples 
were incubated in the thermal cycler and PCR products were electrophoresed on 1.5% agarose 
gel to confirm amplification and product size. 
Subsequently, PCR products were subjected to an additional (last hot) PCR cycle consisting of  
95oC denaturation, 2 minutes annealing at 58oC and extension for 8 minutes at 72oC, 
following the addition of 0.25µl of α-32P-dCTP, 1µl of forward primer, 1µl of reverse primer 
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and 0.25ul of Taq polymerase to the reactions. Labelled samples were precipitated in 50µl 
dH2O, 2µl pellet paint, 50µl ammonium acetate, and 200µl absolute ethanol. Samples were 
then left for 1 hour at room temperature followed by centrifugation at 13000 rpm for 10 
minutes. Supernatants were removed and the pellets were washed with 100µl of 70% ethanol. 
Samples were then centrifuged again for 10 minutes at full speed, supernatants aspirated and 
pellets were allowed to air-dry for 10 minutes. 
Radioactivity in each sample was measured using a Cerenkov counter. Pellets were 
resuspended in dH2O to give a final concentration of 1000 counts per 17µl. For digestion, 
17µl of radiolabelled PCR product, 1µl of restriction endonuclease, and 2µl of enzyme-
specific buffer were mixed and incubated overnight at the optimal working temperature for 
each enzyme. An uncut sample (no digestion enzyme) and a control sample were always 
included. Finally, 20µl of product were mixed with 3µl of 10X loading dye and loaded onto 
12% Polyacrylamide gel electrophoresis. 
2.2.11 Polyacrylamide gel electrophoresis 
12% polyacrylamide gels were prepared by mixing 12ml of 40% acrylamide 
(29:1bisacrylamide), 4ml of 10XTBE, 24ml of water, 75µl of 25% ammonium persulfate 
(APS), and 75µl of N,N,N`,N`-tetramethylenediamine (TEMED). Gels were then poured into 
a vertical gel cast with a comb to form wells and allowed to polymerize at room temperature. 
Then 1X TBE buffer was added into the tank and 20µl of digested PCR product mixed with 
3µl of 10X loading buffer, were loaded into wells. Gels were electrophoresed at 100V for the 
first hour and then the voltage was turned up to 150V. Samples were allowed to separate 
further for approximately 5-6 hours. Gels were transferred onto a Whatman paper, covered 
with saran wrap and allowed to dry for 1-2 hours at 65oC in a gel dryer. Dried gels were 
exposed to a PhosphorImager screen overnight and the following day gels were scanned using 
a Storm scanner. Radioactivity in each band was quantified using ImageQuant software. 
2.2.12 Long-range PCR  
An expanded long-range PCR system was used to investigate possible mtDNA deletions in 
patient samples. Muscle DNA was screened for mtDNA rearrangements by 10 or 11 kb long-
range PCR assays. The PCR reaction, with a total volume of 50µl, contained 0.5µl of 
100ng/µl DNA, 10µl of 1x reaction buffer, 2.5µl of 10mM dNTPs-Mix, 1.5µl of 20pmol of 
each primer, 1.5µl of 100% DMSO, 0.7µl of the enzyme mix (5U/µl) and 31.3µl of dH2O. 
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The PCR conditions for the amplification included initial denaturation at 92oC for 2 minutes 
to activate the polymerase followed by 10 cycles of denaturation at 92oC for 10 seconds, 
annealing at 58oC for 15 seconds, and a 68oC primer extension for 11 minutes, followed by 15 
cycles at 92oC for 10 seconds, 25 cycles at 58oC for 15 seconds, and 68oC for 11 minutes plus 
5 seconds/cycle. A final extension step of 68oC for 7 minutes followed.  
5µl of PCR product were mixed with 2µl of 10x loading buffer and loaded onto a 0.7% 
agarose gel, alongside 5µl of Hyperladder IV. The gel was electrophoresed at 65-80Volts and 
PCR products were visualized under UV light. 
2.2.13 Real time PCR 
To quantify the possibility of both mtDNA rearrangements and depletion in patients, a real 
time PCR assay was used. The PCR primers for ND1 were the forward  
primer L3485–3504 (5`-CCCTAAAACCCGCCACATCT-3`) and the reverse primer H3532–
3553 (5`-GAGCGATGGTGAGAGCTAAGGT-3`). The PCR primers for ND4 were the 
forward primer L12087–12109 (5`-CCATTCTCCTCCTATCCCTCAAC-3`) and the primer 
H12140–12170 (5`-GTGTTAGACTACAAAACCAATTTGATATAAA-3`). The fluorogenic 
probes were for ND1 L3506–3529 (5`-CCATCACCCTCTACATCACCGCCC-3`) and for 
ND4 L12111–12138 (5`-CCGACATCATTACCGGGTTTTCCTCTTG). The PCR reaction 
contained: 5µl of cell lysate from a single muscle fibre, 12.5µl of TaqMan Universal PCR 
Master Mix, 0.5µl of both ND1 and ND4 probes (100nM), 0.75µl of both forward and reverse 
ND1 and ND4 primers (300nM) and 7.5µl of dH2O. The PCR amplification conditions were: 
2 minutes at 50°C, 10 minutes at 95°C, 40 cycles of 15 seconds at 95°C, and 1 minute at 60°C 
for probe/primer hybridisation and DNA synthesis. 
2.2.14 Measurement of activity of respiratory chain complexes 
2.2.14.1 Preparation of mitochondrial fractions from cultured cells 
Mitochondrial fractions were prepared from confluent cultured fibroblast cells. Cells were 
harvested as previously described (section 2.2.4.2), except pellets were resuspended in 1ml of 
Buffer B (120mM KCl, 20mM HEPES, 5mM MgCl2, 1mM EGTA, 5mg/ml BSA). Cells were 
transferred to a glass homogeniser and disrupted with 20 strokes of a motor-driven, Teflon 
plunger on ice. Homogenates were transferred to a new 1.5 eppendorf tube, centrifuged for 10 
minutes at 600g, and supernatants were kept on ice in 1.5ml tube. Pellets were resuspended in 
0.8ml of buffer B, homogenised again and centrifuged for 10 min at 600g. Supernatants from 
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this step were added to the retained supernatants and combined samples were centrifuged for 
20 minutes at 20,000g. Supernatants were removed, while the resulting pellets containing 
mitochondria were resuspended in an appropriate volume of buffer B (~ 80µl) according to 
the pellet size, prior to being stored at -80oC until use. 
Measurement of the activities of repiratory chain complexes were carried out in triplicate, at at 
30oC and final volume of 1ml, using a Varian Cary 300 Bio spectrophotometer with 
temperature controller and WinUV software. The mitochondrial fractions of pig heart were 
used as standard control. All mitochondrial fractions were washed prior to use and diluted 1:5 
in a hypotonic buffer, containing 25mM potassium phosphate, 5mM magnesium chloride, pH 
7.2, followed by rapid freezing in liquid nitrogen and thawing at 30oC. Measurement of 
complexes I and II and citrate synthase from mitochondrial fractions were performed 
individually as described in [235, 319, 320]. 
2.2.14.2 Complex I (NADH: ubiquinone oxidoreductase) activity 
The specific activity of complex I was measured by following the decrease in absorbance due 
to the oxidation of NADH at 340nm with 425nm as the reference wavelength. 978.5µl of 
complex I buffer (hypotonic buffer plus 2.5mg/ml of albumin bovine serum (BSA) and 1M 
KCN), 10µl of 9mg/ml NADH, 2.5µl of 65µM of ubiquinone-1, and 2µl of 1mg/ml of 
antimycin A were mixed in each cuvette and the absorbance change was recorded for about 20 
seconds to ensure that the baseline was stable. Then 5µl of mitochondrial dilution were added 
and the NADH: ubiqunione oxidoreductase activity was measured for 5 minutes. 2µl of 
2µg/ml of rotenone were added and the activity was measured for an additional 4 minutes. 
Complex I activity is the rotenone-sensitive NADH:ubiqunione oxidoreductase activity.  
2.2.14.3 Complex II (Succinate: ubiquinone oxidoreductase) activity 
The specific activity of complex II was measured by following the reduction of 2, 6-
dichlorophenol-indophenol (DCPIP), which was used as an artificial acceptor, at 600nm. 
5µl of diluted mitochondria, 958.5µl of complex II buffer (complex I buffer but without 
BSA), and 2µl of 1M sodium succinate were preincubated for10 minutes at 30oC prior to use. 
Then 10µl of 5mM DCPIP, 2µl of antimycin A, and 2µl of rotenone were added to the 
previous mix and the baseline rate was recorded for 10 seconds. The reaction was started by 
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adding 2.5µl of ubiqunione1 and the enzyme-catalysed reduction of DCPIP was measured for 
4 minutes. 
2.2.14.4 Citrate synthase activity 
The activity of citrate synthase was assayed by measuring the rate of production of coenzyme 
A (CoA.SH) from oxaloacetate by measuring free sulfhydryl groups using the thiol reagent 
5,5`-dithio-bis-(2-nitobenzoyic acid) (DTNB) which reacts with sulfhydryl groups to produce 
free 5-thio-2-nitrobenzoate anions with yellow colour that can be detected at 412nm. 
967µl of citrate synthase buffer (0.1M Tris-HCl, pH8.0), 3µl of 5mM acetyl Coenzyme, 10µl 
of 10mM DTNB, 10ul of 10% Triton X-100, and 5µl of mitochondrial dilution were mixed in 
a cuvette then the baseline rate was recorded for 20 second. The reaction was started by 
adding 5µl of 50mM oxaloacetate and the activity was recorded for at least 2 minutes. 
Citrate synthase is the most commonly used mitochondrial matrix marker enzyme for the 
integrity of the mitochondria and all activities are referenced to citrate synthase activity [235]. 
2.2.15 Histological and histochemical analysis 
2.2.15.1 Haematoxylin and Eosin (H&E) staining  
Muscle sections were cut from muscle biopsies frozen at -80oC using a cryostat. For 
Haematoxylin and Eosin staining, muscle sections were cut at 12μM onto glass microscope 
slides and allowed to air dry for an hour. Slides were fixed in formal calcium solution for 15 
minutes and washed in tap water until the water ran clear. Sections were immersed for 1 
minute in Meyer’s Haematoxylin solution (1% (w/v) Haematoxylin, 50% (w/v) Potassium 
Alum, 0.2% (w/v) Sodium Iodate, 1% (w/v) Citric Acid, and 50% (w/v) Chloral Hydrate). 
Sections were washed in water for 1 minute. Then sections were immersed for 30 seconds in 
Eosin solution (1% Eosin, 0.4% (w/v) Erythrosin B and 0.2% (w/v) Phloxin B) and washed in 
water for 1minute. Stained sections were dehydrated in a graded ethanol series (70%, 95%, 
2x100%), and immersed in absolute ethanol for 10 minutes. Finally, sections were mounted in 
DPX with a glass coverslip and stored at room temperature. 
2.2.15.2 Cytochrome c oxidase & succinate dehydrogenase staining 
To investigate cytochrome c oxidase (COX) activity, sections were cut at 12µm onto 
polyethylenenaphthalate (PEN) membrane slides and allowed to air dry for 1 hour prior to 
74 
 
being stained. For COX staining, sections were incubated for 45 minutes at 37oC in COX 
media (4mM diaminobenzidine Tetrahydrochloride (DAB), 100mM cytochrome c, and 
20µg/ml catalase in 0.1M phosphate buffer, pH7.0). Subsequently, sections were rinsed twice 
in PBS and dried using tissue paper. Finally, sections were dehydrated in a graded ethanol 
series and allowed to dry. Slides were stored at -20oC in sealed slide mailers until used. 
For succinate dehydrogenase (SDH) activity, sections were cut as previously described onto 
glass microscope slides and allowed to air dry for 1 hour. For staining, slides were incubated 
for 45 minutes at 37oC in SDH media (1.5mM Nitro Blue Tetrazolium (NBT), 130mM 
sodium succinate, 0.2mM phenazine methoslphate (PMS), and 0.1mM sodium azide in 0.1M 
phosphate buffer, pH7.0). Slides were then rinsed twice in PBS, dehydrated as above, and then 
immersed in absolute ethanol for 10 minutes to remove purple monoformazan reaction 
product of the SDH reaction. Eventually, sections were dehydrated in a graded ethanol series 
to dry, and stored at room temperature. 
2.2.16 Immunohistochemisry 
To investigate protein localization and expression patient tissues, X-Cell-Plus HRP Detection 
kit and Liquid Stable DAB kit were used. Sections from muscle biopsies were cut at 12µM 
onto glass microscope slides and allowed to air dry for 1 hour prior to staining. Sections were 
fixed in 4% Paraformaldehyde in 0.1M for 10 minutes, washed in dH2O in a fume hood and 
washed in TBS containing 0.1% Tween 20 for 10 minutes. Sections were then permeablised 
and endogenous peroxidise activity was inhibited by immersion in  a graded methanol series 
(10% for 10 minutes, 95% + 0.3% H2O2 for 10 minutes, absolute methanol for 20 minutes, 
95% + 0.3% H2O2 for 10 minutes, 10%  for 10 minutes and TBST for 5 minutes). Diluted 
primary antibodies in TBST were then applied to sections for an hour at room temperature. 
Sections were washed twice with TBS for 5 minutes and once with TBST for 5 minutes. 
Sections were overlaid with the universal probe for 30 minutes and followed by 2X wash for 5 
minutes with TBS and once with TBST for 5 minutes. The HRP polymer was applied to 
sections and followed with 3X wash with TBS for 5 minutes. After drying the sections, DAB 
was applied and sections were left at room temperature until a brownish colour appeared. 
Sections were washed, immersed for 1 minute in Haematoxylin solution and washed in dH2O. 
A graded ethanol series (70%, 95%, and 100%) was used to dehydrate the sections before 
immersing them in Histoclear. Finally, sections were mounted in DPX with a glass coverslip 
and stored at room temperature. 
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2.2.17 Bradford assay 
This assay was used to quantify protein in whole cell lysates. Two sets of measurements at a 
final volume of 800µl were made. The first mix contained 1µl of cell lysis, 200µl of Bradford 
reagent and 799µl of d.H2O. The second mix contained 5µl of the same sample, 200µl of 
Bradford reagent, and 795µl of dH2O. To create a standard curve, different concentration of 
bovine serum albumin (0µg, 2µg, 5µg, 10µg, 15µg, 20µg) were also prepared. The samples 
were then loaded in an optical bottom 96-well plate which was loaded into an automated plate 
reader. Finally, the generated standard curve report was used to calculate protein 
concentrations. 
2.2.18 Western blotting assay 
2.2.18.1 Sample preparation 
To prepare samples, cultured fibroblasts were allowed to reach confluence before being 
harvested with trypsin as described (section 2.2.4.2). After the last wash with 1xPBS, 100µl of 
cell lysis buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 2mM MgCl2), 28µl of proteinase 
inhibitor and 2µl of Nonidet P-40 were added to the pellets (from75cm2 flasks). Samples were 
then vortexed for 30 seconds and centrifuged at 562g for 3 minutes at 4oC. Supernatant were 
moved to new 1.5ml eppendorf tubes and equal volumes of buffer containing 10mM Tris-HCl 
were added. Finally, samples were mixed and quantified by Bradford assay or frozen at -80oC 
until use. 
2.2.18.2 Gel preparation 
Gels were prepared using a minigel system (Mighty Small II SE250) and were cast in gel 
caster. Prior to pouring the gels, leakage was checked with water. The separating gels (3.75ml 
30% acrylamide, 2.81ml 1M Separating buffer, 0.82ml dH2O, 37.5µl 20% SDS,75µl 10% 
AMPS and 7.5µl TEMED) were poured first, overlaid with dH2O-butanol to give a flat gel 
and allowed to polymerise for 30 minutes. Gels were washed with dH2O to remove the d.H2O-
butanol before pouring the stacking gels (0.67ml 30% acrylamide, 0.25ml 0.5M stacking 
buffer, 4.05ml dH2O, 25µl 20% SDS,25µl 10% AMPS and5µl TEMED). Combs were 
inserted and the gels were left to polymerise for 15 minutes. 
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2.2.18.3 Western blot electrophoresis 
After protein quantification, 10-25 µg/µl of protein and 5µl of sample buffer containing 2% β-
mercaptoethanol were mixed. Lysis buffer was added to a final volume of 10µl. In addition, 
5µl of sample buffer were added to 5µl of Kaleidoscope prestained standard. Samples were 
denatured at 90oC for 10 minutes in a heat block and were pulse spun prior to loading. 
Wells were washed with running buffer before loading the samples. Gels were run at 75V 
(17mA) for ~ 15 minutes and then the voltage was increased to 150V once the dye front 
entered the separating gel. Electrophoresis was stopped when the dye ran off the bottom of the 
gel. 
2.2.18.4 Protein transfer 
For protein transfer, the blotting sandwich was set up as follows: black side of the cassette, a 
wet pad, 2x filter papers, the flipped gel, PDVF membrane, 2x filter papers, wet pad and the 
white side of the cassette. To avoid bubbles between gel and membrane, a glass roller was 
used to roll over the membrane. Protein transfer was carried out using a Hoefer TE series 
electrophoresis unit. The assembled cassette was placed into the transfer tank with the black 
side adjacent to the negative electrode. The transfer tank was filled with a cold transfer buffer 
containing (25mM Trizma base, 192mM Glycine, 0.02% SDS, and 15% methanol). The 
transfer was performed at 4ºC by electrophoresis at 65V (300mA) for 3 hours with continual 
stirring. 
2.2.18.5 Membrane immunoblotting 
Non-specific binding was blocked by incubating the membrane in 5% milk in TTBS (20 mM 
Trizma base, 136mM NaCl, pH7.6 and 0.1% Tween 20) for at least one hour at room 
temperature or overnight at 4ºC on a shaking platform. The membrane was incubated with the 
primary antibodies for 90 minutes at 4ºC on a shaking platform. The membrane was then 
washed with TTBS twice for 5 minutes and once for 10 minutes on the shaker at room 
temperature to remove excess primary antibody. The membrane was incubated with the 
secondary antibody for 90 minutes as previously described. Eventually, the membrane was 
washed in TTBS on the shaking platform twice for 5 minutes and once for 15 minutes. 
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2.2.18.6 Signal detection 
To visualise bands, an ECL Plus Western blotting Detection kit was used. The membrane was 
incubated with 500µl of reagent A and 12.5µl of reagent B for 5-10 minutes. To visualize the 
fluorescent signals, a Storm 860 PhosphorImager and ImageQuant software were used. 
2.2.19 First dimension blue native-PAGE assay 
2.2.19.1 Crude mitochondrial purification  
Fibroblasts were cultured until they reached confluence and were then washed twice with 
1XPBS at room temperature to remove all traces of serum from the culture media. Cells were 
harvested as described (section 2.2.4.2) by using 1ml of trypsin for < 3 minutes at 37oC and 
then 9ml of serum containing culture medium were added to inhibit trypsin. Cells were then 
centrifuged at 1200rpm for 3 minutes at room temperature and pellets were washed twice with 
cold 1XPBS. The recovered pellets were resuspended in 100µl of cold 1XPBS. Cell 
suspensions were transferred to new 1.5ml eppendorf tubes on ice and 100µl of (8mg/ml in 
cold PBS) digitonin were added. Cell suspensions were vortexed, incubated for 10 minutes on 
ice and centrifuged for 10 minutes at 10,000g at 4oC. Supernatants were aspirated and 
mitochondrial pellets were washed twice in cold 1XPBS and centrifuged as previously 
described. After the last wash, supernatants were aspirated and mitochondrial pellets were 
snap frozen in liquid nitrogen to limit the effect of ice crystals prior to being stored at -80oC. 
2.2.19.2 Solubilising mitochondria proteins 
Mitochondrial pellets were solubilised by vigorously pipetting up and down in 100µl of 
AC/BT Buffer (2M aminocaprioc acid and 50mM Bis-Tris/HCl adjusted to pH7.0 with HCl) 
and 20µl of 10% detergent dodecylmaltoside (10% w/v in dH2O) on ice. Samples were then 
vortexed and incubated on ice for 5-10minutes. Lastly, they were centrifuged at 20,000g for 
20 minutes at 4oC and supernatants were transferred to new 1.5ml eppendorf tubes on ice. 
A small volume of the supernatants was taken to quantify the mitochondrial proteins by 
Bradford assay. 10µl of blue native sample buffer (750mM aminocaprioc acid, 50mM Bis-
Tris/HCl, pH7.0, 0.5mM EDTA and 5% Coomassie Blue) were added to the mitochondrial 
suspensions on ice and samples were loaded onto the blue native gels as soon as possible. 
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2.2.19.3 BN-PAGE gradient polyacrylamide gel preparation  
A minigel system (Mighty Small II SE250) was used to carry out the blue native page 
electrophoresis. The gel sandwich was assembled and placed on the manual casting stand. 
Prior to pouring gels, leakage was checked using water. The gradient casting set-up (gradient 
mixer, peristaltic pump, and gel casting stand) was assembled and the gradient mixer outflow 
tubing was inserted between the glass plates. 
The separating (5% & 12%) gel solutions and stacking (4%) gel solution were prepared at 4oC 
to slow down polymerisation (Table 2-3).  
Table 2-3 Summary of BN-PAGE gel preparation. 
 
Before pouring the 5% separating gel solution in compartment A and the 12% solution in 
compartment B of the gradient mixer, the connection valve between them was closed, 
Continual stirring was applied to compartment B, at low speed to avoid air-bubble formation, 
which can affect gel polymerisation. The 12% gel solution was released first from the gradient 
mixer, with the peristaltic pump’s speed set at 10ml/min and the switch set to 4 for 20 
seconds. The connection valve between compartments A and B was then opened to allow the 
Components 4% Stacking Gel 5% Separation Gel 12% Separation Gel 
 40% Acryl: bis 
(29:1) 
0.50 ml 0.44 ml 1.05 ml 
Gel Buffer 1.67 ml 1.16 ml 1.16 ml 
Glycerol - - 0.55 ml 
dH2O 2.83 ml 1.9 ml 0.74 ml 
Volume 5 ml 3.5 ml 3.5 ml 
10% APS 55µl   21µl 21µl 
TEMED 5.5µl 2.1µl 2.1µl 
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5% gel solution to mix with the remaining 12% solution and the flow rate was set to 1ml/min 
and the switch to 8 until both compartments were empty. Gels were then overlaid with dH2O-
Butanol and allowed to polymerise at room temperature. After polymerisation, the dH2O-
Butanol was washed with dH2O and then the 4% stacking gels were poured. Combs were 
inserted and the gels were allowed to polymerise at room temperature.2.2.19.4 BN-PAGE 
electrophoresis 
After gel casting and prior to loading the samples, the comb was removed and wells were 
washed with cathode Buffer A. 10µl of sample buffer was added to 50µg of protein on ice and 
samples were loaded into the wells as soon as possible. Anode Buffer (50mM Bis-Tris; 
pH7.0) was added to at positive electrode and cathode Buffer A (15mM Bis-Tris, 50mM 
Tricine, 0.02% Serva Blue G-250; pH7.0) to the negative electrode. Gels were run at 30V for 
30 minutes until the samples started to enter the stacking gel, then the voltage was increased to 
80V for 90 minutes. The cathode Buffer A was changed to cathode Buffer B (15mM Bis-Tris, 
50mM Tricine, pH7.0) once the dye front had progressed to half or two-thirds of the way 
through the separating gel. Gels were left to run at 80V for >60 minutes until the dye front ran 
off the end of the gel. 
2.2.19.5 In gel enzyme activity assay 
BN-PAGE gels were incubated for one hour at room temperature with complex I activity 
detecting solution containing 2mM Tris-HCL, pH7.4, 0.1mg/ml NADH and 2.5mg/ml 
nitrotetrazolium blue (NTB). Gels were then washed with dH2O and scanned using EPSON 
Expression 1680 pro scanner and EPSON scan software. 
2.2.19.5 Western blot of BN-PAGE 
For protein transfer, gels were covered with a dissociation solution (1% of SDS and 1% β-
mercaptoethanol) in a fume hood for one hour at room temperature and then excess solution 
was removed by washing with dH2O. The blotting sandwich was assembled as follows: black 
side of the cassette, a wet pad, 2X filter papers, the gel, PDVF membrane, 2X filter papers, 
wet pad, and the white side of the cassette. To avoid bubbles between the gel and membrane, a 
glass roller was used to roll over the membrane. Protein transfer was carried out using a 
Hoefer TE series electrophoresis unit. The assembled cassette was placed into the transfer 
tank with the black side adjacent to the negative electrode. The transfer tank was filled with 
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blotting Buffer (25mM Bis-Tris, 192mM glycine, 20% methanol, 0.02% SDS pH8.2) and 
transfer was performed at 4ºC by electrophoresis at 100V for 1 hour with continual stirring. 
2.2.19.5.1 Membrane immunoblotting of BN-PAGE 
Non-specific binding was blocked by incubating the membrane in 5% milk in TTBS (20mM 
Trizma base, 136mM NaCl, pH7.6, 0.1% Tween 20) for at least an hour at room temperature 
or overnight at 4ºC on a shaking platform. The membrane was then incubated with the primary 
antibody for 90 minutes at 4ºC on a shaking platform. Later, the membrane was washed with 
TTBS twice for 5 minutes and once for 10 minutes on the shaker at room temperature to 
remove excess primary antibody. The membrane was then incubated with the secondary 
antibody for 90 minutes on a shaking platform at room temperature. Eventually, the membrane 
was washed twice with TTBS on the shaking platform for 5 minutes and once for 15 minutes. 
2.2.19.5.2 Signal detection of BN-PAGE gel 
For signal detection, an ECL Plus Western Blotting Detection kit was used. The membrane 
was incubated with 500µl of reagent A and 12.5µl of reagent B for 5-10 minutes. To visualize 
the fluorescent signals a Storm 860 PhosphorImager and ImageQuant software were used. 
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Chapter 3 : An Investigation into the role of complex I mtDNA 
mutations in mitochondrial disease  
3.1 Introduction  
Mitochondria are the main site for energy production in the form of ATP generation by 
oxidative phosphorylation. This task is achieved by five multi-protein complexes embedded in 
the inner mitochondrial membrane. OXPHOS disorders are the most frequent causes of 
metabolic diseases in paediatric neurology [321] with an incidence of 1:5000 live births [231, 
322]. They are heterogeneous and range from fatal encephalomyopathies of early childhood to 
severe diseases of adulthood [323]. They can affect different organs, tissues, or be 
multisystemic, however, tissues which require more energy such as the brain, heart, and 
skeletal muscles are more likely to be affected [82]. The OXPHOS system contains ~ 85 
proteins, the majority of them are encoded by nuclear DNA; the remaining 13 proteins are 
encoded by the mitochondrial genome. OXPHOS diseases are therefore associated with a 
variety of different clinical phenotypes [324]. Such disorders can affect mitochondrial 
membrane potential, ATP synthesis, ROS production, and calcium homeostasis [324]. 
Complex I is the largest and least understood of the respiratory chain complexes, as described 
earlier in chapter 1. Mitochondrial energy metabolism disorders due to deficiencies in 
complex I are the most frequently seen cases. Only ~20% of those disorders seen in children 
are due to mutations in the mtDNA suggesting that the majority of such disorders are due to 
mutations in nuclear genes [324, 325]. Most of the clinical phenotypes due to mutations in the 
nuclear subunits of complex I occur in infancy and early childhood, whereas, clinical 
phenotypes due to mutations in the mitochondrial subunits present between both childhood 
and adulthood [82]. 
Mitochondrial DNA mutations causing isolated complex I disease have been reported in all of 
the seven subunits of complex I [323]. Mutations in the ND1 subunit have been associated 
with encephalopathy [326], MELAS [327], and sudden infant death [328]. Mutations in the 
ND2 subunit have been linked to encephalomyopathy [329], Leigh syndrome [330], and 
LHON [331]. Mutations in the ND3 subunit resulted in LHON [332] and Leigh syndrome 
[333]. Mutations in the ND4 subunit have been linked to MELAS [334] and LHON [335]. 
Several diseases have been linked to mutations in the ND5 subunits such as LHON [336], 
MELAS [337], optic neuropathy/retinopathy [338-340], MELAS/Leigh disease [339], ataxia, 
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and PEO [341]. Finally, mutations in the ND6 subunit result in LHON [342], MELAS [343], 
Leigh disease [341], and myopathy [344]. Interestingly, mutations in the mt-tRNALeu(UUR) (the 
m.3302A>G) [212, 345] and the mt-m.3243A>G [346] also caused isolated complex I defects. 
In addition, defects in one or more of complex I subunits may give rise to defects or instability 
of its assembly suggesting that integrity of this complex is essential for its function. Several 
patients have been reported with mutations in the mitochondrial genome or  the nuclear 
genome had a defect in complex I assembly (Table 3-1). At least half of all observed cases of 
complex I deficiency are caused by defects in the assembly of the complex [82]. Mutations in 
complex I assembly chaperones reduce both the activity of complex I and the assembly of the 
holoenzyme [72]. A mutation in complex I intermediate associated protein (CIA30), termed 
NDUFAF1, caused a cardioencephalomyopathy, reduced levels and activity of complex I [89, 
91]. Also, a mutation in the complex I assembly chaperone B17.2L caused progressive 
encephalopathy and reduced complex I assembly [89, 347]. Recently, a mutation in the 
chromosome 6 open reading frame 66 gene (C6ORF66) caused infantile mitochondrial 
encephalomyopathy, antenatal cardiomyopathy, and reduced assembly of complex I [325]. 
Furthermore, a defect in the apoptosis-inducing factor (AIF) reduced both complex I 
enzymatic activity and assembly [348-350]. Lastly, mutations in other genes that interact with 
the complex I assembly chaperones resulted in complex I assembly defects. For example, the 
evolutionarily conserved signaling intermediate in Toll pathways protein (Ecsit), which is 
essential for the inflammatory response and embryonic development [351, 352] impaired 
complex I assembly and disturbed mitochondrial function [353].  
As mentioned previously in Chapter 1, mitochondrial complex I is the first step in the electron 
transport oxidizing NADH to NAD+ and transferring electrons to coenzyme Q10. During 
glycolysis, pyruvate is produced from glucose in the cytoplasm of the cell. Pyrvate can be 
converted into lactate by lactate dehydrogenase (LDH), under anaerobic conditions or 
transported into the mitochondria and converted into acetyl-coenzyme A (CoA) by the 
pyruvate dehydrogenase (PDH) complex. The PDH complex is regulated by two enzymes: 
pyruvate dehydrogenase phosphatase and pyruvate dehydrogenase kinase in addition to the 
ratio of both NADH/NAD+ and acetyl-CoA/CoA. Increases in these ratios inhibit the PDH 
complex. Acetyl-CoA and fatty acids are oxidized in the citric acid cycle, producing NADH 
and FADH2. Complex I oxidizes NADH to NAD+ and complex II oxidizes FADH2 which 
together initiate the electron transport chain (Figure 3-1). A defect in complex I or other 
84 
 
OXPHOS complexes results in a disturbed oxidation ratio of NADH to NAD+ leading to 
mitochondrial disease [70]. In addition, the NADH to NAD+ ratio and concentrations have 
been shown to regulate the production of ROS in studies from isolated mitochondria [62, 
354], which can explain the involvement of ROS production in some OXPHOS disorders.  
Table 3-1 List of mutations in patients reported to affect complex I assembly. 
Human Gene References 
mtDNA  
MTND1 [316, 355] 
MTND2 [330] 
MTND3 [242, 333] 
MTND4 [356, 357] 
MTND5 [315, 358] 
MTND6 [359, 360] 
Nuclear  
NDUFA1 [361] 
NDUFS1 [362, 363] 
NDUFS2 [364] 
NDUFS4 [365, 366] 
NDUFS6 [367] 
NDUFS7 [368] 
NDUFS8 [369, 370] 
NDUFV1 [347, 362] 
Assembly proteins 
 
NDUFAF1 [91] 
NDUFA12L [347] 
C6orf66 [325] 
C20orf7 [371] 
C3orf60 [372] 
 (Taken and modified from [72]). 
 Figure 3-1 Schematic representation of ATP synthesis through the oxidation of pyruvate.
In the cytoplasm of the cell, pyruvate is produced from glucose and either converted into lactate by lactate 
dehydrogenase (LDH). Alternatively, pyruvate is transported into the mitochondria and converted into acetyl
coenzyme A by the pyruvate dehydrogenase (PDH2)
pyruvate dehydrogenase kinase, and NADH/NAD
acid cycle, initiate the electron transport chain by binding to complex I and II respectively to produ
coenzyme A, OMM: outer mitochondrial membrane, and IMM: inner mitochondrial membrane
complex II, III: complex III, IV: complex IV, and V: complex V
3.2 Aims  
This chapter will present the clinical, biochemical, and molecular genetic investigations in a 
cohort of patients. Some of the patients were already confirmed to have a defect in complex I 
based on initial biochemical investigations including direct measurements of complex I 
activity by spectophotometry or BN
complex I due to the expression of clinical phenotypes previously
deficiency. Although this Chapter describes patients with complex I, also it describes another 
patient with a mutation in Complex IV. This patient was referred based on 
related to complex I deficiency. 
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 complex through pyruvate dehydrogenase phosphataise, 
+ ratios. NADH and FADH2, which are produced from citric 
 (taken from [70]). 
-PAGE. Some others were suspected to have a defect in
-
 
 
 
-
ce ATP. CoA: 
, I: complex I, II: 
 
related to complex I 
clinical phenotypes 
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3.3 Summary of clinical presentations 
All clinical phenotypes and other information related to the investigated patients are 
summarized in Table 3-2. 
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Table 3-2 Summary of clinical phenotypes and other related information for investigated patients. 
 
 
 
Patients 
 
Age Clinical phenotypes Biochemical  investigations Identified mt-DNA mutations 
Canadian patients 
(4) adults                                       - 
Complex I deficiency 
 
No pathogenic mtDNA mutations 
identified 
Japanese patients 
(7) 
 
 
children Congenital lactic acidosis, cardiomyopathy Complex I deficiency 
 
No pathogenic mtDNA mutations 
identified 
1 11 Seizure, weakness, strokes, lactic acidosis. COX deficient fibres, Isolated complex IV defect in muscle m.7023G > A MTCO1 
2 42 LHON- like optic neuropathies. Normal complex I activity m.11453G>A MTND4 
 
3 
 
14 Ataxia, bulbar palsy, extensive progressive deterioration, and  white matter changes on MRI 
Complex I deficiency 
 
m.11777C>A MTND4 
4 
 
10 
Leigh syndrome phenotypes: delayed milestones, 
deafness, ataxia, bilateral basal ganglia changes on 
MRI; and  high levels of lactate in CSF 
Normal respiratory chain enzymes m.13051G>A MTND5 
5 4 
Leigh syndrome phenotypes: developmental delay, 
acquired microcephaly, microcephaly, left ventricle 
hypertrophy, and high blood and CSF lactate. 
 
Complex I deficiency in muscle 
 
 
m.13513G>A MTND5 
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6 8 
Spasms, pigmentary retinopathy, encephalopathy, 
increased blood lactate, and  changes in basal 
ganglia on  MRI , 
Complex I deficiency in muscle 
 
m.14453G>A MTND6 
 
7 10 Hypotonia, failure to thrive, elevated blood and CSF lactate, and  abnormal MRI Isolated complex I defect  
m.7792C>G MTCO2 
 m.12055A>G MTND4 
(silent changes) 
8 - General body ache  and weakness - m.10632T>C MTND4 (silent change) 
9 4 
Fever, acute deterioration in consciousness; high 
blood  and CSF  lactates; left ventricular 
hypertrophy;and white matter changes on MRI 
 
Normal COX activity and  low complex 
I and IV activity; 
m.12645C>T MTND5 
(silent change) 
10 46 CPEO COX deficient fibres m.13095T>C MTND5 (silent change) 
11 
 
35 Unusual multiple sclerosis presentation with optic 
atrophy Normal biochemistry in muscle 
No pathogenic mtDNA mutations 
identified 
12 
 
8 months Hypertrophic cardiomyopathy Reduced complex I and IV activities COX defect 
No pathogenic mtDNA mutations 
identified 
13 
 
17 Myoclonic epilepsy, diabetes, and learning difficulties 
Many pale staining COX fibres 
       Rreduced complex I activity 
No pathogenic mtDNA mutations 
identified 
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3.4 Materials and methods 
3.4.1 Patients` samples preparation 
Upon arrival of the patient samples in the lab, the DNA was extracted from the different 
tissues (blood, buccal, fibroblasts, hair, and urine) as previously described (section 2.2.1). 
3.4.2 Mitochondrial DNA sequencing 
The entire mitochondrial genome from total muscle homogenate, blood, or fibroblasts was 
performed as described (section 2.2.6) to search for mtDNA point mutations or 
rearrangement leading to the disease.  
3.4.3 Generation of cybrids 
To establish the pathogenic role of the identified mtDNA mutations, transmitochondrial 
cytoplasmic hybrids (cybrids) were generated by fusing cytoplasts from patient carrying 
the m.11777A>C with the osteosarcoma cell line 143BTK- and were grown under selection 
conditions as previously described (section 2.2.5). 
3.4.4 PCR-RFLP analysis 
PCR-RFLP analysis was carried on DNA samples from different tissues from patient and 
relatives where available to quantify mutation load in investigated tissues and to determine 
whether the mutation is sporadic or maternally transmitted. Table 3.3 summarises details 
for this analysis such as primer position, sequences, restriction endonuclease enzymes, and 
annealing temperatures. All restriction fragments were separated on a 12% polyacrylamide 
gel as previously described (section 2.2.11). 
3.4.5 Measurement of activity for respiratory chain complexes 
The specific activities of complex I, II, and citrate synthase were measured in these 
patients as previously described (section 2.2.14). 
3.4.6 Flow cytometry 
 
Flow cytometry was used to assess different cellular properties of fibroblasts from the 
patient with the identified mtDNA. This included measuring ROS production levels, 
membrane potential, and mitochondrial mass. Statistics were performed using SigmaStat 
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3.5 software (Systat Software Inc, USA) and two-sample unpaired Student t-tests between 
each patient and control sample were carried out to determine statistical significance. This 
part was done in association with Dr.Gabriele Saretzki (International centre for Life, 
bioscience Centre). 
 
3.4.6.1 Cells preparation 
Cells were grown until confluent using serum supplemented DMEM and then were 
harvested as described (section 2.2.4.2). Cells (~200,000) were transferred to 15ml Falcon 
tubes for centrifugation at 1200rpm for 3 minutes at room temperature. Supernatants were 
removed by aspiration and replaced with the specific probe solution. 
3.4.6.2 MitoSOX staining 
The working concentration for MitoSOX was 5µM (1µl stock solution/1ml serum-free 
DMEM). To measure mitochondrial superoxide levels, cells (~200,000) were resuspended 
in MitoSOX solution (200µl of solution/sample), mixed well and incubated for 15 minutes 
at 37oC. Cells were then centrifuged at 1200rpm for 3 minutes at room temperature and 
supernatants were aspirated. Finally, cells were resuspended in 3ml of DMEM without 
serum and FL3 median fluorescence intensity was measured by flow cytometry. 
3.4.6.3 DHR staining 
The working concentration for DHR was 30µM (15ul stock solution/5ml serum-free 
DMEM). Cells (~200,000) were resuspended in DHR solution (2ml of solution/sample), 
mixed well and incubated for 30 minutes at 37oC in the dark. Cells were then centrifuged 
at 1200rpm for 3 minutes at room temperature and supernatants were aspirated. Finally, 
cells were resuspended in 3ml of DMEM containing serum to analyse samples by flow 
cytometry. 
3.4.6.4 JC1 staining 
To measure mitochondrial permeability transition, a JC1 probe (1µg/1ml PRMI media) 
was used. Cells (~200,000) were resuspended in 500µl of JC1 solution, mixed well and 
incubated for 30 minutes at 37oC. Cells were then centrifuged at 1200rpm for 3 minutes at 
room temperature and supernatants were aspirated. Cells were washed twice with cold 
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1XPBS and after the second wash pellets were resuspended in 3m 1XPBS. Finally, cells 
were resuspended in 3ml of DMEM without serum to analyse samples by flow cytometry. 
3.4.6.5 NAO staining 
Fluorescent dye 10-n-nonyl-acridine orange (NAO) probe (10mML NAO/1ml DMEM free 
serum) was used to measure mitochondrial mass. Cells (~200,000) were resuspended in 
1ml of NAO solution, mixed well, and incubated for 10 minutes at 37°C. Cells were then 
centrifuged at 1200 rpm for 3 minutes, supernatants were aspirated, and pellets were 
resuspended in 3ml of DMEM without serum to analyse samples by flow cytometry. 
3.4.7 Western blot  
To assess the pathogenicity of identified mtDNA mutations, fibroblasts from patients were 
collected and subjected to Western blot analysis as previously described (section 2.2.18).  
3.4.8 First dimension blue native-PAGE assay 
BN-PAGE was used to assess the pathogenicity of identified mtDNA mutations by 
investigat whether the mutations can affect complex I activity and assembly. This approach 
was carried out as previously described (section 2.2.19). 
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Table 3-3 Summary of PCR-RFLP analysis. 
 
 
 
          
Mutation Primer Position Primer Sequence 
Primer 
Annealing 
Temperature 
(oC) 
Enzymes and 
Digestion site 
Digest 
Temperature 
(oC) 
Uncut 
product 
(bp) 
Wild-type 
products 
(bp) 
Mutant 
products 
(bp) 
m.11453G>A 
L11343 
 
H11498 
5`-TATGACTAGCTTACACAATAGC-3` 
 
5`-TGAGGCGTATTATACCATAGC-3` 
60 Fun4HI (GC/NGC) 37 156 112+22+22 134+22 
m.13051G>A 
L12947 
 
H13104 
5`-TAAACGCTAATCCAAGCCTC-3` 
 
5`-TCCT GCTACAACTATAGTGC-3` 
56 HaeIII 
 (GG/CC) 37 158 34+72+52 34+124 
m.13513G>A 
L13491 
 
H13663 
5`-CCTCACAGGTTTCTACTCCGAA-3` 
 
5`-TGTTAGTAAGGGTGGGGAAGC-3` 
57 
BbsI 
(GAAGACN(2)/N 
(6) 
37 173 146+27 173 
m.11777C>A 
 
M13-
L11754 
 
H12038 
 
5`-tgtaaaacgacggccagt 
CAAACTACGAACGCACTCAGAG-3` 
 
5`-TTCTCGTGTGAATGAGGGTTT-3` 
57 HinfI  (G/ANTC) 37 323 176+38+109 14+109 
m.14453G>A 
L14425 
 
H14613 
5`-
CCCCCATGCCTCAGGATACTCCTCAGTA-
3` 
 
5`-TCTAAGCCTTCTCCTAGTTACGGG-3` 
58 MaeIII  (GTNAC) 37 189 168+21 25+143+21 
 3.5 Results 
3.5.1The m.7023G>A mutation
3.5.1.1 Mitochondrial DNA sequencing
Sequencing of the entire mitochondrial genome from a 
who presented with seizure, weakness, aphasia, multiple inf
resulted in the identification of the pathogenic m.7023G>A mutation.
changes the amino acid at position 374 from valine to methionine in the 
complex IV (Figure 3-2). All other sequence changes identified
summarized in Table 3.4.  
Figure 3
 (A) Sequence chromatogram showing the m.7023G>
compared to control. (B) Alignment of amino acids sequences at position 374 (as indicated by asterisk) 
within COX1 showing the high conservation in different species.
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muscle sample from patient #1, 
arcts and l
 in this patient are 
-2 Conservation of the nucleotide at position m.7023
A transition in the patient (indicated by arrow) and 
 
earning difficulties 
 This transition 
COX1 subunit of 
 
. 
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Table 3-4 Sequence changes identified in the patient carrying the m.7023G>A mutation. 
 
 
Sequence change Previously reported as a SNP or pathogenic? Mitomap or mtDB Amino acid change Location 
m.73A>G Yes - D-Loop 
m.152T>C Yes - D-Loop 
m.263A>G Yes - D-Loop 
m.TC310ins Yes - D-Loop 
m.310T>C Yes - D-Loop 
m.750A>G Yes - 12SrRNA 
m.C3106ins Yes - 16SrRNA 
m.1438A>G Yes - 12SrRNA 
m.4769A>G Yes NO ND2 
m.6776T>C Yes NO CO1 
m.7023G>A No Val374Met CO1 
m.7034C>T No NO CO1 
m.8860A>G Yes Thr112Ala ATPase6 
m.13404T>C Yes NO ND5 
m.13404T>C Yes NO ND5 
m.14125C>T No NO ND5 
m.15326A>G Yes Thr112Ala Cytb 
m.15326A>G Yes Thr194Ala Cytb 
m16239C>G Yes - D-Loop 
m.16519T>C Yes - D-Loop 
 3.5.1.2 The m.7023G>A mutation is pathogenic 
DNA muscle sample from patient #1, who presented with 
referred to our lab to carry out full genome sequencing. After we identified the pathogenic 
m.7023G>A mutation, the investigations to support the role of this mutation in 
pathogenicity was carried out in Dr. Brian Robinson`s lab.
The m.7023G>A mutation is a strong candidate for causing disease in this patient for 
several reasons. It was heteroplasmic with high levels in muscle and low in different 
tissues (buccal, blood, and fib
reported in the two mitochondrial DNA databases 
in complex IV activity as measured in both muscle and fibroblasts
with a clear decrease in protein expression level
compared to controls (Figure 3
Figure 
Protein expression levels were decreased in all COX IV subunits in samples from 
is the Leucine-rich PPR motif-containing protein and CS is citrate synthase
The m.7023G>A affects the
of subunit I, within the close packed in
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a MELAS-
 
roblasts). It was not found in normal individuals and not 
[69, 252]. It caused a biochemical defect 
. This defect associated 
 in subunits of COX IV in the patient when 
-3).  
3-3 Immunoblot of patient and control COX subunit. 
patient`s muscle. LRPPRC 
 (taken from 
 amino acid valine at position 374, which is found in helix 17 
terior of the complex (Figure 3
like syndrome was 
 
 
[373]. 
-4). This mutation 
 results in adding more methionine residue affecting the tertiary structure formation of 
COX1 and its ability to interact normally with heme 
quaternary complex formation 
Figure 3-4 
In addition to Val374, this structure c
m.7023G>A affects Valine 374 tertiary formation of COX1 and its interaction with Heme a, by disturbing 
existing hydrogen bonds (taken from 
The existence of the m.7023G>A mutation in a h
patient, together with the absence 
showed no symptoms, strongly suggests 
novo. 
Because the investigations were done in 
to this mutation can be found in 
3.5.2 The m.11453G>A
3.5.2.1 Mitochondrial DNA sequencing
Sequencing of the entire mitochondrial genome from a blood sample from patient #2, who 
presented with LHON, resulted in the identification of a novel m.11453G>A variant. Th
transition changes the amino acid at position 232 from alanine to threonine in the 
subunit of complex I. In addition; it affects a strictly conserved amino acid of the protein 
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a, therefore, this will affect the 
[373].  
The crystal structure of cytochrome c oxidase in B.taurus
ontains His61, His376, and His 378 which interact with Heme. The 
[373]. 
eteroplasmic state in tissues from 
of mutation in tissues from the mother and
that this mutation is pathogenic and 
another diagnostic lab, further information
the following article [373]. 
 mutation 
 
 
. 
the 
 brother who 
occurred de 
 relating 
is 
ND4 
 (Figure 3-5). All other sequence changes identified in this patient are s
3-5. 
Figure 3-5 Conservation
(A) Sequence chromatogram showing the m.11453G>A transition in the patient (indicated by arrow) and 
compared to control. (B) Alignment of amino acids sequences at position 232 (as indicated by asterisk) 
within MTND4 showing the high conservation in different species.
3.5.2.2 PCR-RFLP analysis
PCR-RFLP analysis was carried out t
mother using different primers and endonuclease.
loss of Fun4HI recognition site
wild-type mtDNA into 112 bp and du
mtDNA into 134 bp and 22 bp products. Results revealed the presence of the m.11453G>A 
in all the investigated tissues (Figure 3
tissues from mothers confirms t
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ummarized in Table 
 of the nucleotide at position m.11453G>A transition
 
 of the m.11453G>A mutation 
o quantify mutation load in tissues from patient and 
 The m.11453G>A mutation causes the 
 (GC/NGC) in the mutant mtDNA. This endonuclease cuts 
plicate 22 bp products, while it cuts the mutant 
-6). The existence of the m.11453G>A mutation in 
hat this mutation was transmitted to the patient.
 
.  
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Table 3-5 Sequence changes identified in the patient carrying the m.11453G>A mutation. 
Sequence change Previously reported as a SNP or pathogenic? Mitomap or mtDB Amino acid change Location 
m.73A>G Yes -  D-Loop 
m.93A>G Yes -  D-Loop 
m.150C>T Yes -  D-Loop 
m.152T>C Yes -  D-Loop 
m.263A>G Yes -  D-Loop 
m.295C>T Yes -  D-Loop 
m.CT309 ins Yes -  D-Loop 
m.310T>C Yes -  D-Loop 
m.,489T>C Yes -  D-Loop 
m.750A>G Yes -  12S rRNA 
m.1438A>G Yes -  12S rRNA 
m.2404T>C Yes -  12S rRNA 
m.2706A>G Yes -  12S rRNA 
m.3107C del. Yes -  16S rRNA 
m.4216T>C Yes Tyr-304>His MTND1 
m.4769A>G Yes No MTND2 
m.5633C>T Yes -  MTTA 
m.6962G>T Yes No MTCOX1 
m.7028C>T Yes No MTCOX1 
m.7211G>A Yes No MTCOX1 
m.7476C>T Yes -  MTTS1 
m.8860A>G Yes Thr112Ala MTATP6 
m.10172G>A Yes No MTND3 
m.10389T>C Yes No MTND3 
m.10398A>G Yes No MTND3 
m.11251A>G Yes No MTND4 
m.11453G>A No Ala232Thr MTND4 
m.11719G>A Yes No MTND4 
m.12612A>G Yes No MTND5 
m.13708G>A Yes Ala458Thr MTND5 
m.14766C>T Yes Ile7Thr MTCYB 
m.15257G>A Yes Asp171Asn MTCYB 
m.15326A>G Yes Thr194Ala MTCYB 
m.15452C>A Yes Leu236Ile MTCYB 
m.15812G>A Yes Val356Met MTCYB 
m.16069C>T Yss -  D-Loop 
m.16126T>C Yes -  D-Loop 
m.16193C>T Yes -  D-Loop 
m.16519T>C Yes -  D-Loop 
 Figure 3-6 PCR-RFLP
(A) Schematic diagram showing sizes of PCR products after digestion with the restriction endonuclease 
(Fun4HI). (B) Quantification of mutation load in different tissues
negative control DNA sample; lanes 3 is 
patient`s blood sample; lane 5 is 
sample; and lane 7 is DNA from 
3.5.2.3 Measurement of respiratory chain complexes 
Measurement of the activity of the individual respiratory chain complexes I and II and the 
matrix marker citrate synthase in patient fibroblasts appeared to show a minor
complex I activity (patient, 0.101 nmols NADH oxidized.min
(CI/CS); controls, 0.197±0.034 nmols NADH oxidized.min
(mean±SD, n=8). However, the ratio of complex I:II activities showed no apparent 
abnormality (patient, 0.819 (CI/CII); controls, 0.58
demonstrate a complex I deficiency by both these criteria 
diagnostic laboratory; I felt that 
reliably demonstrated an observable biochemical defect involving complex I.
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 analysis of the m.11453G>A mutation in patient and mother.
: lane 1 is an uncut sample; lane 2 is a 
DNA from patient`s fibroblasts sample; lane 4 is 
DNA from mother`s blood sample, lane 6 is DNA from 
mother’s buccal sample. 
activity 
-1
.unit 
-1
.unit citrate synthase
-0.90 (CI/CII)). Given 
that are routinely used within our 
I could not equivocally show that the patient fibroblasts 
 
 
DNA from 
mother’s urine 
 
 decrease in 
citrate synthase-1 
-1 (CI/CS) 
I could not 
 
 3.5.2.4 Measurement of 
from the m.11453G>A 
To assess the pathogenic role of the m.11453G>A, ROS levels and mitochondrial mass 
were investigated in fibroblasts from the patient. Results showed a slight increase in ROS 
levels (with no significance, 
to fibroblasts from three different control samples: control 1 (C1) is a healthy neonatal, 
control 2 (C2) is a pediatric, and control 3 (C3) is embryonic lung fibroblasts (MRC5) 
(Figure 3-7). 
Figure 3-7 Measurement of ROS production 
This figures shows a slight increase in ROS production 
mitochondrial mass as compared to control samples
C3 is embryonic lung fibroblasts (MRC5). 
 
3.5.2.5 Western blot analysis and protein expression levels in fibroblasts 
from the m.11453G>A patient
Western blot analysis was carried out to investigate whether this mutation affects 
expression levels in fibroblasts from 
Complex I subunit NDUFB8
100 
ROS levels and mitochondrial mass in fibroblasts 
patient 
n=6) and no change in mitochondrial mass (
levels and mitochondrial mass in fibroblasts from patient with the 
m.11453G>A mutation. 
without any significance and no change in 
. C1 is a healthy neonatal, C2 is a 
Error bars represent SEM. 
 
the patient. Three monoclonal antibodies were used. 
 (20kDa) protein expression levels were shown to b
n=4) as compared 
 
healthy pediatric, and 
protein 
e 
 increased in the patient fibroblasts. Also, MnSOD (24kDa) protein levels showed a slight 
increase. However, the increase in both cases was not statistically significant when 
compared to controls. The monoclonal antibody against complex II subunit (70kDa)
used as control for loading 
Figure 3-
 A high increase in CI-20kDa (NDUFB8) protein expression levels was seen, while MnSOD levels showed a 
slight increase when compared to CII
graph represents quantification of bands intensity
3.5.2.6 Is the m.11453G>A mutation pathogenic?
Leber's hereditary optic neuropathy 
bilateral visual loss and the majority of cases are caused by three primary 
mutations (m.3460G>A MTND1
Blindness is due to optic nerve degeneration and visual loss usually occurs between the 
ages of 20 and 40 [190]. 
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(Figure 3-8). 
8 Western blot analysis for the m.11453G>A mutation
-70kDa subunit. C1, C2, and C3 represent healthy control samples.
 and error bars represent SEM. 
 
(LHON) is a maternally inherited 
, m.11778G>A MTND4 and m.14484T>C 
 was 
 
. 
 The 
disease leading to 
pathogenic 
MTND6) [374]. 
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Patient #2 presented with a LHON-like phenotypes but full genome sequence analysis of 
the patient`s DNA sample did not reveal any of the primary LHON mutations. Instead, 
mutation in MTND4, the m.11453G>A, was identified. This mutation is homoplasmic and 
is present at high levels in blood and fibroblasts from the patient. In addition, it affects a 
highly conserved sequence in the MTND4 gene in different species (Figure 3-5-B). 
Moreover, this mutation was not found in normal individuals.  
The existence of the m.11453G>A mutation in a homoplasmic state in the carrier mother 
can be explained by several factors which can affect expression of LHON phenotypes in 
different members of the same family. First, environmental factors such as: medications, 
industrial toxins, alcohol drinking, and smoking [250, 375-377]. Second, some mtDNA 
polymorphisms can influence the expression of phenotypes in individuals with the same 
mtDNA mutation [378]. Third, the nuclear genetic background can also influence the 
phenotype [379, 380]. 
This mutation was present at homoplasmic levels in all investigated tissues from the 
patient`s healthy mother. The finding of this mutation in the mother without expressing 
LHON phenotypes suggests she is asymptomatic. Several mtDNA mutations, identified as 
homoplasmic, have been confirmed to be pathogenic [69] and some individuals with such 
mutations have remained asymptomatic [246]. The existence of the mutation in a 
homoplasmic state does not exclude its involvement in pathogenicity as LHON is usually 
found as a homoplasmic disease [381] and inherited from carrier females to all offspring 
but affecting 50% of males and only 10% of females [190, 254, 382]. All together these 
data suggest that this mtDNA mutation may be related to the clinical presentation in this 
patient. 
3.5.3 The m.11777C>A mutation 
3.5.3.1 Mitochondrial DNA sequencing 
Sequencing the entire mitochondrial genome from a blood sample in patient #3 resulted in 
the identification of the pathogenic m.11777C>A mutation. This transversion changes the 
amino acid at position 340 from arginine to serine in the ND4 subunit of complex I. In 
addition, it affects a highly conserved sequence of the protein, which is part of the 
transmembrane region (Figure 3-9). All other sequence changes that were found in the 
patient are summarised in Table 3-6. 
 Figure 3-9 Conservation
(A) Sequence chromatogram showing the m.11777C>A transversion in the patient (indicated by arrow) and 
compared to control. (B) Alignment of amino acids sequences at position 340 (as indicated by asterisk) 
within MTND4 showing the conservation in different spec
3.5.3.2 PCR-RFLP analysis
PCR-RFLP was used to correlate the genotype with the expressed phenotype in the patient 
and also to quantify the mutation load in different tissues. In this experiment, the forward 
primer was designed to have a mismatch base to create an extra 
mutant mtDNA is cut into 214 bp and 109 bp products while wild
176 bp, 109 bp, and 38 bp products (Figure 3
mtDNA in muscle (78%), blood (64%), and fibroblast DNA (52%) samples. 
Subsequent RFLP analysis in tissues from patient’s mother and sister confirmed the 
presence of this mutation in all investigated tissues. In the mother the mutation load was 
16% in blood, 36% in buccal epithelia and 17% in urine. However, the mutation load was 
greater in the sister`s tissues at 30%, 43.5% and 36.35 % in blood, buccal and urine
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Table 3-6 Sequence changes identified in the patient carrying the m.11777C>A mutation. 
Sequence change Previously reported as a SNP or pathogenic? Mitomap or mtDB Amino acid change Location 
m.73A>G Yes  - D-Loop 
m.150C>T Yes  - D-Loop 
m.263A>G Yes  - D-Loop 
m.C311C ins. Yes  - D-Loop 
m.750A>G Yes  - 12S rRNA 
m.896A>G Yes  - 12S rRNA 
m.1438A>G Yes  - 12S rRNA 
m1721C>T Yes  - 16S rRNA 
m.2706A>G Yes  - 16S rRNA 
m.3106C  del. Yes  - 16S rRNA 
m3197T>C Yes  - 16S rRNA 
m.4732A>G Yes Asn88Ser MT ND2 
m.4769A>G Yes No MT ND2 
m.7028C>T Yes No MT COX1 
m.7768A>G Yes No MT COX2 
m.8860A>G Yes Thr112Ala MT ATP6 
m.9477G>A Yes Val91lle MT COX3 
m.11467A>G Yes No MT ND4 
m.11719G>A Yes No MT ND4 
m.11777C>A Yes Arg340Ser MT ND4 
m.12308A>G Yes  - MT TL2 
m.12372G>A Yes No MT ND5 
m.13617T>C Yes No MT ND5 
m.13637A>G Yes Gln434Arg MT ND5 
m.14182T>C Yes No MT ND6 
m.14766C>T Yes Lle7Thr MT CYB 
m.15326A>G Yes Thr194Ala MT CYB 
m.15511T>C Yes No MT CYB 
m.16185C>T Yes  - D-Loop 
m.16192C>T Yes  - D-Loop 
m.16270C>T Yes  - D-Loop 
m.16311T>C Yes  - D-Loop 
m.16250C>T Yes  - D-Loop 
m.16252A>C Yes  - D-Loop 
m.16270C>T Yes  - D-Loop 
m.16311T>C Yes  - D-Loop 
 respectively (Figure 3-11). The presence of the mutation in different tissues from patient`s 
mother and sister suggests that this mutation was transmitted from the 
offspring. 
Figure 3-10 PCR
(A) Schematic diagram showing the sizes of PCR products after digestion with the restriction endonuclease 
(HinfI). (B) Quantification by PCR
DNA sample, lane 2 is DNA from a negative 
muscle (78% mutant), blood (64%
In addition, these results were consistent with previous results found in two patients in 
unrelated cases with the same mutation. Both patients showed a high mutation load in 
affected tissues such as muscle, blood and fibr
Figure 3-11 PCR
Lane 1 is uncut DNA sample, lanes 2 and 3 are DNA from 
muscle DNA with the m.11777C>
blood (16% mutant), buccal (36%
are DNA from the patient`s sister`s blood (30%
samples, respectively. 
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-RFLP analysis of patient with the m.11777C>A mutation
-RFLP of mutation load in different tissues from patient:
control, lanes 3, 4, and 5 show DNA samples from patient 
 mutant) and fibroblasts (52% mutant), respectively.
oblasts [357]. 
-RFLP analysis of the m.11777C>A in patient’s family
negative control samples, lane 4 is patient’s 
A mutation (positive contro)l, lanes 5, 6 and 7 are DNA from mother’s 
 mutant), and urine (17% mutant) samples, respectively.
 mutant), buccal (43.5% mutant) and 
mother to her 
 
.  
 lane 1 is uncut 
 
 
. 
 Lanes 8, 9 and 10 
urine (36.35% mutant) 
 3.5.3.3 Measurement of respiratory chain complexes 
Measurement of the individual of respiratory chain complexes I and II and of the citrate 
synthase from patient’s fibroblasts 
(0.306 (CI/CII)) and (0.1054 nmols NADH oxidized.min
as opposed to the normal complex I activity in human fibroblasts (0.58
(0.197±0.034 nmols NADH oxidized.min
n=8) (Figure 3.12). These results confirm and support the involvement of this mutation in 
the previously isolated complex I defects in muscle. In addition, measurement of complex I 
activity in other unrelated case, which p
complex I deficiency which suggests the involvement of the m.11777C>A mutation in 
pathogenicity [357]. 
Figure 3-12 Measurement of respiratory chain complex activity in patient’s 
This figure shows a significant decrease in complex I activity (CI/Cs and CI/CII) in fibroblasts from patient 
when compared to fibrblasts from control. 
3.5.3.4 Generation of cybrids
To further confirm pathogen
fibroblasts carrying this mutation were fused to the 
cybrid cells started to appear as a new generation that morphologically differed from the 
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activity 
showed a significant decrease in complex I activity 
-1
.unit citrate synthase
-1
.unit citrate synthase-1 (CI/CS))
atient had the m.11777C>A mutation, revealed 
fibroblasts carrying the 
m.11777C>A mutation. 
 
 
icity of the 11777C>A mutation, cytoplasts from patient`s 
143BTK- cell line. Within 4
 
-1 (CI/CS)) 
-0.90 (CI/CII)) and 
 (mean ± SD, 
 
-5 weeks, 
 input cells. Cells were harvested when they reached confluence and subjected to PCR
RFLP analysis to quantify mutation loads in the resulting cybrid clones. Results showed 
the successful generation of 11 cybrid clones with mutation loads (Figure 3
Figure 3-13 PCR-RFLP analysis of cybrid clones carrying the m.11777C>A mutation
Lanes 1 and 2 are uncut DNA samples. Lanes 3 and 4 are 
DNA from patient`s blood sample with the 
from different cybrid clones. 
To confirm that the 143BTK p
either selection media, which has BrdU but lacks uridine, or normal media, which 
uridine but no BrdU. Upon treatment with selection media, we expected the death of 
143TK po cells and only cells with mtDNA to survive. As expected, treatment with 
selection media led to morphological changes in 143TK p
Moreover, the cells eventually died (Figure 3
143BTK po cells were treated with normal media (
test the presence of any mtDNA. Treatment with normal media
treatment with selection media led to morphological change
panel). 
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DNA from negative control samples. Lane 5 is 
m.11777C>A mutation (positive control), Lanes 6
o cells had no mitochondrial DNA, cells were treated with 
0 cells, which started to shrink.
-14). 
Figure 3-14 Treatment of the 143BTK po cells. 
-BrdU, +uridine) and selection media (+Brdu, 
 showed normal growth (left panel
s and death of cells due to lack of mtDNA (right 
-
-13). 
 
. 
-15 are DNA 
has 
 
 
-uridine) to 
), while 
 In addition, to exclude the possibility of any mtDNA contamination in the p
was extracted as described (section 2.2.1.1). Four random primer sets specific to mtDNA 
were used as described (section 2.2.6.2 and 2.2.7). Results showed absence and presence of 
mtDNA in some lanes (Figure 3
cells could be due to similar 
are common in eukaryotes. 
Upon successful generation of cybrids, 2 clones (lane #6 and lane #11 from Figure 3
were further expanded to obtain differ
analysis was carried out and results showed that presence of this mutation with varying 
mutation loads ranging between 63% (subclone #6) and 81% (subclone #11) (Figure 3
Mutation loads in all the dif
Figure 3-15 PCR
Lane 1 is Hyperladder IV; lanes 2, 4, 6, and 8 are 
Lanes 3, 5, 7, and 9 are PCR products 
3 are PCR products amplified by primer specific for fragment 2.
by primer specific for fragment 6. Lanes 6 and 7 
15. Lastly, lanes 8 and 9 are PCR products
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-15). However, the presence of some m
nuclear DNA sequences or mitochondrial pseudogenes, which 
 
ent subclones varying in their mutation loads. RFLP 
ferent subclones are summarised in Table 3-
 analysis to test the 134B-po cell contamination with mt
PCR products from control samples containing mt
from 143B-p 0 cells. Lane 10 is a negative control
 Lanes 3 and 4 are PCR products 
are PCR products amplified by primer specific for fragment 
 amplified by primer specific for fragment 18.
o
 cell, DNA 
tDNA in the po 
-13) 
-16). 
7.  
 
-DNA. 
DNA. 
 (water). Lanes 2 and 
amplified 
 
 Figure 3-16 PCR-RFLP analysis of 
Lane1 is an uncut DNA sample; lane 2 is 
mutation (positive control); lane 3 is DNA from
from the obtained subclones labelled from 1
Table 3-7 Summary of both mutant and wild
Subclone # % of mutant mtDNA
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
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subclones from cybrids with the m.11777C>A mutation
DNA from patient`s blood DNA sample with the m.11777C>A 
 a negative control sample. The remaining lanes are 
-11. 
-type mtDNA percentages in all subclones.
 % of wild-type mtDNA
71 29
68 32
66 34
70 30
68 32
63 37
74 26
77 23
77 23
76 24
81 19
 
. 
DNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.5.3.5 Measurement of ROS levels and mitochondrial mass in fibroblasts 
from patient with the m.11777C>A mutation 
To further support the pathogenicity of the m.11777C>A mutation, ROS levels in 
fibroblasts from the patient was assessed. Results showed a significant increase in the ROS 
levels (P<0.001, n=5) when cells were stained with DHR when compared to fibroblasts 
from three different control samples (section 3.5.1.4). In addition, the increase in ROS 
correlated with a significant increase in mitochondrial mass (P<0.00, 
stained with NAO and compared to previous controls (Figure 3
Figure 3-17 Measurement of ROS levels
Patient cells showed a significant increase in both ROS 
three healthy control samples. C1 is a healthy neonatal, C2 is a healthy pediatric, and C3 is embryonic lung 
fibroblasts (MRC5). Error bars represent SEM.
3.5.3.6 Western blot analysis and protein expression levels in fibroblasts 
from the m.11777C>A patient
Western blot analysis was carried out to investigate whether this mutation affects 
expression levels in fibroblasts from 
protein expression levels were slightly increased. MnSOD (24kDa) were also slightly 
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n=4) when cells were 
-17). 
 and mitochondrial mass in fibroblasts from the m.11777C>A patient
levels and mitochondrial mass when compare
 
 
the patient. Complex I subunit NDUFB8
 
.  
d to the 
protein 
 (20kDa) 
 upregulated, likely due to increased levels of ROS production. 
against complex II subunit (70kDa) was used as a control for loading
 
Figure 3-18 Western blot analysis in the m.11777C>A patient fibroblasts
Both protein expression levels were slightly increased to almost the same levels as probed by antibody 
against CI-20 subunit and antibody against MnSOD when compared to control (CII
and C3 are healthy controls and error bars represent SEM.
3.5.3.7 Measurement of ROS production and mitochondrial mass in 
cybrids from the m.11777C>A patient
ROS production and mitochondrial mass were analysed in two subclones, subclone #6 
which showed the lowest percentage of heteroplasmy and subclone #11 which showed the 
highest. Results from MitoSOX probe staining, DHR staining, and NAO staining showed 
neither changes in ROS prod
compared to control ( n = 3) (Figure 3
111 
The monoclonal antibody 
 (Figure 3
 
-70kDa subunit). 
 
 
uction nor mitochondrial mass when subclones #11 and #6 
-19). 
-18). 
 
. 
C1, C2, 
 Figure 3-19 Measurement of ROS levels and mitochondrial mass in cybrid subclones carrying the m 
Measurement of mitochondrial superoxides using MitoSOX
(A), and intracellular peroxides using DHR probe
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11777C>A mutation.  
 probe, mitochondrial mass using NAO probe
 (B) showed normal levels. Error bars 
 
 
represent SEM. 
 3.5.3.8 Western blot analysis and protein 
subclones carrying the m.11777C>A mutation
Western Blot analysis showed an almost similar decreased in NDUFB8 (CI
expression levels in both subclones
Figure 3-20 Western blot analysis of cybrid subclones carrying the m.11777C>A mutation. 
NDUFB8 (CI-20kDa) protein expression levels in both subclones were decreased similarly whilst the levels 
of MnSOD expression in these subclones were 
2 and 3). Samples were loaded in triplet and
3.5.3.9 BN-PAGE analysis of Cybrids
This analysis was carried out to assess the effect of the m.11777C>A mutation on complex 
I assembly and further support reduced activity. Three cell lines were used: 143B parental 
cell line as a control, cybrids carrying the m.11777C>A mutation with 63% heteroplasmy 
(subclone #6) and cybrids with 80% heteroplasmy (subclone #11) as in Figure (3
gel enzyme activity revealed no change in complex I activity between control (143B 
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expression levels in cybrid 
 
, but no change in the levels of MnSOD (Figure 3
normal compared to the 143B parental control cell line (Ctr.1, 
 error bars represent SEM. 
 
-20kDa) protein 
-20). 
 
 
-16). In-
 parental) and subclone #6 (lane #1) and subclone #11(lane #2) (Figure 3
addition, Western blot analysis of 1D BN
in fully assembled complex I, which was visualised with an antibody against complex I 
subunit NDUF3 (30kDa), when compared to control (Figure 3
complex II-70kDa was used as a control for loading. This showed reduced loading for 
subclone #11 (Figure 3-21-
in complex I activity and a slight decrease in fully assembled complex I, which was 
visualised with NDUF3 (CI
not consistent and experiment was repeated only twice, due to time limit, it was difficult to 
give a clear-cut interpretation for these results.
(A) In-gel enzyme activity showing the activity of complex I in control (Ctr
heteroplasmy levels of the m.11777C>A mutation. Lanes 1 is subclone #6 (with 63% heteroplasmy) and lane 
2 is subclone #11 (with 80% heteroplasmy)
assembled complex (~ 900kDa) in control (Ctr.), subclones #6 (lane #1), and su
Repeat of both in-gel enzyme activity and Western blot 
(lane #2). 
3.5.3.10 The m.11777C>A mutation is pathogenic
Full genome sequencing results fro
extensive progressive deterioration, white matter changes
muscle and fibroblasts revealed the identification of the m.11777C>A in 
lines of evidence suggest this mutation is pathogenic 
First, this mutation is heteroplasmic and 
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-PAGE showed, in a similar manner, no change 
-21-B). An antibody against 
B lane #2). However, a repeat of experiment showed no change 
-30kDa) (Figure 3-21-C). However, because the results were 
 
Figure 3-21 BN-PAGE analysis. 
.) and cybrids with different 
 (duplicate). (B) Western blot of BN-PAGE showing the fully 
bclone #11 (lane #2). (C) 
for samples from control (lane #1) and subclone #11 
 
m patient #3, who presented with a
 and complex I deficiency in both 
and is the main cause of the disease
was found to affect different tissues in the patient 
-21-A). In 
 
taxia, bulbar palsy, 
MTND4. Several 
. 
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and relatives. Second, it changes the amino acid arginine to serine at position 340, which is 
highly conserved in different species (Figure 3-9-B). Third, measurement of respiratory 
chain complex activities revealed isolated complex I deficiency in both muscle and 
fibroblasts from the patient. Fourth, measurement of ROS levels in fibroblasts from the 
patient showed increased levels of ROS. Interestingly, fibroblasts from this patient showed 
an increase in mitochondrial mass, a possible compensatory response to defect in the 
mitochondrial respiratory chain system or the mutant mtDNA.  
ROS production levels and mitochondrial mass can increase as a consequence of 
mitochondrial defect. It has been demonstrated that ROS production can be increased as a 
consequence of respiratory chain defects caused either by mtDNA mutations or inhibition 
of the respiratory chain [324, 383]. This is consistent with the increase in ROS production 
levels in the m.11777C>A case, which showed a defect in OXPHOS.  
In addition, mitochondrial mass has been shown to be increased in fibroblasts exposed to 
oxidative stress through a feedback mechanism compensating for a defective respiratory 
chain or mutant mtDNA [384, 385]. This can be achieved by increasing mitochondrial 
proliferation and/or mtDNA copy number [386]. Similarly, this can explain the increase in 
mitochondrial mass in fibroblasts from the m.11777C>A patient who showed a defect in 
complex I activity.  
Previous studies have shown that mRNA levels of several respiratory chain subunits [387] 
and many nuclear encoded proteins involved in mitochondrial biogenesis [384] are 
upregulated in cells with mtDNA depletion. In addition, the import and expression of 
transcription factors, such as that of transcription factor A (Tfam), were increased as well 
in response to mitochondrial DNA defects [388]. Those findings are consistent with the 
slight increase of protein expression levels in both CI-20 and MnSOD in fibroblasts from 
patient but not cybrids. Also, the expression levels of MnSOD in cybrids carrying the 
m.11777C>A mutation showed no significant change despite the increase in ROS 
production. This is not entirely unexpected as other patients with complex I deficiency 
have shown variable levels of MnSOD expression, ranging from high to low in response to 
increases in ROS [383, 389].  
 3.5.4 The m.13051G>A mutation
3.5.4.1 Mitochondrial DNA sequencing
Sequencing of the entire mitochondrial genome from a blood sample
presented with Leigh syndrome, resulted in the identification of the potentially pathoge
m.13051G>A mutation. This transition changes
position 239 in the ND5 subunit of complex I. In addition, it affects a region of the 
membrane protein spanning toward the matrix,
species (Figure 3-22). All other sequence changes found in the patient are summarised in 
Table 3-8. 
Figure 3-22 Conservation of the 
(A) Sequence chromatogram showing the m.13051G>A transition in the patient (indicated by arrow) and 
compared to control. (B) Alignment of amino acids sequences at position 239 (as indicated by asterisk) 
within MTND5 showing the conservation in different species.
3.5.4.2 PCR-RFLP analysis of the m.13051G>A mutation
To quantify mutation load in tissues from patient and related family members, including 
mother, sister and grandmother, PCR
loss of one site for a recognition s
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Table 3-8 Sequence changes identified in the patient carrying the m.13051G>A mutation. 
Sequence change Previously reported as SNP or pathogenic? Mitomap or mtDB Amino acid change Location 
m195T>C Yes - D-Loop 
m.207G>A Yes - D-Loop 
m.263A>G Yes - D-Loop 
m.303CC ins. Yes - D-Loop 
m.311C ins. Yes - D-Loop 
m.750A>G Yes - 12S rRNA 
m.961T>G Yes - 12S rRNA 
m.1438A>G Yes - 12S rRNA 
m.3106C del. Yes - 16S rRNA 
m.4769A>G Yes - MTND2 
m.8448T>C Yes Met28Thr MTATP8 
m.8860A>G Yes Thr112Ala MTATP6 
m.13051G>A Yes Gly239Ser MTND5 
m.13759G>A Yes Ala475Thr MTND5 
m.14361A>G No Trp105Arg MTND6 
m.15326A>G Yes Thr194Ala MTCYB 
m.16293A>G Yes - D-Loop 
m.16311T>C Yes - D-Loop 
The enzyme therefore cuts mutant mtDNA into 124 bp and 34 bp products, while it cuts 
wild-type mtDNA into 72 bp, 52 bp and 34 bp products (Figure 3-23). Results showed 
 almost homoplasmic levels of the m.13051G>A mutation in the patient’s blood and buccal 
epithelia and high levels of heteroplasmy (88%) in the patient`s hair sample. In addition, 
high levels of mutation were observed in the mother’s blood (65%) and almost 
homoplasmic levels in the grandmother’s muscle sample (98%). The presence of the 
mutation in tissues from the grandmother and mother confirms this mutation was 
transmitted to the patient. 
Figure 3-23 PCR
(A) Schematic diagram showing the sizes of the PCR products after digestion with the restriction 
endonuclease (HaeIII). (B) Quantification of mutation load in different tissues from patient and relatives: 
lane 1 is an uncut DNA sample; lanes 2 and 3 are DNA f
Dutch patient blood DNA sample with 77% heteroplasmy level (positive control); Lane 5 is DNA from 
mother’s blood sample (65% mutant
DNA from patient hair’s sample (88% 
and lane 9 is DNA from grandmother’s muscle sample (98% 
experiment. 
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-RFLP analysis in patient with the m.13051G>A mutation
rom negative control samples; lane 4 is DNA from 
); lane 6 is DNA from patient’s blood sample (homoplasmic
mutant); lane 8 is DNA from patient’s buccal sample (
mutant). Boxed lane was taken from another 
 
. 
); lane 7 is 
homoplasmic); 
 3.5.4.3 Measurement of respiratory chain comple
Measurement of the activity of the individual respiratory chain complexes I and II and of 
citrate synthase from patient’s 
activity (1.2 (CI/CII)) and (447 nmols NADH oxidized.min
(CI/CS)) as opposed to the normal complex I activity in human fibroblasts (0.58
(CI/CII)) and (0.197±0.034 nmols NADH oxidized.min
(mean ± SD, n=8). However, these values are still slightly above 
can be attributed to the quality of the cells.
3.5.4.4 Measurement of 
fibroblasts from the m.13051G>A patient
Results from measuring ROS production in the patient`s fibroblasts, stained with
probe, showed a significant increase in ROS production (
control samples. This was accompanied by a significant increase in mitochondrial mass (P 
<0.001, NAO probe, n=4) (Figure 3
Figure 3-24 Measurment of ROS
A significant increase in both ROS levels 
samples (C1 is a healthy neonatal, C2 is a 
Error bars represent SEM. 
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P<0.001, n=5
-24). 
 levels and mitochondrial mass in fibroblasts from the m.13051G>A patient.
and mitochondrial mass was observed when compared to control 
healthy pediatric, and C3 is embryonic lung fibroblasts (MRC5)
 
citrate synthase-1 
-0.90 
-1 (CI/CS)) 
 DHR 
) as compared to 
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 3.5.4.5 Western blot analysis and protein expression levels in fibroblasts 
from the m.13051G>A patient
Results from Western blot ana
expression levels and a greater increase in MnSOD levels consistent with the increased 
levels of ROS (Figure 3-25).
Figure 
This figure shows a slight increase 
levels. Error bars represent SEM.
 
3.5.4.6 Is the m.13051G>A mutation pathogenic?
Leigh syndrome is a heterogeneous progressive neurod
infant and adults, It is associated with defects in mitochondrial energy production 
mainly affects the central and peripheral nervous systems in children as well as adults due 
to mutations in either the 
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lysis showed a slight increase in the CI-20kDa protein 
 
3-25 Western blot analysis of the m.13051 G>A. 
in the CI-20 protein expression levels and more
 
 
egenerative disease 
nuclear or mitochondrial genomes [391]. D
 
 increase in MnSOD 
that affects 
[390]. It 
eficiencies in the 
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respiratory chain complexes I, II, IV or V have been seen in patients with Leigh or Leigh-
like syndrome [392]. 
Full mitochondrial genome sequencing of DNA from patient #3, who presented with Leigh 
syndrome and normal respiratory chain enzymes activities, identified the m.13051G>A 
mutation in the subunit ND5 of complex I. This mutation was present in all investigated 
tissues from patient, mother and grandmother. It was almost homoplasmic in the patient’s 
samples, with the exception of the patient`s hair sample, and the grandmother`s muscle. 
High levels of heteroplasmy were identified in the mother’s blood sample. In addition, it 
affected a highly conserved sequence in the MTND4 gene in different species (Figure 3-22-
B), which resulted in the substitution of serine instead of glycine with serine at position 
239. Moreover, this mutation was not found in healthy individuals and other patients with 
mitochondrial disorders. 
As mentioned previously (section 1.5.1) ND5 may be involved in proton machinery [84] 
and ubiquinone binding [85]. The m.13051G>A mutation within this gene had not effect 
on complex I activity in this patient which makes it difficult to explain the role of this 
mutation in causing the observed clinical phenotype. However, this does not exclude a 
pathogenic role for this mutation in this patient. Moreover, the statistically significant 
increase in both ROS levels and mitochondrial mass in fibroblasts from this patient 
supported the involvement of the mutation in the disease pathogenesis. However, it is not 
clear what caused the increased levels of ROS production and mitochondrial mass in this 
patient who had normal energy production.  
3.5.5 The m.13513G>A mutation 
3.5.5.1 Mitochondrial DNA sequencing 
Sequence analysis of patient #5 with Leigh syndrome, identified the potentially pathogenic 
m.13513G>A mutation. This mutation changes the highly conserved aspartic acid to an 
asparagine at residue 393 of the ND5 subunit of complex I (Figure 3-26). In addition to 
this pathogenic mutation, other sequence changes were identified as summarized in Table 
3-9.  
 Figure 3-26 Conservation
(A) Sequence chromatogram showing the m.13513G>A transition in the patient (indicated by arrow) and 
compared to control. (B) Alignment of amino acids sequences at position 393 (as indicated by asterisk) 
within MTND5 showing the high conservation in different species.
 
3.5.5.2 PCR-RFLP analysis of the m.13513G>A mutation
PCR-RFLP analysis was carried out to quantify mutation load
from patient. A mismatch forward primer was designed to introduce a recognition site for 
the endonuclease BbsI (GAAGACN(2))
mtDNA as 173bp products, while it cuts the mutant mtDNA 
(Figure 3-27). Results showed ~ 50% of mutation load levels in patient muscle sample.
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into 147bp and 27bp products 
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Figure 3-27 PCR-RFLP analysis of patient with the m.13513G>A mutation.  
(A) Schematic diagram showing the sizes of the PCR products after digestion with the restriction 
endonuclease (BbsI). (B) Quantification of mutation load; lane 1 is an uncut sample; lane2 is a control 
sample; and lane 3 is a skeletal muscle sample from the patient (50% heteroplasmy).  
Table 3-9 Sequence changes identified in the patient carrying the m.13513G>A mutation. 
Sequence change Previously reported as a SNP or pathogenic? Mitomap or mtDB Amino acid change Location 
m.309CT ins. Yes - D-Loop 
m.310T>C Yes - D-Loop 
m.750A>G Yes - 12S rRNA 
m.1438A>G Yes - 12S rRNA 
m.3106C del. Yes - 16S rRNA 
m.4769A>G Yes No MTND2 
m.8860A>G Yes Thr112Ala MTATP6 
m.11016G>A Yes Ser86Asn MTND4 
m.13513G>A Yes Asp393Asn MTND5 
m.15326A>G Yes Thr194Ala MTCYB 
m.16519T>C Yes - D-Loop 
 3.5.5.3 Measurement of respiratory chain complex
Measurement of the activity of the individual respiratory chain complexes I and II and of 
citrate synthase from the patient’s muscle 
I activity (0.062 nmols NADH oxidized.min
(CI/CII) as opposed to the normal complex I activity in human muscle (0.104±0.036
NADH oxidized.min-1.unit citrate
SD, n=25). 
3.5.5.4 Measurement of 
from the m.13513G>A patient 
Patient fibroblasts, stained with DHR probe, showed an increase in ROS levels relative to 
controls but without statistical significance (
showed no change in mitochondrial mass as compared to controls (
Figure 3-28 Measurement of ROS 
DHR staining showed an increase in ROS levels but NAO staining showed no change in mitochondrial mass. 
C1 is a healthy neonatal, C2 is a 
represent SEM. 
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 activity 
sample revealed a biochemical defect in complex 
-1
.unit citrate synthase-1 (CI/CS)) and (0.334 
 synthase-1 (CI/CS)) and (0.52-0.95 (CI/CII)) (mean ± 
ROS levels and mitochondrial mass in fibroblasts 
 
n=5). Fibroblasts stained with NAO probe 
n=4) (Figure 3
levels and mitochondrial mass in fibroblasts from the m.13513G>A patient
healthy pediatric, and C3 is embryonic lung fibroblasts (MRC5). 
 
 nmols 
-28). 
 
.  
Error bars 
 3.5.5.5 Western blot analysis and expression of protein levels in 
fibroblasts from the m.13513G>A patient. 
CI-20kDa protein expression levels were highly increased in this 
were markedly upregulated, which could be as a response to the increase in ROS 
production (Figure 3-29). 
Figure 3-29 Western blot analysis in fibroblasts from patient with the m.13513
A high increase of protein expression levels was seen in CI
levels was seen in MnSOD. C1, C2, and C3 are healthy controls and error bars represent SEM.
3.5.5.6 Is the m.13513G>A mutation 
The m.13513G>A mutation 
syndrome and had a biochemical defect in complex I in muscle. 
(Figure 3.26.A) showed that this mutation was heteroplasmic with hig
mutation affects an evolutionary conserved nucleotide 
aspartic acid to asparagine at amino acid position 393 in the ND5
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patient. MnSOD levels 
-20, while a sligh increase of protein expr
pathogenic?  
was identified in patient #5, who presented with Leigh 
Sequence chromatogram 
and leads to the change of an 
 (Figure 3
 
G>A mutation. 
ession 
 
h levels. This 
-26-B). It 
126 
 
caused a biochemical defect in the patient`s muscle sample. This mutation was not found 
in normal individuals and other patients with mitochondrial disorders. 
The 13513G>A in this patient was not novel since the same mutation was reported in at 
least 16 other cases most of which presented with Leigh or Leigh-like syndrome [393]. 
Initially, m.13513G>A was associated with MELAS [337]. Subsequently, other cases were 
reported and associated with LHON/MELAS overlap syndrome [394], MELAS [395], 
mitochondrial encephalomyopathy [395] and Leigh syndrome [315, 392]. More recently, 
this mutation was reported, in our lab, in a child who was referred with a suspected with 
mitochondrial disorder. PCR-RFLP analysis using the endonuclease BbsI (Table 3-3) 
revealed ~ 60% mutation load in urinary epithelia cells from this child. In addition, this 
mutation was absent in tissues from the mother suggesting the mutation is sporadic (Figure 
3.30). 
 
Figure 3-30 PCR-RFLP analysis of the m.13513G>A mutation in a recent patient and mother.  
Lane 1 is an uncut DNA sample; lane2 is DNA from a negative control sample; lane 3 is DNA from patient`s 
muscle DNA sample with the m.13513G>A mutation (positive control); lane 4 is mother’s blood DNA 
sample; lane 5 is mother’s DNA urine sample; and 6 is patient`s DNA urine sample (60% mutation load 
levels).  
Finally, all previous reasons make the m.13513G>A mutation in the MTND5 gene of 
complex I a strong candidate for causing the disease in this patient. In addition, this 
mutation should be considered in individuals suspected with Leigh or Leigh-like 
phenotypes associated with complex I deficiency. 
Although the m.13513G>A mutation affects the nucleotide directly next to the 
m.13514A>G, which was described in two patients with MELAS, it does not result in the 
same change in amino acid, aspartic acid to glycine with m.13514A>G. This indicates that 
the amino acid at position 393 is likely to be highly important for complex I structure and 
function [395] since both mutations are believed to change the secondary  structure of the 
protein [315, 396]. Moreover, the 393 position within complex I is thought to be involved 
 in ubiquinone binding, therefore this mutation may disrupt this binding, therefore leading 
to a defect in mitochondrial oxidative phosphorylation
complex I activity in muscle from this patient and other cases with the m.13513G>A 
mutation could also be att
whole complex activity [337]
3.5.6 The m.14453G>A
3.5.6.1 Mitochondrial DNA sequencing
Sequencing of the entire mitochondrial genome from 
presented with spasms, pigmentary retinopathy, encephalopathy
and changes in basal ganglia resulted in the ident
mutation. This transition changes the amino acid at position 47 from alanine to valine in 
the ND6 subunit of complex I, which 
spanning domain now considered a hot spot for 
highly conserved sequence of the protein (Figure 3
identified in this patient are summarized in Table 3
Figure 3-31 Conservation
(A) Sequence chromatogram showing the m.14453G>A transition in the patient (indicated by arrow) and 
compared to control. (B) Alignment of amino acids sequences at position 74 (as indicated by an asteri
within MTND6 showing the high conservation in different species.
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Table 3-10 Sequence changes identified in the patient carrying the m.14453G>A mutation. 
Sequence change Previously reported as a SNP or pathogenic? Mitomap or mtDB Amino acid change Location 
m.311C ins. Yes - D-Loop 
m.263A>G Yes - D-Loop 
m.750A>G Yes - 12S rRNA 
m.1438A>G Yes - 12S rRNA 
m.3106C del. Yes - 16S rRNA 
m.4769A>G Yes No MTND2 
m.6776T>C Yes No MTCO1 
m.7148T>C Yes No MTCO1 
m.8860A>G Yes Thr112Ala MTATP6 
m.11914G>A Yes No MTND4 
m.12681T>C Yes No MTND5 
m.14020T>C Yes No MTND5 
m.14453G>A Yes Ala47Val MTND6 
m.15326A>G Yes Thr194Ala MTCYB 
m.16519T>C Yes - D-Loop 
 
 3.5.6.2 PCR-RFLP analysis
PCR-RFLP analysis using mismatched primers, to introduce an additional 
(GTNAC), was carried out to quantify the mutation loads in different tissues from the 
patient and mother. This endonuclease cut wild
products, while it cuts mutant mtDNA into 143 bp, 25 bp, and 21 bp products (Figure 3
32). Results showed high levels of mutation in the patient`s muscle (65%) but low levels in 
fibroblasts (39%). The mutation was not found in investigated tissues from the mother
suggesting this occurred as a sporadic mutation in the patient.
Figure 3-32 PCR
(A) Schematic diagram showing the sizes of the PCR products after di
endonuclease MaeIII (B) Quantification of mutation load in different tissues: 
lane 2 is DNA from a negative control sample; lane
DNA from patient’s fibroblasts 
urine samples, respectively.    
3.5.6.3 Measurement of respiratory chain complex
Measurement of the activity of the individual respiratory chain complexes 
citrate synthase from patient’s 
activity (0.334 nmols NADH oxidized.min
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 of the m.14453G>A mutation 
-type mtDNA into 168 bp and 21 bp 
 
-RFLP analysis in patient with the m.14453G>A mutation
gestion with the restriction 
lane 1 is 
 3 is DNA from patient’s muscle (65% 
(39% mutant). Lanes 5, 6, and 7 are DNA from mother’s blood, buccal and 
 activity 
fibroblasts showed no biochemical defect in complex I 
-1
.unit citrate synthase-1 (CI/CS))
MaeIII site 
-
 
 
.  
an uncut DNA sample; 
mutant); lane 4 is 
 
I and II and of 
 as opposed to 
 the normal complex I activity in human fibroblasts (0.197±0.034 n
oxidized.min-1.unit citrate synthase
showed complex I deficiency in muscle as initially investigated prior to referral.
3.5.6.4 Measurement of ROS levels and mitochondrial mass in fibroblasts 
from the m.14453G>A patient
Patient fibroblasts stained with DHR probe showed a high increase in ROS levels with no 
statistical significance when compared to each control (
with NAO probe showed no change in mitochondrial mas
Figure 3-33 Measurement of ROS 
A high increase in ROS levels with no statistical significance 
change in mitochondrial mass wh
pediatric, and C3 is embryonic lung fibroblasts (MRC5). 
3.5.6.5 Western blot analysi
fibroblasts from the m.14453G>A patient
Results from Western blot analysis showed an increase in CI
levels and no change in MnSOD levels as compared to controls (Figure 3
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-1 (CI/CS)) (mean ± SD, n=8). However, this patient 
 
n=6), however, fibroblasts stained 
s (n=4) (Figure 3
levels and mitochondrial mass in fibroblasts from patient with the 
m.14453G>A mutation. 
was observed in patient sample, while no 
en compared to control samples. C1 is a healthy neonatal, C2 is a 
Error bars represent SEM. 
s and expression of protein levels in 
 
-20kda protein expression 
mols NADH 
 
-33). 
 
healthy 
-34). 
 Figure 3-34 Western blot analysis in fibroblasts from the patient with the m.14453G>A mutation.
A high increase of protein expression levels was seen in CI
observed when compared to control.
3.5.6.6 The m.14453G>A mutation is pathogenic 
Full genome sequencing of DNA samples from patient 
pigmentary retinopathy, encephalopathy, 
and defect in complex I activity in muscle
subunit of complex I. This mutation is believed to be the main cause of the disease for 
several reasons. First, it is a
47 from alanine to valine. This is a highly conserved nucleotide in the ND6 subunit of 
complex I (Figure 3-31-B). Several mutations have previously been reported within this 
region of the N-terminus of this subunit, which is thought to be a hot spot for mutations 
[397]. Second, the mutation was present in all investigated tissues from this patient, with a 
high mutation load in muscle and a low load in fibroblasts. Third, it caused a biochemical 
defect in complex I activity in muscle. 
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-20 and a slight increase in MnSOD levels 
 C1, C2, and C3 are healthy controls and error bars represent SEM.
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PCR-RFLP analysis revealed high levels of mutation load in patient’s muscle and low 
levels in fibroblasts. This is consistent with results from respiratory chain enzyme activity 
measurement, which showed a biochemical defect in complex I activity in muscle but not 
in fibroblasts. The maintenance of complex I activity in fibroblasts can be attributed to the 
low levels of mutation in these cells, which suggests it is still below the threshold to cause 
a defect. 
Lastly, the presence of this mutation in tissues from patient and the absence in mother’s 
tissues confirms that the m.14453G>A has arisen de novo and is only restricted to the 
patients’ tissues. In conclusion, all given data confirms the involvement of the 
m.14453G>A mutation in causing the disease in this patient. 
3.3 Discussion 
Those identified complex I mtDNA mutations in patients are main candidates to cause 
pathogenicity in investigated patients because they fulfill the canonical criteria for 
pathogenicity. They are heteroplasmic except the m.11453G>A mutation, which was 
homoplasmic. Those transitions change the amino acids in subunits of complex I. In 
addition, they affect a highly conserved sequence of the protein. They are present in 
investigated samples from patients with variable mutation loads.  
To further support the roles of those mutations in pathogenicity, other cellular properties 
were investigated such as ROS levels, mitochondrial mass, membrane potential, and 
protein expression level.  
The m.11777G>A and the m.13051G>A mutations were the only mutations which showed 
significant results as both revealed increases of in both ROS levels and mitochondrial mass 
in fibroblasts, while the remaining mtDNA mutations showed no significant changes from 
controls. In addition, measurement of membrane potential in fibroblasts from all patients 
revealed no statistically significant changes (Figure 3-35). 
 Figure 3-35 Membrane potential measurement in fibroblasts from investigated patients.
Results from measurement of membrane potential in patient`s cells using JC
change when compared to contol samples
healthy control and control 2 is a healthy neonatal
The increase of ROS level 
defect due to mtDNA mutation,
carries the m.11777C>A mutation. 
inhibition of complex I activity by
the complex, rotenone prevents
from transport. This results in the increase of electrons concentration and their
to produce more ROS [62], which can explain the observed 
patient. However, it is not clear what caused the increased levels of ROS 
has the m.13051G>A mutation but 
production in the other patients could be explain by that those mutations did not cause 
structural modifications of complex I, which may play a crucial role in ROS production 
process when they affect the specific
phosphorylation of mitochondrial proteins
dysfunction, may affect levels of ROS production 
Mitochondrial mass also was increased in fibroblasts from both patients (#2 & #3). This 
increase results from a feedback mechanism to compensate for defective respiratory chain. 
Similarly, this can explain the increase of mitochondrial mass in patient with the 
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can be explained as a consequence of the 
 which caused a respiratory chain defect in patient #2 
The biochemical defect in complex I activity mimics 
 rotenone. In the process of electron transport
 the electrons from leaving complex I preventing electrons 
increased levels of ROS in this 
has normal OXPHOS. The normal levels of ROS 
 sites to cause ROS production 
, which protect mitochondria against 
[398]. 
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 availability 
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m.11777C>A mutation, who showed a defect in complex I activity. It is still not known 
what causing the increase of mitochondrial mass in the patient with the m.13051G>A 
mutation. However, mitochondrial mass does not increase in all pathogenic conditions due 
to mutations in the mtDNA [399].  
Because the increase of mitochondrial mass may increase protein expression levels, we 
checked this by western blotting; however, measurement of protein expression levels in all 
patients showed no significance since fibroblasts from patients (2 & 3) showed low levels 
when compared to the other patients which revealed high levels of expression. The 
expression levels of MnSOD revealed no significant change in the m.11777G>A and the 
m.13051G>A patients even with the observed increase of mitochondrial mass. 
Together, results from biochemical and molecular genetic investigations revealed that 
these mutations fulfilled the canonical criteria for pathogenicity, which make these mtDNA 
mutations in complex I strong candidates in causing the disease in the investigated patients. 
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Chapter 4 : Identification of two novel and pathogenic mt-tRNA 
mutations 
4.1 Introduction 
An extensive range of molecular defects have been identified in the human mitochondrial 
genome, many associated with well-characterised, progressive neurological syndromes. 
These mutations may affect mitochondrial protein synthesis such as mtDNA deletions or 
single nucleotide substitutions, which predominantly affect mitochondrial transfer RNA 
(mt-tRNA) genes [1, 400]. A recent survey of an adult population with mtDNA disease has 
shown that mt-tRNA mutations are the most prevalent genetic defect, accounting for 
approximately 50% of all genetically-diagnosed cases [232]. Those mutations are either 
homoplasmic (all copies of the mtDNA are mutated) or heteroplasmic (a mixture of 
mutated and wild-type genomes in the same cell or tissue). Heteroplasmic mutations are 
most frequently observed in patients, with variation in levels of heteroplasmy contributing 
to the major differences in clinical phenotypes [401] . 
To date, more than 250 mt DNA mutations have been associated with human diseases 
[402]. Mutations in the mitochondrial tRNA genes were identified after the discovery and 
characterization of the MERRF mutation (m.8344A>G) and MELAS mutation 
(m.3243A>G), respectively, in the late 1980s and early 1990s [403-405]. Some of the 
mutations in the tRNA genes are correlated with specific phenotypes and the clinical 
phenotypes can be different from mild to severe or even lethal [118]. Interestingly, there is 
considerable overlap in many cases in which mutations in the same mt-tRNA gene can 
give rise to different clinical phenotypes and conversely the same clinical phenotype can 
be caused by mutations in different mt-tRNA genes (Figure 4-1). Notably, although mt-
tRNA genes represent ~10% of the mtDNA genome, almost 75% of mtDNA–related 
diseases are caused by mutations in these genes [406]. 
Mutations in the mitochondrial tRNA genes usually cause generalised impairment of 
mitochondrial protein synthesis. Individual mutations may affect mt-tRNA function by 
different mechanisms, including inhibition of aminoacylation [407], impairment of mt-
tRNA stability [408], altered processing of the mt-tRNA [409], modification of wobble-
bases [410, 411], reduced association of mt-tRNA with the ribosome [412] or a 
combination of these mechanisms. These mutations generally cause a ‘loss-of-function’ of 
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the affected mt-tRNA and are considered functionally recessive, as it is only when they 
affect most mtDNA molecules in a cell (70–90%) that a biochemical phenotype is 
observed [207]. However, this concept was recently challenged with the identification of 
an mt-tRNA mutation found to cause a biochemical defect at low levels of heteroplasmy 
[402, 413]. Initially, mt-tRNA mutations have been associated with multisystem 
syndromes, but they also have been observed in patients with tissue-specific disorders. 
Almost 50% of these mutations occur in only three mt-tRNA genes (mt-tRNALeu(UUR), mt-
tRNALys, and mt-tRNAIle. The greater susceptibility of these mt-tRNA genes to 
mutagenesis than others can be explained by the weak stabilised tertiary structure of mt-
tRNALeu(UUR) and mt-tRNALys [414] and the high content of A-U base-pairs in mt-tRNA Ile 
[415]. In addition, this can explain as well why one mt-tRNA mutation, such as 
m.3243A>G, can cause such a broad spectrum of clinical phenotypes while different 
mutations can be associated with the same clinical phenotype as explained by Giuseppe 
Attardi and colleagues [412]. 
Sequence changes in the mt-tRNA genes can be either pathogenic or polymorphic. Some 
of these genes are known to be hotspots for polymorphisms: mt-tRNAThr, mt-tRNAAsp, mt-
tRNAArg, mt-tRNACys, mt-tRNAGln and mt-tRNAHis. Conversely, some are known to be 
hotspots for pathogenic mutations: mt-tRNALeu(UUR), mt-tRNALys, and mt-tRNAIle. 
Sequence changes are randomly distributed throughout the different structural domains of 
the mt-tRNAs that, suggests that all domains are equally prone to mutagenesis [118, 416]. 
However, the mt-tRNALeu(UUR) gene was shown to have the greatest pathogenic mutation to 
neutral changes ratio and the mt-tRNA Pro gene had the least changes with only one 
pathogenic change. Almost 73% of mutations occurred in the stem structures and ~ 94% of 
the pathogenic mutations that occurred in stem structures disrupted Watson–Crick base 
pairing, while ~44% of neutral changes occurred in the stem structures and only 57% 
disrupted Watson–Crick base pairing [248]. Only a few mutations have been identified in 
the anticodon triplet region, which is known to be highly conserved in all mt-tRNAs. These 
are the m.12298T>C polymorphism in mt-tRNALeu(CUN) [417], the m.15990G>A 
pathogenic mutation in mt-tRNAPro [418] , and the m.5545C>T pathogenic mutation in mt-
tRNA Trp [402]. 
Finally, although some of mt-tRNA mutations exhibit maternal transmission within 
families, sporadic cases are rare [419]. The mt-tRNA mutation selection in a rapidly 
 replicating tissue such as blood is an important factor in determining whether this mutation 
is transmitted to offspring. Recent results showed that sporadic mt
low levels of mutation load in blood cells are likely to be inherited 
Figure 4-1 Association between mt
The majority of mtDNA–related diseases are caused by mutations in mt
minority of the mtDNA genome. In many cases, overlap was observed between mutations and clinical 
phenotypes. Associated clinical phenotypes and syndromes a
ophthalmoplegia; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke
episodes; MERRF, myoclonic epilepsy and ragged red fibres; PEO,
MNGIE, mitochondrial neurogastrointestinal encephalopathy syndrome; KSS,
(modified from a Figure courtesy of Dr
4.2 Aims  
In this chapter, I will describe the histochemical, biochemical, and molec
investigation of two patients. T
developed a clear clinical 
second patient (Portland-4) 
on the basis of their clinical phenotypes for mitochondrial DNA investigations, their 
muscle biopsies revealed biochemical o
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Table 4-1 Summary of the clinical presentations and other related investigations in the studied cohort of patients. 
 
 
Patient   Age Clinical phenotypes 
Biochemical and histochemical 
investigations 
Identified mtDNA mutations 
Portland-1   24 
Learning disability, seizures, hearing loss, 
and stroke 
COX negativity with ragged red fibres. 
-Mild COX deficiency. 
m.6299A>G, MTCOX1 
silent change 
 
Portland-2   34 
Recurrent muscle cramps and exercise 
fatigue 
- Ragged red fibres without COX negativity. 
m.6794A>G, MTCOX1 
silent change 
 
Portland-3    62 
Severe fatigue, exercise intolerance, progressive 
ataxia,peripheral neuropathy 
-Decrease Complex I and COX activities. 
-High percentage of COX negativity but 
no ragged red fibres. 
No pathogenic mtDNA 
mutation identified 
Portland-4   28 
Some developmental delay, motor and speech delay, 
hearing loss. Grand mal seizures, vision loss 
 and retinitis pigmentosa 
-Mild complex I deficiency. 
- Many ragged red fibres and some 
COX deficient fibres. 
m.12261G>A, MTTL2 
 
Portland-5   71 Muscle pain with weakness, ptosis, chest pain, and 
decreased attention span and memory 
- COX deficient fibers but no ragged 
red fibres. 
- Mild complex I deficiency. 
m13497A>G, MTND5 
silent change 
 
Portland-6   74 
Muscle weakness, CPEO, ptosis, and   
retinitis pigmentosa 
 
-Numerous ragged red fibres and scattered  
COX deficient fibres. 
m.5450C>T, MTND2 
silent change 
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4.3 Material and methods  
4.3.1 Needle muscle biopsy analysis 
Sections from frozen muscle biopsies were cut using a cryostat to perform routine 
histological analysis. Haematoxlyin and eosin (H&E) staining was carried out as described 
(section 2.2.15.1). In addition, combined COX/SDH staining was carried out as decribed 
(section 2.2.15.2). 
4.3.2 Long-range PCR analysis 
Long-range PCR analysis was carried out as described (section 2.2.12) to screen for large-
scale mtDNA rearrangements in total muscle DNA. 
4.3.3 Mitochondrial DNA sequencing 
Entire mitochondrial genome sequencing from total muscle homogenate or blood was 
performed as described (section 2.2.6) to search for mtDNA point mutations.  
4.3.4 PCR-RFLP analysis 
Table 4.2 summarises details for this analysis such as primer position, sequence, restriction 
endonuclease enzyme, and annealing temperatures in investigated patients.  
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Table 4-2 Summary of PCR-RFLP analyses for the m.618T>G and m.12261T>C mutations in NCL-1 ansd Portland-4 patients. 
Mutation Primer Position Primer Sequence 
Primer 
Annealing 
Temperature 
(oC) 
Enzymes and 
Digestion site 
Digest 
Temperature 
(oC) 
Uncut 
PCR 
product 
(bp) 
Wild-type 
products 
(bp) 
Mutant 
products 
(bp) 
m.618T>G 
L503 
 
H639 
 
5`-GCACACACACACCGCTGC-3` 
 
5`-GGGTGATGTGAGCCCGTTTAA-3` 
 
61 
Mismatch reverse 
primer to 
introduce a DraI 
site (TTT/AAA) 
37 127 108 + 19 127 
 
m.12261T>C 
L12221 
 
H122468 
5`-GAACTGCTAACTCATGCCC-3` 
 
5`-AAAGGTGGATGCGACAATGG-3` 
58 
Mutation creates 
another Mn1I site 
(CCTC(N)) 
 
37 248 192+56 141+56+51 
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4.4 The m.618T>G mutation case 
4.4.1 Summary of clinical representations for the m.618G>A case  
The NCL-1 patient is a 50-year old female who presented at age 25 with left sided ptosis 
that became bilateral. She had limb and respiratory weakness. In addition, she had CPEO, 
myopathy, diplopia, dysphagia, and exercise intolerance. Initial results from long-range 
PCR appeared to show multiple mtDNA deletions; however, no evidence of mutations in 
the three major mtDNA maintenance genes (POLG, SLC25A4, and PEO1) was noted. 
Combined COX-SDH histochemical analysis showed ~25% COX deficiency in her muscle 
biopsy (Figure 4-2). 
She had two daughters. The first (NCL-2) is 28-years old and clinically asymptomatic. 
However, muscle biopsy analysis revealed ~ 3% COX deficiency, which is abnormal at 
this age although no evidence of mtDNA deletions was detected on long-range PCR. 
Her other daughter (NCL-3) is 27-years old. She presented with deafness and a stroke-like 
episode at the age of 19. A CT scan showed that she had had two mini strokes. Muscle 
biopsy investigations showed no evidence of mtDNA deletions and biochemical 
assessment of respiratory chain activity was normal. In addition, histochemical and 
histological analyses showed normal results. 
4.4.2 Results 
4.4.2.1 Histochemical analysis 
The combined COX/SDH staining of the patient`s muscle biopsy showed ~ 25% COX 
deficiency with several fibres showing evidence of subsarcolemmal mitochondrial 
accumulation typical of ragged-red changes which are suggestive of an underlying 
mitochondrial genetic abnormality (Figure 4-2). 
 Figure 4-2 Histological and histochemical analysi
The figure shows the combined COX/SD
COX deficiency in the patient. COX
4.4.2.2 Long-range PCR analyses
Total muscle DNA was assessed for large
full-length wild-type 10kb amplicon, a number of faint, s
amplified, which were initially 
although a great proportion of mtDNA deletions were expected given the marked 
histochemical changes seen in muscle.
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s of muscle biopsy from patient with the m618T>G
H staining in muscle biopsy from patient, which revealed ~25% of 
-positive fibres are brown and COX-deficient fibres are blue.
 
-scale mtDNA rearrangements. In addition to the 
maller products were also 
suggestive of multiple mtDNA deletions (Figure 4
 
 
Figure 4-3 Long-range PCR analysis of muscle biopsy 
from patient NCL
Lane 1 is a 10 kb DNA ladder, lane 2 is a PCR 
product from a patient who has 
deletion (positive control), lanes 3 is 
from a person who has no mtDNA deletion
(control), lane 4 is the resultant PCR product from 
NCL-1 muscle DNA sample, and lane 5 is a PCR 
product from a patient who has 
deletions (positive control). 
 
 
. 
 
-3) 
-1. 
a single mtDNA 
a PCR product 
 
multiple mtDNA 
 4.4.2.3 Real- time PCR analysis
Real-time PCR was carried out 
molecular basis of the COX 
from laser-microdissected COX
sets of primers and probes were used to quantify the amount of mtDNA. These were 
located in the MTND1 gene, which is rarely deleted in patients and the 
which is deleted in the majority of patients. 
mtDNA deletion in the MTND4
for mtDNA deletion, which is about 65% 
Figure 4-4 Real-Time PCR analyse
This figure shows no evidence of mtDNA deletion in 
fibres as levels of mutation load 
4.4.2.4 Whole mitochondrial genome
To further investigate the COX
mtDNA deletion, whole mitochondrial genome sequencing 
muscle DNA. Results showed the ident
in the MTTF gene (mt-tRNA
previous reported in the main mitochondrial databases 
disrupts a highly conserved base pairing 
4-6). A mutation at the same location was 
the change observed was m.
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as described (section 2.2.13) to further investigate the 
deficiency in individual muscle fibres. DNA was prepared 
-positive (n=13) and COX-deficient fibres
However, results revealed no evidence of 
 gene since all values are below the known threshold levels 
[421] (Figure 4-4). 
 
s of individual muscle fibres from NCL-1 patient to assess mtDNA deletion
the investigated COX-positive and COX
fall below threshold levels of mtDNA deletion.  
 sequencing 
-deficient fibres, which we had proven were devoid of 
was carried out
ification of the heteroplasmic m.618T>G mutation 
Phe) (Figure 4-5) in addition to other changes (Table 4
[69, 252]. The 
in the anticodon stem of the mt
previously reported as novel and pathogenic but 
618 T>C [422]. 
 (n=15). Specific 
MTND4 gene, 
. 
-deficient 
 on skeletal 
-3), all 
MTTF mutation 
-tRNA Phe (Figure 
 Figure 4-5 Sequence chromatogram showing the m
Position of the m.618 is shown in both control and patient (indica
Table 
Sequence change Previousl
m.263A>G 
m.303C ins. 
m.414T>C 
m.618T>G 
m.750A>G 
m.1438A>G 
m.3107delC 
m.4769A>G 
m.5663C>T 
m.8860A>G 
m.14470T>C 
m.15326A>G 
m.16519T>C 
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Yes - 
No - 
Yes - 
Yes - 
Yes - 
Yes No
Yes - 
Yes Thr112
Yes No
Yes Thr194
Yes - 
 
 NCL-1. 
 
 Location 
D-Loop 
D-Loop 
D-Loop 
MTTF 
12S rRNA 
12S rRNA 
16S rRNA 
 MTND2 
MTTN 
Ala MTATP6 
 MTND6 
Ala MTCYB 
D-Loop 
  
Figure 4-
(A) Schematic representation of the mt
the anticodon stem (taken and modified from 
Phylogenetic conservation of this region of the 
conserved base pairing (boxes). 
4.4.2.5 PCR-RFLP analysis
A mismatch reverse primer was designed to introduce a 
type mtDNA. The endonuclease 
mutant mtDNA and uncut samples resu
showed high levels of m.618T>G in skeletal muscle from the patient as high 
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6 Conservation of the nucleotide at position m.618T>G.
-tRNAPhe cloverleaf structure showing the position of the mutation in 
http://mamit-trna.u-strasbg.fr/mutations.asp?idAA=20
MTTF gene sequence in different species sho
 
DraI site (TTT/AAA) in the wild
DraI cuts wild-type into 108bp and 19bp, while the 
lt in 127bp products (Figure 4
 
 
). (B) 
wing the highly 
-
-7-A). Results 
(as high as 
 76%) but the mutation was absent in
m.618T>G was absent in s
(Figure 4-7-B). 
Figure 4-7 PCR
 (A) Schematic diagram of PCR
restriction endonuclease DraI. (B) PCR
from the patient and her daughters. Lane 1 is
negative controls, lane 4 is a patient’s muscle (76% mutant), lanes 5 6 is patient’s blood, and lane 6 is 
patient`s urine. Lanes 7-9 are NCL
muscle, blood, and urine. The boxed lanes are a repeat of the two samples to confirm absence of mutation.
To determine whether the m.618T>G mutation segregates
individual cells. DNA was prepared fro
COX-deficient fibres (n=18
mutation were detected in COX
positive fibres (22.35 ± 33.61%) (
genotype with respiratory chain dysfunction (Figure 4
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 the patient’s blood and urine samples.
keletal muscle, blood, and urine samples from two daughters 
-RFLP analysis of the m.618T>G mutation in patient NCL
-RFLP analysis showing the sizes of the products after digestion with 
-RFLP analyses to quantify the m.618T>G levels in different tissues 
 an uncut DNA sample, lanes 2 and 3 are 
-2 patient`s muscle, blood, and urine. Lanes 10-12 are NCL
 with the biochemical defect
m laser-microdissected COX-positive (
). Results showed that the higher levels of the m.
-deficient fibres (96.56 ± 11.77%) 
P<0.0001), confirming segregation of the m.
-8).  
 In addition, the 
 
-1. 
DNA samples from 
-3 patient`s 
 
s in 
n=20) and 
618T>G 
than in the COX-
618T>G 
 Figure 4-8 Graphical representation of single PCR
This graph shows the mean percentage and SE values of PCR
deficient fibres. COX-positive (
P<0.0001 confirming segregation of the m.
4.4.3 The m.618T>G mutation is pathogenic 
Many pathogenic mtDNA mutations have been identified in association with a wide 
spectrum of clinical phenotypes.
genes, resulting in translational 
dysfunction [423, 424]. Patients with extraocular muscle involvement 
have pathogenic mtDNA rearrangements
limb weakness, myalgia , and exercise intolerance usually have an mtDNA point mutation 
in a protein-encoding gene 
usually associated with COX 
muscle tissue [419]. 
This patient was described to have
limbs. Histochemical analyse
muscle fibres with ragged red fibres
identified m.618T>G mutation within mt
pathogenic mutation causative of the disease for several reasons. This mutatio
neutral polymorphic variant 
genome databases [69, 252]
tissues but absent in other tissues. Furthermore, 
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-RFLP analysis of the m.618T>G
-RFLP analysis of COX
n=20, 22.35 ± 33.61%), COX-deficient fibres (n=18, 96.56 ± 11.77%) and 
618T>G genotype with respiratory chain dysfunction.
 
 The majority of these mutations are found in mt
defects and subsequent mitochondrial respiratory chain 
 [236], while patients with myopathy
[1, 236]. Pathogenic point mutations in the mt
deficiency and abnormal proliferation of mitochondria in 
 CPEO and weakness in respiratory muscles and both 
s of the patient’s muscle biopsy showed COX 
, which suggest mitochondrial accumulation
-tRNAPhe in this patient appeared to be the 
and has not been reported in either of the mitochondrial 
. It is a heteroplasmic change present at high
it affects and disrupts 
. 
-positive and COX-
 
-tRNA 
(CPEO) usually 
, proximal 
-tRNA genes are 
negativity in 
.  The 
n is not a 
 levels in muscle 
a highly conserved 
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base pairing within the tRNAPhe anticodon stem suggesting this nucleotide has an 
important function and its loss may be harmful (Figure 4-6-B), Finally, higher mutation 
load was observed in the COX-deficient fibres as compared to the COX-positive fibres 
confirming segregation of the mutation with the biochemical defect.   
In summary, the m.618T>G mutation was present in high levels in DNA samples from 
skeletal muscle of the patient and absent in DNA samples from blood and urine. Also, it 
was absent from DNA samples in different tissues (muscle, blood, and urine) from her two 
daughters. This strongly indicates that the m.618T>G is sporadic and not transmitted. 
However, it is still not known what is causing COX negativity in her daughter (NCL-2) as 
PCR-RFLP analysis showed absence of the m.618T>G and long-range PCR revealed no 
evidence of mtDNA deletion.  
4.5 The m.12261T>C MTTS2 mutation 
4.5.1 Summary of clinical presentations for Portland-4 patient  
 
As mentioned before (section 4.2), Portland-4 patient was from a cohort of six patients, 
whose their samples were sent to be investigated. The patient is a 28-year old male who 
presented with some developmental delay. He had motor and speech delay and hearing loss 
at the age of 6 years. At 12 years of age, he had grand mal seizures, vision loss, and 
retinitis pigmentosa, which are features of Noonan syndrome. His father had a history of 
migraines, sarcoidosis, and joint pain. His mother had migraines, heart problems, fatigue, 
and aerobic exercise intolerance. All observed clinical phenotypes and other related 
information for this patient and the other patients from the cohort are summarised in Table 
4-1. 
4.5.2 Results  
4.5.2.1 Mitochondrial DNA sequencing 
Full mitochondrial genome sequencing of muscle homogenate DNA from all patients 
identified mostly silent changes or non-pathogenic mutations (Table 4-4). The only 
pathogenic mutation identified was in portland-4 patient, which was a transition mutation 
at nucleotide m.12261T>C in the MTTS2 gene, mt-tRNASer(AGY) (Figure 4.9). The 
m.12261T>C sequence change was not previously reported in either of the mitochondrial 
genome databases [69, 252]. This mutation resides in a highly conserved position in the 
aminoacyl acceptor stem and disrupts a Watson-Crick base pairing (Figure 4-10). 
 Figure 4-9 Sequence chromatogram showing the m.12261T>C transition in 
Position of the m.12261 nucleotide 
Figure 4-
(A) Schematic representation of the mt
mutation in the aminoacyl ac
strasbg.fr/mutations.asp?idAA=22
sequence in different species show
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is shown in both control and patient (indicated by arrow).
 
10 Conservation of the nucleotide at position m.12261. 
-tRNA Ser(AGY) cloverleaf structure showing the position of the 
ceptor stem (taken and modified from 
). (B) Phylogenetic conservation of this region of the 
ing the highly conserved base pairing (boxes).
 
-4 patient. 
 
 
 
http://mamit-trna.u-
MTTS2 gene 
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 Table 4-4 Sequence changes identified in Portland-4 patient. 
 
Sequence change Previously reported as a SNP or pathogenic? Mitomap or mtDB 
Amino acid 
change Location 
m.73A>G Yes 
 - D-Loop 
m.263A>G Yes 
 - D-Loop 
m.1438A>G Yes  - 12S rRNA 
m.1811A>G Yes  - 16S rRNA 
m.2352T>C Yes  - 16S rRNA 
m.2706A>G Yes  - 16S rRNA 
m.3106C ins. Yes  - 16S rRNA 
m.3720A>G Yes No MTND1 
m.4733T>C Yes No MTND2 
m.4769A>G Yes No MTND2 
m.5390A>G Yes No MTND2 
m.5426T>C Yes No MTND2 
m.6045T>T Yes No MTCOX1 
m.6152T>C Yes No MTCOX1 
m.7028C>T Yes No MTCOX1 
m.8860A>G Yes Thr112Ala MTATP6 
m.10876A>G Yes No MTND4 
m.11467A>G Yes No MTND4 
m.11719G>A Yes No MTND4 
m.12261T>C No  - MTTS2 
m.12308A>G Yes  - MTTL2 
m.12372G>A Yes No MTND5 
m.13020T>C Yes No MTND5 
m.13734T>C Yes No MTND5 
m.15326A>G Yes Thr194Ala MTCYB 
m.15907A>G Yes - MTTT 
m.16051A>G Yes  - D-Loop 
m.16189T>C Yes  - D-Loop 
m.16129G>C Yes  - D-Loop 
m.16182A>C Yes  - D-Loop 
m.16183A>C Yes  - D-Loop 
m.16189T>C Yes  - D-Loop 
m.16362T>C Yes  - D-Loop 
m.16519T>C Yes  - D-Loop 
 4.5.2.2 PCR-RFLP analysis
The m.12261T>C mutation 
(CCTC(N)) in the mutated mtDNA
while the restriction enzyme only cuts the wild
56bp (Figure 4-11-A). Results showed 
ranged from 13%-94% in analysed tissues (Figure 4
very low (<1%) in different tissues from relatives (Figure 4
Figure 4
(A) Schematic diagram of PCR
restriction endonuclease MnlI. 
tissues from patient and relatives. Lane 1 is 
control, lane 3 is patient`s muscle 
mutant), and lane 5 is patient’s buccal 
and lane 7 is mother’s buccal DNA sample. Lane 8 is grandmother’s urine DNA sample, 
grandmother’s buccal DNA sample. 
relatives. Lane 1 is an uncut DNA sample, lane 2 is DNA sam
from patient`s muscle with the m.12261T>C mutation (
blood DNA sample (13% mutant
DNA sample, lanes 7 & 8 are patient
blood DNA samples. Boxed lanes are taken from another experiment.
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leads to the creation of an additional endonuclease 
 resulting in three products: 141bp,
-type mtDNA into two products: 
high levels of the m.12261T>C in the patient that 
-11-B). However, mutation load was 
-11-C). 
-11 PCR-RFLP analysis of the m.12261T>C mutation
-RFLP analysis showing the sizes of the products after digestion with 
(B) PCR-RFLP analysis to quantify the m.12261T>C levels in different 
an uncut DNA sample, lane 2 is DNA sample from a negative 
DNA sample (94% mutant), lane 4 is patient’s urine 
DNA sample (15% mutant). Lane 6 is mother’s urine DNA sample,
(C) Levels of the m.12261T>C in blood DNA samples from patient and 
ple from a negative control, lane 3 is 
positive control, 94% mutant), and lane 4 is patient
). Lane 5 is mother `s blood DNA sample, lane 6 is grandm
’s brothers blood DNA samples, and lanes 9 & 10 are pati
 
Mn1I site 
 56bp, and 51bp, 
192bp and 
 
.  
DNA sample (78% 
 
and lane 9 is 
DNA 
`s 
other’s blood 
ent`s sisters 
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To determine whether the m.12261T>C mutation segregates with the biochemical defects 
in individual cells, DNA was prepared from laser-microdissected COX-positive (n=11) and 
COX-deficient fibres (n=10). Although high levels of mutation load (up to 94%) were seen 
in DNA sample from muscle, a significant difference between the percentage of the mutant 
mtDNA in the COX-positive and COX-deficient fibres was seen. Results showed that 
higher levels of the m.12261T>C mutation were detected in COX-deficient fibres (97.10 ± 
1.101%) than in COX-positive fibres (85.82 ± 16.59%) (P<0.0001), confirming 
segregation of the m.12261T>C genotype with respiratory chain dysfunction (Figure 4-12).  
 
Figure 4-12 Graphical representation of single PCR-RFLP analysis of the m.12261T>C mutation.  
This graph shows the mean percentage and SE values of PCR-RFLP analysis of COX-positive and COX-
deficient fibres: COX-positive (n=11, 85.82 ± 16.59%), COX-deficient fibres (n=10, 97.10 ± 1.101), and 
P<0.0001 confirming segregation of the m.12261T>C genotype with respiratory chain dysfunction. 
4.5.2 The m.12261T>C mutation is pathogenic  
Portland-4 patient was described to have developmental delay, motor and speech delay and 
hearing loss. In addition, he had seizure, vision loss and retinitis pigmentosa. Initial 
analysis of patient’s muscle biopsy showed COX negativity in muscle fibres and many 
ragged red fibres, which suggest mitochondrial accumulation. Moreover, biochemical 
analysis showed a mild defect of the respiratory chain complex I. The identified mt-
tRNASer(AGY) sequence variant  in this patient  was demonstrated to be the pathogenic 
mutation, causative of the observed clinical presentations. This mutation fulfilled the 
canonical criteria for pathogenicity of mtDNA mutations [199]. It is not a neutral 
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polymorphic variant and has not been reported in either of the mitochondrial genome 
databases [69, 252]. It is a heteroplasmic change with higher levels in postmitotic muscle 
than mitotic cells and affects a highly conserved nucleotide within the tRNA structure. In 
addition, it disrupts a Watson-Crick base pair in the aminoacyl acceptor stem (Figure 4-8). 
Finally, this mutation showed high levels of mutation load in COX-deficient fibres as 
compared to COX-positive fibres confirming segregation with the biochemical defect. All 
these given data provide a strong evidence that the m.12261T>C mutation is causative of 
the disease. 
Not only did this mutation show different levels of heteroplasmy in different tissues from 
the patient, but it was also present in different tissues from mother and grandmother with 
low levels of heteroplasmy, which suggests transmission of the mutation to patient. The 
presence of this mutation with low levels in both mother and grandmother explains why 
they are asymptomatic, while the presence of this mutation in the patient but not in the 
other siblings can be attributed to mtDNA segregation.  
 
Further conclusions from the analysis of the two patients investigated in this Chapter will 
be discussed in the General Discussion (Chapter 7). 
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Chapter 5 : Neuromuscular disease presentation with three 
genetic defects involving two genomes 
5.1 Introduction 
Mutations in the human mitochondrial genome (mtDNA) have been shown to cause 
progressive neurological syndromes [1]. These commonly include mutations that affect 
mitochondrial protein synthesis such as single, large-scale mtDNA deletions and single 
nucleotide substitutions affecting mitochondrial transfer (mttRNA) genes [400]. The 
majority of mt-tRNA mutations are heteroplasmic, with clinically-affected tissues such as 
skeletal muscle exhibiting high mutation loads, leading to a respiratory chain defect. This 
is best illustrated in individual muscle fibres with cells exhibiting a mutation load above a 
critical threshold, typically ~90% for most mt-tRNA mutations, lacking demonstrable 
histocytochemical cytochrome c oxidase (COX) activity [317, 425, 426]. However, the 
pathogenic threshold may be influenced by several factors, including mitochondrial 
morphology and dynamics. Also the situation may be different in replicating cells 
compared with that of non-dividing muscle fibres [402]. 
The recent description of a patient with a multisystem presentation due to a novel mt-
tRNATrp (MTTY) gene mutation that was present at low mutant loads in clinically-affected 
tissues has challenged the accepted dogma that all mt-tRNA mutations are “functionally-
recessive”. The m.5545C>T mutation within the mt-tRNATrp caused a severe multisystemic 
disorder and marked respiratory chain deficiency even at low levels of heteroplasmy 
(<25%) in affected tissues. The pathogenic threshold for the mutation in cybrids was 
between 4 and 8%, confirming a dominant mechanism of action regardless of the precise 
mechanism [402]. Two hypotheses were proposed to better understand this phenomenon. 
First, the central base (ACU) of the anticodon triplet of the mt-tRNATrp at position 5545 
interacts with the central base (G) of the codon triplet (UGA) and (UGG) in the mRNA and 
is essential to determine tRNA specificity. However, the m.5545C>T changes the 
anticodon from ACU to AUU which makes the mutated mt-tRNA decode UAA or UAG, 
which are termination codons. So the mutated mt-tRNATrp may cause a read-through of the 
mRNA adding one Trp residue at the position of the stop codon followed by the 
incorporation of a tail of lysine residues specified by the poly-A sequence at the end of the 
transcript. Second, since the third base of the codon in the mitochondrial genome is usually 
 not essential to determine tRNA specificity 
and UGU codons and incorporat
Figure 5-1 Schematic representation showing the structure of the mt
This figure shows structure of 
mutation on codon recognition. The wild
the mRNA that encodes the mt
ACU to AUU which makes the mutated mt
recognize UGC and UGU codons and incorporate tryptophan in the place of tyrosine 
from [402]). 
This chapter presents the m.12283G>A mutation within the mt
which is another mutation present at low levels that clearly segregates with a functional, 
biochemical defect as measured by COX activity in individual muscle fibre
this novel mtDNA mutation represents only one of three, confirmed genetic abnormalities 
in this patient. 
The identification of such mutations has led to a rethink about the way to diagnose some 
pathogenic mtDNA mutations since these mutat
standard diagnostic screening methods. Indeed, failure to identify the m.12283G>A 
mutation the first time I sequenced muscle homogenate mtDNA from this patient was due 
to mutation load levels, which were below detection 
patient has highlighted that such mutations may only be detected by performing full 
genome sequencing on biochemically
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[427], the mutated tRNA could recognize UGC 
e tryptophan in the place of tyrosine [402]
-tRNA
the wild-type mt-tRNATrp, mutant mt-tRNATrp, and the possible effect of 
-type mt-tRNATrp anticodon (ACU) recognises the
-tRNATrp. However, the m.5545C>T mutation changes the anticodon from 
-tRNA decodes UAA or UAG, which are 
-tRNA
ions may easily escape detection by 
threshold levels. Investigation of this 
-affected individual muscle fibres (COX
 (Figure 5-1). 
 
Trp
.  
 (UGA) codon on 
stop codons, or could 
(taken and modified 
Leu(CUN) (MTTL2), 
s. Interestingly, 
-deficient). 
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5.2 Aims  
This chapter will present the clinical, histochemical, biochemical and molecular genetic 
investigations in a patient with a neuromuscular disease presentation due to three genetic 
defects involving two genomes. 
5.3 Clinical presentations 
The patient is a thirty-one year old gentleman who first presented to a specialist 
mitochondrial clinic for investigation of progressive bilateral ptosis, chronic progressive 
external ophthalmoplegia and increasing difficulties with walking but who has an 
extensive past medical history going back to childhood. He had always been poor at 
running and jumping at school and at the age of eleven was investigated for drooping 
eyelids, difficulty holding a pen and difficulty with walking. He was found to have a 
demyelinating polyneuropathy on neurophysiological testing and HMSN type 1A was 
confirmed genetically by the demonstration of duplication of the PMP22 gene on the short 
arm of chromosome 17 at another diagnostic centre. 
At the age of 25 years he developed gout and presented in acute renal failure at the age of 
30 years. He was found to have a grossly elevated plasma urate level of 1.35mmols/L 
(normal < 420µmol/L) and was subsequently investigated for a possible HPRT mutation. 
Direct sequencing at another diagnostic Centre revealed a c.481G>T mutation predicting a 
missense mutation (p.A161S) in a recognised mutation hotspot of the gene. His mother 
was later confirmed as being a carrier of this X-linked recessive mutation.  
His ptosis had progressed to the point that he had required bilateral eyelid elevation 
surgery earlier in the year. At that time he had been noted to have external 
ophthalmoplegia but described no diplopia. He had weak grip in both hands, required a 
stick to walk, and found that his legs often gave way. He has bilateral ptosis despite the 
previous surgery. Eye movements are restricted in all directions to less than 300. There is 
reduced muscle bulk in his limbs and power was reduced to MRC grade 4/5 in both 
proximal and distal muscles. Deep tendon reflexes were absent throughout and there was 
impaired sensation to pin prick, light touch and joint position sense to above the ankles. 
His father and paternal grandfather were described as ‘shaky’. The patient’s youngest son 
had recently developed difficulty walking. 
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5.4 Methods 
5.4.1 Needle muscle biopsy analysis. 
Sections from a frozen muscle biopsy were cut using a cryostat to perform routine 
histological analysis. Hematoxlyin and eosin (H&E) staining was carried out as described 
(section 2.2.15.1) followed by electron microscopy to identify any structural changes 
within the muscle. In addition, combined COX/SDH staining was carried as decribed 
(section 2.2.15.2). 
5.4.2 Long-range PCR analysis 
Long-range PCR analysis was carried out as described (section 2.2.12) to screen for large-
scale mtDNA rearrangements in total muscle DNA. 
5.4.3 Mitochondrial DNA sequencing. 
The entire mitochondrial genome of both total muscle homogenate and individual laser- 
captured single fibres mtDNA was performed as described (section 2.2.6) to search for 
point mtDNA mutations.  
5.4.4 Real time PCR analysis 
MtDNA from individual laser-captured COX-positive and COX-deficient fibres was 
assessed for any possible mtDNA copy number depletion or deletions [428] by real-time 
PCR as described (section 2.2.13). 
5.4.6 PCR-RFLP analysis 
PCR-RFLP analysis was carried out from DNA samples from muscle homogenate, 
individual single fibres, and other tissues as described (section 2.2.10). Table 5-1 
summarises details for this analysis such as primer position, sequence, restriction 
endonuclease enzyme, and annealing temperatures. 
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Table 5-1 Summary of PCR-RFLP analysis of patient with the m.12283G>A mutation. 
 
 
Primer Sequence 
Primer Annealing 
Temperature 
(oC) 
Enzyme and Digestion 
site 
Digest 
Temperature 
(oC) 
Uncut PCR 
product (bp) 
Wild-type 
products (bp) 
Mutant 
products (bp) 
 
Forward-L12177 5`-
ACAACAGAGGCTTACGACC-3` 
Reverse-H12336- 
5`-TACTTTTATTTGGAGTTGCACC-3` 
 
59 Alu1 (AG/CT) 37 160 70+53+37 123 +53 
 5.5 Results 
5.5.1 Histochemical analysis
H&E staining showed a minor variation in fibre size (21
there was some fat and connective tissue replace
(Figure 5-2-A). In addition, occasional internal nuclei and agonal fibres were observed (not 
shown in the Figure 5-2-A). The combined COX/SDH stai
negativity with several fibres showing evidence of subsarcolemmal mitochondrial 
accumulation typical of ragged
mitochondrial genetic abnormality (Figure 5
Figure 5-2 Histochemical analysi
(A) H&E staining of patient muscle showing different sizes in fibres, splits, and minor inflammatory 
changes. (B) COX/SDH staining 
(brown), and mitochondrial proliferation.
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–96 µm). Fibres had splits and 
ment but only minor inflammator
ning showed ~ 15% COX 
-red changes, which are suggestive of an underlying 
-2-B).  
s of muscle biopsy from patient with the m.12283G>A mutation
showed some COX negativity (blue-stained fibres), COX
 
 changes 
 
.  
-positive fibres 
 5.5.2 Long-range PCR analysis:
Total muscle DNA was assessed for large scale mtDNA rearrangements using 11
16-kb primers. However, results showed no signs of mtDNA abnormality (Figure 5
Figure 
Lane 1 is a 1kb ladder, lane 2 is the resultant PCR product from patient`s
PCR products from a patient who has a single mtDNA deletion (positive control), lane 4 is a negative control 
(water). 
5.5.3 Initial screen for mtDNA point mutations.
DNA from muscle homogenate from patient
changes by sequencing the whole mitochondrial genome
any novel mtDNA point mutation could cause the disease. However, reanalysis was carried 
out as described (section 5.5.5).
5.5.4 Real time PCR ana
Real time PCR was carried out to further investigate the molecular basis of the COX 
negativity within the COX-
had a mutation in the HPRT
nucleosides for de novo 
nucleoside salvage within mitochondria
maintenance, manifesting as mtDNA depletio
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5-3 Long-range PCR analysis for the m.122813G>A. 
 muscle DNA, lane 3 is the resultant 
 
 was initially screened for any 
. Results showed failure to detect 
 
lysis 
deficient muscle fibres. This was carried out because the patient 
 gene, which is involved in the purine salvage to provide 
DNA synthesis. Mutations in various enzymes involved in
 have been shown to cause a defect in mtDNA 
n leading to COX deficiency
-kb and 
-3). 
mtDNA 
 
 [429-432]. On 
 this basis, mtDNA copy number was measured in individual, laser
and COX-deficient fibres. 
deletions within individual cells, h
mtDNA deletion (Figure 5
from long-range PCR data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4 Real-time PCR analysi
Results showed no mtDNA deletion because all values from analysed COX
fibres were below the threshold for mtDNA deletion detection. 
5.5.5 Whole mitochondrial genome
To further investigate the COX
on DNA samples from three random COX
identification of the novel m.12283G
high levels in two COX-deficient fibres (F
COX-positive fibres. In addition, other 
mitochondrial DNA databases 
muscle homogenate sequencing chromatogram 
was initially determined as 
(Figure 5-5-C), which explain why
described earlier (section 5-
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-captured COX
In addition, the same technique was used to quantify mt
owever, results showed neither mtDNA depletion
-4). The latter results supported the previous results obtained 
s of individual muscle fibres to assess mtDNA deletion.
-positive and COX
 
 sequencing 
-deficient fibres, whole genome sequencing was carried out 
-deficient fibres. Results showed the 
>A mutation in the MTTL2 (mt-tRNA
igures 5-5-A and 5-5-B), but was absent in the 
previously reported changes, listed in the two 
[69, 252], were identified (Table 5-2). R
revealed the m.12283G>A mutation, which 
‘‘wild-type” due to low levels of heteroplasmy at this site
 it was missed in the initial analysis of the sequence as 
5-3). 
-positive 
DNA 
 nor 
 
-deficient 
Leu(CUN)) gene at 
eanalysis of the 
 
 Figure 5-5 Sequencing electropherograms show
This mutation was present at high levels of mutation load in individual COX
(A & B), while low levels of mutation load were seen
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ing the m.12283G>A transition
-deficient fibres from the patient 
 in muscle homogenate sample (C).
. 
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Table 5-2 Sequence changes identified in single fibres from the patient with the m.12283G>A mutation. 
 
Sequence change Previously reported as a SNP or pathogenic? Mitomap or mtDB Amino acid change Location 
m.73A>G Yes - D-Loop 
m.185A>G Yes - D-Loop 
m.189A>G Yes - D-Loop 
m.263A>G Yes - D-Loop 
m.309C ins. Yes - D-Loop 
m.310T>C Yes - D-Loop 
m.311C ins. Yes - D-Loop 
m.334T>C Yes - D-Loop 
m.513G>A Yes - D-Loop 
m.750A>G Yes - D-Loop 
m.1438A>G Yes - 12S rRNA 
m.3010G>A Yes - 16S rRNA 
m.3107C del. Yes - 16S rRNA 
m.4769A>G Yes No MTND2 
m.5460G>A Yes Ala331Thr MTND2 
m.8251G>A Yes No MTCOX2 
m.8860A>G Yes Thr112Ala MTATP6 
m.11914G>A Yes No MTND4 
m.12283G>A No - MTTL2 
m.15326A>G Yes Thr194Ala MTCYB 
m15936A>G Yes - MTTT 
m.16148C>T Yes - D-Loop 
m.16519T>C Yes - D-Loop 
 This mutation at this position affects a nucleotide that resides within the variable DHU 
loop of the mt-tRNA Leu (CUN) 
Sequence comparison has shown that this nucleotide is strictly conserved in different 
species suggesting it is of functional importance (Figure 5
Figure 5-6 
(A) Schematic representation of the mt
mutation which affects a nucleotide within the DHU loop structure
trna.u-strasbg.fr/mutations.asp?idAA=17
confirms that this nucleotide at position m.12283 is strictly conserved throughout species, providing 
compelling evidence for pathogenicity
5.5.6 PCR-RFLP analysis
The m.12283G>A mutation leads to the loss
of wild-type mtDNA (cut into three bands of 70, 53 and 37 bp) from mutated
into two bands of 123 and 37 bp)
m.12283G>A mutation load 
homogenate (Figure 5-7-B). Mutation load was quantified in additional tissues from the 
patient and his mother to assess segregation of mutation. The mutation load was 8% in 
DNA from patient’s fibroblasts, 4% 
epithelia. In addition, this mutation was absent in all tissues from mother (blood, buccal, 
and urine) (Figure 5-7-C). 
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structure but does not disrupt Watson-
-6). 
Conservation of the nucleotide at position m.12283
-tRNALeu(CUN) cloverleaf structure, illustrating the position of the 
 (taken and modified from 
). (B) Phylogenetic analysis of this region of the 
 (taken from [413]). 
 
 of AluI restriction site, allowing
 (Figure 5-7-A). Results showed 
in COX-deficient fibres (>90%) and 18% in muscle 
in urinary epithelia cell sediment, and absent in buccal 
Crick base pairing. 
 
.  
http://mamit-
MTTL2 gene 
 the detection 
 mtDNA (cut 
high levels of the 
 Figure 5-7 PCR-RFLP analysis
(A) Schematic diagram shows sizes of PCR products after digestion with the restriction endonuclease. (B) 
Quantification of mutation load in the COX
DNA sample as 160 bp. Lane 2 shows a negative control DN
and 4 show high levels of mutation load in DNA from COX
heteroplasmy in muscle homogenate DNA sample. (C) PCR
tissues from patient and mother. Lane 1 is an uncut DNA sample, lane 2 is DNA sample from a negative 
control, and lane 3 is DNA muscle sample from a patient with 18% mutation load levels (positive control). 
Lanes 4, 5, 6, and 10 are blood, buccal, urine DNA samples (4% mutant), and fibroblasts (8% mutant) from 
patient, respectively. Lanes 7, 8, and 9 are mother’s DNA samples from blood, buccal, and urine 
respectively. The 37bp bands are 
lane is taken from another experiment.
To determine whether the m.12283G>A mutation segregated with the biochemical defect 
in individual cells. DNA was prepared from laser
COX-deficient fibres (n=15
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 of the m.12283G>A in tissues from patient and mother
-deficient fibres and muscle homogenate. Lane 1 shows the uncut 
A sample as 70bp and 53bp
-deficient fibres. Lane 5 shows low levels of 
-RFLP analysis to quantify mutation load in 
not shown in panel B and C because of the trimming of the gel
 
-microdissected COX-
). Results showed higher levels of the m.12283G>A mutation 
 
.  
 products. Lanes 3 
. The boxed 
positive (n=14) and 
 were detected in COX-deficient fibres
(1.38 ± 0.44%) (P < 0.001), 
respiratory chain dysfunction 
between the two groups.  
Figure 5-8 Single fibre PCR
This figure shows that both COX
with biochemical defect as a significance difference between both groups was detected. 
and SE values of PCR-RFLP analysis of
(n=14, 1.38 ± 0.44%), COX-deficient fibres (
the m.12283G>A genotype with respiratory
5.6 The m.12283G>A mutation is pathogenic
In this patient with a neuromuscular phenotype
diseases, all contributing 
responsible for his demyelinating polyneuropathy, an X
mutation leading to a grossly elevated
mitochondrial MTTL2 gene mutation which we show is responsible for the COX
fibres in his muscle biopsy and therefore the mitochondrial
the m.12283G>A mutation 
of evidences have proven this mutation to be pathological and to contribute
neurological phenotype in this pati
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 (98.14 ± 1.35%) than in the COX
confirming segregation of the m.12283G>A genotype with 
(Figure 5-8) with a remarkable skewing of mutation
-RFLP analysis of the m.12283G>A mutation
-positive and COX-deficient fibres confirmed segregation of the m
 COX-positive and COX-deficient fibres as follow
n=15, 98.14 ± 1.35%), and P<0.0001 confirming
 chain dysfunction. 
 
 we have identified three distinct genetic 
to the clinical picture: a dominant PMP22
-linked recessive 
 level of urate in plasma and gout, and a sporadic, 
 CPEO phenotype.
was present at low levels in muscle homogenate,
ent. The m.12283G>A variant is not a 
-positive fibres 
 load 
 
. 
utation 
The mean percentage 
: COX-positive 
 segregation of 
 gene duplication 
HPRT gene 
-deficient 
 Although, 
 several lines 
 to the 
recognised 
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neutral polymorphic variant and it is not represented in either of the large, publically-
available databases of human mtDNA sequences [69, 252]. In addition, this mutation 
affects a highly conserved nucleotide, which resides within the variable DHU loop of the 
mature mt-tRNALeu(UCN) structure and does not disrupt Watson–Crick base pairing (Figure 
5-6). Moreover, results from single muscle fibre analysis clearly demonstrated that the 
m.12283G>A mutation segregated with COX-deficient fibres, which harboured 
significantly higher levels of mutated mtDNA than COX-positive fibres. Interestingly, 
there was a very clear skewing of the segregation of mutated mtDNA since all the COX-
positive fibres showed very low levels of the mutation and all the COX-deficient fibres 
showed high mutation levels close to 100%. This pattern was not observed previously in 
the majority of pathogenic mt-tRNA mutations in which mutation levels in COX-positive 
fibres can approach the critical threshold and may often exceed 90% mutated mtDNA 
[317, 425, 426]. 
Because this patient developed CPEO, IT WAS initially hypothesised that he had either a 
mtDNA point mutation or mtDNA rearrangements. This was supported by the 
identification of the pathogenic mtDNA mutation, m.12276G>A, which like the previously 
reported mt-tRNALeu(CUN) mutation, m.12283G>A, was located in MTTL2 and caused 
CPEO with low levels of mutation load (18%) [433]. However, initial full genome 
sequence and long-range PCR results from muscle homogenate in this patient failed to 
detect neither mtDNA point mutation nor mtDNA rearrangements. 
This patient was identified with a mutation in the nuclear-encoded HPRT gene, which is 
known to salvage and recycle purine nucleotides during DNA synthesis, converting 
hypoxanthine to inosine monophosphate (IMP) and guanine to guanosine monophosphate 
(GMP) [434]. In view of the known role of several nucleotide salvage enzymes (e.g.TK2) 
in mtDNA maintenance [432], two hypotheses were suggested. First, are the COX-
deficient fibres a secondary phenomenon to the HPRT defect leading to a depletion of mt 
DNA copy number in these cells, similar to the tissues of patients harbouring mutations in 
the TK2 gene [435-437]? Second, do the COX-deficient fibres exhibit mtDNA depletion or 
mtDNA rearrangements? Given that these results showed that the COX-deficient fibres 
had neither mtDNA depletion nor deletion, it is possible that the HPRT mutation is 
influencing mtDNA segregation. In summary, all presented evidence points towards the 
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m.12283G>A mutation being a strong candidate in the development of the clinical 
phenotypes related to the mitochondrial defect in this patient. 
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Chapter 6 : GeneChip resequencing array 2.0 
6.1 Introduction 
To date, more than 250 pathogenic mtDNA mutations have been identified within the 
mitochondrial genome in association with diseases [69]. Given the highly polymorphic 
nature of the mitochondrial genome, it is necessary to distinguish between pathogenic 
mtDNA mutations and the common polymorphic variants or SNPs. To facilitate the 
identification of cases caused by pathogenic mtDNA mutations, accurate and rapid 
techniques, which can reduce time and cost are required. In addition, these techniques must 
be able to detect both single nucleotide changes and small rearrangement (single nucleotide 
deletion or insertion) mutations, or possibly mtDNA inversions [438, 439].  
Currently, several techniques have been developed to detect single nucleotides 
substitutions or deletion/insertion mutations within the mitochondrial genome. Single-
stranded conformational polymorphism (SSCP) uses the electrophoretic separation of 
single-stranded nucleic acids based on a single base pair, which results in a different 
secondary structure and hence an altered mobility of the PCR product through a gel. The 
SSCP method was first used in 1989 and applied to a range of DNA polymorphisms and 
sequence variations. This method has been described as an inexpensive, convenient, and 
sensitive to detect genetic variation [440], although false negative results have been 
reported [441]. It is sensitive to electrophoresis temperature, buffer concentration and gel 
concentration [442], and limited to small and selected DNA mtDNA regions [443]. 
Denaturing gradient gel electrophoresis (DGGE) is another technique that has been applied 
to identify single nucleotide changes. It is based on the electrophoresis of PCR-amplified 
fragments through polyacrylamide gels containing a linearly increasing gradient of 
denaturants, so when DNA enters the gradient gel, double-stranded DNA molecules 
become partially melted, and their gel-electrophoretic mobility decreases [444]. DGGE is a 
sensitive method to detect single-base changes in amplified DNA fragments, 
heteroduplexes, and does not involve the use of any radioactivity. UV is used to visualise 
fragments after staining with ethidium bromide [445]. However, this method is only 
limited to small DNA fragments [443], costly, and is not quantitative [446]. 
Denaturing high-performance liquid chromatography (DHPLC) allows the detection of 
single base substitutions and small insertions and deletions, and has been applied to to the 
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study of the mitochondrial genome. DHPLC is based on mismatches between amplified 
DNA fragments resulting in the formation of heteroduplices. The formed heteroduplices, 
which are thermally less stable than homoduplices, are then separated by liquid 
chromatography at elevated column temperatures [447]. DHPLC has been has been used to 
screen the entire mitochondrial genome [448], providing an automated, accurate and rapid 
method [449]. It can be applied to genotyping, loss of heterozygosity and gene expression 
analysis [447], although it is still sensitive to temperature [447] and is not considered to be 
a cost effective method [450].  
Pyrosequencing technology has also been applied to the detection and estimation of 
heteroplasmic mtDNA point mutations [451]. This technology offers a real-time, minimal 
sequencing method for the analysis of short to medium length DNA sequences [452] and 
uses the detection of pyrophosphate release when nucleotides are incorporated into the 
extending template [451]. Pyrosequencing has shown to be rapid, accurate, quantitative 
and provided 100% sensitivity and specificity[451], whilst it is also relatively cheap and 
does not take a lot of time to runit is [453]. On the other hand, pyrosequencing still has a 
number of disadvanteges: it is limited to short sequences, unable to determine the correct 
number of incorporated nucleotides and the occasional occurrence of nonsynchronized 
extension of some sequences due to minus or plus frameshifting, which limits the length of 
obtained reliable and correct sequences [452, 454, 455]. 
Conventional Sanger di-deoxy sequencing is routinely used to detect sequence changes 
within the entire mitochondrial genome, which can be PCR-amplified using pairs of 
overlapping primers. It is preferred because it provides quick, accurate results and allows 
the researchers to identify all changes within a genome; it can also be applied to the study 
of somatic mtDNA point mutation in single cells [456, 457]. Although it is able to detect 
point mutations and small mtDNA rearrangements, it is relatively costly and mutations 
present at low heteroplasmic level (20% or below) may easily escape detection [448, 458].   
Surveyor Nuclease has been used to detect heteroplasmic mtDNA mutations [459]. It uses 
mismatch-specific DNA endonuclease, named Surveyort Nuclease, which cleaves DNA 
heteroduplexes formed by the hybridisation of PCR products from wild-type and mutant 
mtDNA [460, 461]. This method provided the ability to sequence the entire mitochondrial 
genome. It is able to detect heteroplasmic mtDNA mutatons but noted to be time-
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consuming [459]. However, a drawback of this technology is that it is not able to detect 
homoplasmic mtDNA mutations [461]. 
More recently, suspension array technology has been used to detect both heteroplasmic and 
homoplasmic mtDNA point mutations. The suspension array analysis is based on the use 
of multi-microspheres combined with multiple sequence-specific oligonucleotide (SSO) 
customized probes and flowmetry [462]. This technique has been described as rapid 
detection system with a detection limit of approximately 2%, mtDNA heteroplasmy levels, 
is suitable for screening large numbers of samples, and the analysis is relatively cheap as 
compared to conventional sequencing [463]. However, the detection system in this method 
is currently limited to mtSNPs of Japanese ethnicity only [463]. 
The complexity and limitations associated with previous methods have led to the 
development of the Affymetrix oligonucleotide-based array MitoChip, which allows the 
analysis of 29 mitochondrial genomes per day [464]. The Affymetrix MitoChip (V2.0) is 
an oligonucleotide tiling array for the resequencing of the human mitochondrial genome.  
The first generation of MitoChip, MitoChip (V1.0), was developed early in 2004. It was 
not capable of sequencing the non-coding D-loop region of the mitochondrial genome 
[465] [466], so a second chip, the MitoChip (V2.0) was developed in 2006; this contains 
probes that match the revised Cambridge Reference Sequence (rCRS) [467]. In addition to 
tiling of sequences for the most common haplotypes including single-nucleotide changes, 
insertions and deletions, it contains segments of the control region allowing sequence of 
the entire mitochondrial genome [464, 466]. The MitoChip system is based on the use of a 
standard chip, which is 1.28 cm x 1.28 cm in size. On each chip there are over 6.5 million 
sections known as features or squares, with each feature containing millions of identical 
DNA probes. A probe is a 25 base pair (25-mer) length piece of DNA that is attached to 
the chip and only differs in SNP at position #13 (Figure 6-1). Each base of the 
mitochondrial genome is interrogated by hybridization of fluorescent- labeled DNA 
fragments. A comparison study between both MitoChip versions carried out by Zhou et al., 
revealed that MitoChip (V2.0) gave 99.99% reproducibility. In addition, 31 variations in 
the D-loop region, which were not detected by (V1.0), were successfully detected in the 
(V2.0) chips.  
 Figure 6-1 Shwoing the structure of GeneChip used in the MitoChip V2.0 Technique. 
For simplicity one square is shown, which contains millions of identical probes that diffe
at position #13 known as reversed tilling. The Biotin labelled PCR fragments bind to the complimentary 
revised tilled probe (modified from Dr. Tony Sierra, Affymetrix).
The high sensitivity of the MitoChip (V2.0) makes it a suitable to
detection and clinical screening of 
population genetics [464]. 
allows the MitoChip to be used in forensic applications 
mitochondrial genome on the MitoChip involves only three reactions, reducing both the 
time, labour and cost involved in analysing human mtDNA. 
MitoChip (V2.0) is unable to detect mitochondrial inseretion and deletion mutations. It 
does not cover the whole genome sequence for all haplogroups and not quantitative. 
give miscalls and often results need to be validated by conventional sequencin
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On the other hand, the 
 
 
r only in nucleotide 
rs [468, 469] and 
 [470] 
It may 
g. 
176 
 
6.2 Aims 
The aim of this chapter is to investigate the reliability of detecting pathogenic human 
mtDNA mutations in nine of our patients with mtDNA disease, previously identified in our 
lab, using the MitoChip (V2.0) and to compare the results obtained from both the 
conventional sequencing and the MitoChip to evaluate whether the MitoChip is a 
reproducible tool in a diagnostic setting. All information related to the investigated patients 
is summarised in Table 6-1. 
 
Table 6-1 Summary of related information to the patients investigated by MitoChip (V2.0). 
Sex Age  Tissue mtDNA mutation Gene 
F 53 muscle m.12315G>A MTTL2 
M 38 blood m.11453G>A MTND4 
M 13 muscle m.11777C>A MTND4 
M 9 muscle m.14709T>C MTTE 
M 5 muscle m.14453G>A MTND6 
M 10 months muscle m.13513G>A MTND5 
M 4 fibroblast m.13513G>A MTND5 
M 53 muscle m.13042G>A MTND5 
F - muscle m.7472Cins MTTS1 
 
6.3 Material and Methods 
This project was undertaken in association with Dr. Andy Duncan and Dr. Shamima 
Rahman, Institute for Child Health, London) using the GeneChip® Resequencing Assay 
Kit and the GeneChip Human Mitochondrial Resequencing Array (V2.0) from Affymetrix 
according to the manufacture’s protocol or as described in [466] . Data were analysed and 
compared with the rCRS [252]. Briefly, this method includes long-range PCR 
amplification, PCR products pooling, fragmentation, labelling, and hybridization, washing 
and staining (Figure 6-2). 
 Figure 6-2 Summary of the methods in the MitoChip (V2.0) analysis.
After amplification of the human mitochondrial genome 
were subjected to two runs of long
bp PCR products. The amplified PCR products were then pooled and fragmented using a fragmentation 
reagent. Fragmented DNA was labelled with biotin to allow visualisation. DNA fragm
hybrodized to the chip followed with washing and staining prior to loading in the system and scanning
6.3.1 Long-range PCR
The entire mitochondrial DNA sequence was amplified 
primers, each containing 50ng of geno
2.1 kit. The Mito3 forward primer sequence 5’
ACC TCC TCG GAC TC-
AAG GGG AAC GTG TGG
forward primer sequence 5’
CC-3’ and the Mito1-2 reverse primer 5’
AGG TGC -3’ were used to amplify 9307 bp. The total PCR reaction volu
thermal cycling conditions were as follows: 
for 7 minutes, 29 cycles, and final extension for 12 minutes. 
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using 45 overlapping primer pairs, the PCR products 
-range PCR using 2 overlapping primer pairs to generate 9307bp and 7814 
 
using two pairs of 
mic DNA, in a 96-well plate using LA PCR Kit Ver. 
-TCA TTT TTA TTG
3’ and the Mito3 reverse primer 5’-CGT GAT
 GCT AT-3’ were used to amplify 7814 bp. 
-ACA TAG CAC ATT ACA GTC AAA TCC
-ATT GCT AGG GTG GCG
95°C for 2 minutes, 95°C for 15seconds, 68°C 
 
 
 
ents were then 
. 
long PCR 
 CCA CAA CTA 
 GTC TTA TTT 
The Mito1-2 
 CTT CTC GTC 
 CTT CCA ATT 
me was 50µl and 
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6.3.2 Quantitation and pooling of PCR products  
The amplified PCR products were analysed for quality and quantity and were cleaned up 
using a DNA Amplification Clean-Up Kit. 
6.3.3 Fragmentation and labelling 
The pooled DNA fragments were digested with Affymetrix fragmentation reagents and 
then incubated at 95°C for 15 minutes to inactivate DNase I. Fragmented DNA was 
labelled by adding 2µl of GeneChip DNA labelling reagent and 3.4µl of 30U/µl terminal 
deoxynucleotidyl transferase according to the manufacture’s protocol.  
6.3.3 Hybridization, staining and washing 
Prehybridization, hybridization and washing were carried out according to the Affymetrix 
CustomSeq Resequencing protocol. The chips were prehybridized for 15 minutes in 80µl 
of a solution containing 3 mol/L tetramethylammonium chloride, 0.1% Tween 20, and 10 
mmol/L Tris, pH 7.8. Next, they were hybridized for 16 hours at 48°C at 60 rpm rotation in 
a hybridization solution containing: 3 mol/L tetramethylammonium chloride, 100µg/ml 
herring sperm DNA, 500µg/ml bovine serum albumin, 10 mmol/L Tris, pH 7.8, 0.01% 
Tween 20, and 200 pmol/L control oligo. Eventually, chips were washed and stained on 
the GeneChip fluidics station using the pre-programmed CustomSeq Resequencing wash 
and stain protocol. 
6.3.4 Microarray data analysis 
Arrays were scanned on a GeneChip scanner that measures the fluorescence intensity for 
all positions. Data were analysed using two software programs: the GeneChip operating 
software (GCOS v1.4) and GeneChip sequence analysis software (GSEQ v4.0). Sequences 
were compared to the rCRS. 
6.4 Results 
6.4.1 Long-range PCR 
Two PCR proucts were amplified using the Mito-3 primers as a 7184 bp (Figure 6-3) and 
the Mito1-2 primers as a 9307 bp (Figure 6-4). 
 
  
 
Figure 
 The first long-range PCR results in the amplification
2 is PCR products from patient with the m.14453G>A mutation; lane 3 is 
m.12351G>A mutation; lane 4 is
products from patient with the 14709T>C mutation; lane 6 is 
m.13042G>A; lane 7 is PCR products from 
from patient with the m.13051 G>A, lane 9 is 
patient with the  m.7472Cins mutation, 
mutation. 
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6-3 First long-range PCR for the MitoChip analysis. 
 of 7184 bp products. Lane 1 is a 1kb DNA ladder; lane 
PCR products from 
 PCR products from patient with the 13513G>A mutation; lane 5 is 
PCR products from 
patient with the 11453G>A mutation; lane 8 is 
a negative control (water) , lane 10 is 
and lane 11 is PCR products from patient with m.11777C>A 
 
patient with the 
PCR 
patient with the 
PCR products 
PCR products from 
 Figure 6
The second long-range PCR results in the amplification of 
from patient with the m.14453G>A mutation; lane 2 is 
mutation; lane 3 is PCR products from 
patient with the 14709T>C mutation; lane 5 is 
PCR products from patient with the 11453G>A mutation; lane 7 is 
m.13051 G>A, lane 8 is a negative control (
mutation, lane 10 is PCR products from 
6.4.2 Microarray data analysis
All information for investigated patients are summarised in Table 6.1, which included e
samples with single nucleotide change
(m.7472Cins). Results showed the ability of the MitoC
changes (Figures from 6-5 to 6
Mitochip does not support identification of insertion
mutation was not detected by
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-4 Second long-range PCR for the MitoChip analysis
the 9307 bp products. Lane 1 is 
PCR products from patient with the m
patient with the 13513G>A mutation; lane 4 is 
PCR products from patient with the m.13042G>A; lane 6 is 
PCR products from 
water), lane 9 is PCR products from patient with the  m.7472Cins 
patient with m.11777C>A mutation; and lane 11 is 1kb DNA ladder.
 
s and one sample with a single nucleotide insertion
hip to pick up all single nucleotide 
-12). However, because the mutation detection 
s or deletions, 
 the MitoChip (Figure 6-13).  
 
 
PCR products 
.12351G>A 
PCR products from 
patient with the 
 
ight 
 
set up in the 
the m.7472insC 
 Figure 6-5 Sequence chromatogram showing the m.11453G>A mutation
Forward (right panel) and reverse (
Figure 6-6 Sequence chromatogram showing the m.11777C>A mutation
Forward (right panel) and reverse (left panel) strands.
Figure 6-7 Sequence chromatogram showing 
Forward (right panel) and reverse (left panel) strands.
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the m.12315G>A mutation
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 Figure 6-8 Sequence chromatogram showing 
Forward (right panel) and reverse (left panel) strands.
 
Figure 6-9 Sequence c
Forward (right panel) and reverse (left panel) 
Figure 6-10 Sequence chromatogram 
Forward (right panel) and reverse (left panel) strands.
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the m.13042G>A mutation.
 
hromatogram showing the m.13051G>A mutat
strands. 
showing the m.13513G>A mutation.
 
 
 
 
ion. 
 
 
 Figure 6-11 Sequence chromatogram showing t
Forward (right panel) and reverse (left panel) st
Figure 6-12 Sequence chromatogram showing t
Forward (right panel) and reverse (left panel) strands.
Figure 6-13 Sequence chromatogram showing the inability to detect the m.7472Cins mutation
Forward (right panel) and reverse (left panel) strands.
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6.5 Discussion 
With the increase identification of pathogenic mtDNA, several techniques have been 
developed and applied in a diagnostic setting; however, some of them are still with 
limitations as previously described (section 6.1). In this associated project, the MitoChip 
array (V2.0) has been to evaluate whether this method is reproducible and accurate in 
detecting mtDNA mutations. This project involved the investigation of DNA samples from 
40 patients in total who has been referred to the diagnostic centre at Queen Square and 
UCL in London. Nine of these samples, which were provided from our lab, had previously 
been identified as harbouring heteroplasmic, pathogenic mtDNA mutations to test the 
ability of the MitoChip (V2.0) to detect these mutations.  
Several reasons make the MitoChip (V2.0) valuable tool in the diagnostic setting. It has the 
ability to sequence the whole mitochondrial genome in a short time and can be applied to a 
range of different applications (medical analysis, forensics and population genetics, rather 
than the simple detection of pathogenic mtDNA mutations. It gave an accuracy and 
reproducibility greater than 90% and is able to detect mtDNA mutations with low level of 
heteroplasmy down to a threshold level of 2% mutated mtDNA [466]. 
On the other hand, MitoChip (V2.0) has some features that could be considered 
disadvantageous. Although, it is capable of detecting mtDNA single nucleotides 
polymorphisms (SNPS), however, it cannot detect mtDNA insertion and deletion 
mutations, this is because the detection method relies on labelled DNA binding to the 25-
mer sequence on the chip. In some cases, non-specific binding may occur causing miscall 
of the nucleotide. The Mitochip (V2.0) has been improved for detecting D-loop region 
mutations but cannot detect mutations from Asian mtDNA, because it is based on the 
revised Cambridge reference sequence [467] which belongs to the European haplogroup 
H2  [463]. During data analysis, the first nucleotide called in the mitochondrial genome is 
the nucleotide at position 13, because all probes, which are tilled on the chip, are identical 
in the sequence except nucleotide #13. Because mtDNA at nucleotide position 3107 is not 
tiled on the chip therefore all bases after this position are shifted 1 base, which does cause 
some problems with the analysis. 
The inability of the MitoChip to detect insertion and deletion mtDNA mutations, is perhaps 
the main issue with this method. According to MitoMAP website, there are more than 250 
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mtDNA mutations have been reported. Simple insertion mtDNA mutations only represent 
~ 2.4% of these reported mutations, which is relatively very small. The inability of the 
MitoChip (V2.0) to detect simple insertion mtDNA mutations, as compared to large-scale 
mtDNA rearrangements that can be identified by other techniques, means simple mtDNA 
rearrangements can be missed when using the MitoChip (V2.0) to detect mtDNA 
mutations and would remain unidentified. 
Although there is similarity in mtDNA sample preparations for sequencing between cycle 
sequencing and MitoChip, the MitoChip is substantially cheaper than cycle sequencing and 
more time-saving when considering running more than one chip at the same time. In 
conclusion, the human MitoChip (V2.0) is a high-throughput tool for mtDNA mutation 
detection but with some limitations. The understanding is that the London lab has reverted 
to the analysis of patient samples by conventional sequencing, and for the time being 
Newcastle Diagnostics are continuing to do the same. The advent of next-generation 
sequencing technologies [471-474], in particular for the mitochondrial genome [475, 476], 
may influence the Newcastle Diagnostics decision again in the near future. 
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Chapter 7 : General Discussion 
Mitochondria are ubiquitous cellular organelles present in all nucleated cells and they are 
the only organelles, which contain DNA within mammalian cells [1]. They are the main 
site for ATP generation within most tissues by oxidative phosphorylation (OXPHOS) [1]. 
Mitochondrial diseases are multisystem disorders exhibiting clinical, genetical and 
biochemical variability [477, 478]. Several factors increase the rate of mtDNA mutations: 
the lack of efficient DNA repair systems [237], a lack of protective proteins such as 
histones and the association with the inner mitochondrial membrane which makes the 
mtDNA a target for ROS-induced damage via OXHPHOS [238]. 
The work presented in this thesis aims to investigate patients with specific mtDNA 
mutations and to understand the role of these mutations in causing a phenotype using 
biochemical and molecular genetic techniques. 
7.1 Investigations of patients with complex I mitochondrial DNA 
mutations 
As mentioned in Chapters 1 and 3, complex I is the largest and least understood of the 
respiratory chain complexes. Mitochondrial energy metabolism disorders due to 
deficiencies in complex I are the most frequently seen cases. Approximately 20-30% of 
those disorders seen in children are due to mutations in the mtDNA. Although this suggests 
that the majority of such disorders are due to mutations in nuclear genes [325] [324], 
mtDNA mutations represent an important cause of complex I deficiency. In this work, 
patients were identified with novel and recurrent mtDNA mutations in complex I. To 
confirm pathogenicity of these mutations several investigations were carried out on 
different tissues from patients. 
Patient #2 presented with LHON-like phenotypes but was negative for any of the primary 
LHON mutations. The m.11453G>A mutation was considered to cause the disease for 
several reasons. It was heteroplasmic, it affected blood and fibroblasts tissues from the 
patient with high levels of mutation, it affected a highly conserved sequence in the MTND4 
gene and it was not found in normal individuals.  
LHON was previously reported in a patient who had the m.11778G>A mutation within the 
ND4 subunit of complex I and this mutation compromised complex I activity [479, 480]. 
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All the primary LHON mutations are distributed within complex I subunits and they all 
cause a biochemical defect in complex I. Measurement of respiration rate revealed that 
these mutations affected this rate differently. The m.3460G>A mutation reduced the rate 
20–28%, the m.11778G>A mutation 30–36% and the 14484T>C mutation 10–15% [356]. 
Conversely, the m.11453G>A mutation, which resides within the same complex and 
affects a highly conserved nucleotide within the same subunit, did not affect complex I 
activity. As described in section 3.5.15, the m.11778G>A mutation disrupts complex I 
binding with ubiquinone, thereby compromising respiratory chain function. However, the 
maintenance of complex I activity and the normal levels of ROS in this patient make it 
difficult to explain the role of the m.11453G>A mutation in causing the disease in this 
patient. One possibility is that the m.11453G>A mutation may cause LHON in this patient 
by affecting either the NADH/NAD ratio or OXPHOS by a different pathway than 
complex I; other mtDNA mutations caused a defect in complex I activity but did not cause 
LHON. Another possibility is that the defect may only be seen in the target cells such as 
retinal or optic nerve cells, and not in fibroblasts [481]. 
Patient #3 was presented with clinical phenotypes related to a mitochondrial disorder. The 
m.11777C>A mutation was identified in this patient and is considered the main cause of 
the disease since it met canonical criteria for pathogenic mtDNA mutations. It is 
heteroplasmic, affected different tissues that were investigated in both the patient and 
relatives and changes a highly conserved amino acid. In addition, this mutation caused a 
defect in complex I activity, which was associated with an increase in both ROS levels and 
mitochondrial mass. Interestingly, this mutation affects the nucleotide directly next to the 
m.11778G>A mutation, which is the most common mutation associated with LHON [254]. 
However, none of the patients with the m.11777C>A mutation presented signs of optic 
neuropathy which are the main clinical phenotypes of LHON patients [482]. In addition, 
patients with the m.11777C>A mutation showed different clinical phenotypes, with 
severity, from patients with 11778G>A mutation. The ND4 subunit in complex I binds to 
ubiquinone during oxidative phosphorlation and this binding is stabilized by the presence 
of positively charged amino acids such as arginine. A change of amino acid charge can 
cause instability of the binding resulting in a defect in the electron transport chain [483, 
484]. The m.11778A>G mutation changes the amino acid at position 340 from arginine to 
histidine but with similar charge, the m.11777C>A mutation changes the arginine to serine, 
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which results in a loss of charge [482]. This could explain the increase in phenotype 
severity in patients with the m.11777C>A mutation. 
In addition, the m.11777C>A mutation was described previously as a disease-causing 
mutation in patients with Leigh syndrome [357] late-onset encephalopathy [482] and  
Leigh-like syndrome [359]. More recently, the m.11777C>A mutation was reported in an 
infant with Leigh syndrome [485]. Similar results between patients with the m.11778G>A 
mutation and the m.11777C>A mutation, i.e. defect in complex I activity and increase in 
mitochondrial mass [399], suggest they were affected by a similar mechanism. 
Patient #4 presented with a clinical phenotype related to Leigh syndrome. The 
m.13051G>A mutation was identified in the subunit ND5 of complex I. It affected all 
investigated tissues, affected a highly conserved amino acid in the ND5 subunit and was 
not found in healthy individuals. It was homoplasmic in patient’s samples and 
heteroplasmic in relatives. However, being homoplasmic does not exclude its role in 
pathogenicity since the m.13051G>A mutation has been previously reported in a few 
patients with Leigh syndrome or Leigh-like disease and associated with isolated complex I 
deficiency [486] [315]. Moreover, this mutation caused a statistically significant increase 
in both ROS levels and mitochondrial mass in fibroblasts from the patient.  
The m.13051G>A mutation was firstly reported as a pathogenic mutation in a Dutch 
pedigree, which included two LHON affected brothers and their visually affected maternal 
aunt, all of whom were negative for the primary LHON mutations [487]. More recently, 
the m13051G>A mutation was identified in two brothers, who were referred to the 
diagnostic lab because they developed phenotypes consistent with a mitochondrial 
disorder. The first patient (deceased) presented with seizures, pigmentary retinal 
degeneration and optic atrophy, while the second patient had very acute onset of blurred 
vision. Based on clinical presentations they were suspected to have LHON, however, full 
genome sequencing from patients’ samples showed they were negative for all primary 
LHON mutations and the m.13051G>A mutation was the only mtDNA mutation identified 
(Figure 7-1).  
 Figure 7-1 Sequence chromatogram showing the m.13051G>A transition in the two brothers
Arrows indicate to the position of the m.13051G>A in the two patients as compared to control. 
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mutation was shown to be pathogenic even when present at low or intermediate levels of 
heteroplasmy [315]. However, it is difficult to correlate between the m.13513G>A 
mutation heteroplasmy levels and complex I activity since different levels of heteroplasmy 
seem to affect complex I activity differently in previously published cases. High levels of 
the m.13513G>A mutation affected complex I activity [392], intermediate levels gave 
normal complex I activity [489] but low levels of heteroplasmy have been reported to 
cause a defect in complex I [315, 393]. This difference can be attributed to several factors 
such as nuclear genetic background, mtDNA haplotypes, age and environment [393]. 
Finally, patient #6 who presented with spasms, pigmentary retinopathy, encephalopathy, 
increased blood lactate, changes in basal ganglia and defect in complex I activity in 
muscle, was found to harbor the pathogenic m.14453G>A mutation in MTND6 subunit of 
complex I. This change is heteroplasmic, it changes the highly conserved amino acid at 
position 47 from alanine to valine and it was found to affect all investigated tissues from 
the patient.  
Several pathogenic mutations have been identified in the MTND6 subunit, which is known 
to be a hotspot for LHON disease [397, 490, 491], LHON/encephalopathy [492] and 
LHON/dystonia [493, 494]. The majority of MELAS syndromes are associated with the 
mtDNA m.3243G>A point mutation in the mt-tRNALeu(UUR gene, the m.14453G>A 
mutation is the first MTND6 mutation to be associated with MELAS [343]. In addition, a 
previous study showed that mutation in the MTND6 subunit caused a defect in complex I 
assembly and sharp decrease in activity [495]. It is possible the m.14453G>A mutation 
may cause pathogencity in this patient by similar mechanism.  
7.2. Identification of two novel, pathogenic mt-tRNA mutations 
mtDNA mutations may affect mitochondrial protein synthesis such as mtDNA deletions or 
single nucleotide substitutions, which predominantly affect mitochondrial transfer RNA 
(mt-tRNA) genes [1, 400]. [402]. Although mt-tRNA genes represent ~10% of the mtDNA 
genome, almost 75% of mtDNA–related diseases are caused by mutations in these genes 
[406]. 
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However, it is still not known what is causing COX negativity in the second daughter 
(patient NCL-2) who had neither evidence of mtDNA deletions nor the m.618T>G 
mutation. Full genome sequence of single COX-deficient fibre from the patient revealed no 
significant change. This raises the possibility that the COX-deficient fibres a secondary 
phenomenon to defect in other nuclear encoded genes leading to a depletion of mtDNA 
copy number in these cells. 
Patient Portland-4 was described with a clinical phenotype consistent with mitochondrial 
defect, with COX negativity in muscle and a mild defect of respiratory chain complex I. 
The m.12261T>C mutation within the mt-tRNASer(AGY) gene was the only pathogenic 
mutation identified. It is not a reported neutral polymorphism, it is a heteroplasmic change 
with higher levels in postmitotic muscle than mitotic cells and it affects a highly conserved 
nucleotide within the tRNA structure. Also, it showed higher mutation loads in COX-
deficient fibres as compared to COX-positive fibres confirming segregation with the 
biochemical defect. 
Another unrelated patient, who was described with mitochondrial phenotypes similar to 
those seen in our patient, was identified with a novel heteroplasmic mtDNA mutation (the 
m.12207G>A mutation) within the same gene [423]. In addition, retinitis pigmentosa and 
progressive sensorineural hearing loss, which were described in our patient, were identified 
in another patient harbouring the pathogenic m.12258C>A mutation within mt-
tRNASer(AGY) [497]. Although, these mutations affect different positions within the same 
gene, they give rise to similar phenotypes, which suggests that they may affect mt-
tRNASer(AGY) function by a similar mechanism. The m.12207G>A mutation is thought to 
affect processing of the precursor RNA and amino acid charging of the tRNA, 
consequently affecting protein translation [423]. 
Generally, the mt-tRNA mutations are considered functionally recessive and give a 
biochemical defect when they affect most mtDNA molecules in a cell (70–90%) [207]. 
However, this concept was challenged after the identifications of two mt-RNA mutations 
that give a biochemical defect with low mutation loads [402, 413].  
A patient was also described (Chapter 5) with three distinct genetic diseases caused by 
three mutations: a dominant PMP22 gene duplication, an X-linked recessive HPRT gene 
mutation and the m.12283G>A mutation within the tRNALeu(UCN). The m.122831G>A 
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mutation was the only mitochondrial mutation identified and was thought to have a 
pathogenic role for several reasons. It is not a reported neutral polymorphism, it is not 
present in control individuals and other patients with mitochondrial disorder and it affects a 
highly conserved nucleotide, which resides within the variable DHU loop of mt-
tRNALeu(UCN). Interestingly, there was a very clear skewing of the segregation of mutant 
mtDNA with the biochemical defect in the COX deficient fibres as compared to the COX-
positive fibres, which showed very low levels of the mutation. This pattern is different 
from those seen in the majority of pathogenic mt-tRNA mutations, where mutation levels 
in COX-positive fibres can approach the critical threshold, and may often exceed 90% 
mutant mtDNA [317, 425, 426]. Although the molecular mechanisms controlling this 
process in humans are poorly understood, they are known to be under the control of the 
nuclear genome [498]. 
Finally, the identification of a patient with three genetic defects due to mutations in two 
genomes is a very rare case. This case and the recent finding of the first, dominant mt-
tRNA mutation [402] further highlights a problem with identifying pathogenic mtDNA 
mutations present at low levels, which may easily escape the established screening 
methodologies such as direct DNA sequencing. The m.12283G>A mutation is not 
behaving in a dominant fashion, but was only identified in this patient by sequencing the 
entire mitochondrial genome of laser microdissected COX-deficient fibres. If this is a 
common phenomenon, data indicate that the prevalence of pathogenic mtDNA mutations 
might be higher in the population than currently predicted [232], which reinforces the 
importance of pursuing a mitochondrial genetic diagnosis in patients with clear 
mitochondrial phenotypes [499]. 
7.3 GeneChip resequencing array 2.0  
MtDNA is known to be a polymorphic [463] and prone to mutations [238]. To facilitate the 
identification and quantification of pathogenic mtDNA mutations, accurate and rapid 
techniques are required. Currently, several techniques have been used and offered 
advantages and both advantages as described in Chapter 6. 
The GeneChip, human mitochondrial resequencing array 2.0, is one of these techniques 
has been used to investigate the entire mitochondrial genome. This approach has been 
widely used for several reasons. It amplifies the entire mitochondrial genome using three 
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reactions reducing time, labor and cost for sample preparation. A quarter of the patients 
with OXPHOS disease can be genetically diagnosed by this technique [500]. It gives 
overall accuracy, reproducibility and call rates greater than 90%. It is able to detect as low 
as 2% of heteroplasmy [501]. Not only can MitoChip be used in identifying mtDNA 
mutations, but it can also be used in different fields such as disease genetics, forensics, and 
population genetics. Although all previous features make the MitoChip a great tool in 
research, it still has disadvantages. It is unable to detect mtDNA deletion and insertion 
mutations. Although the version (2.0) of Mitochip has been improved for detecting D-Loop 
region mutations, the MitoChip version (2.0) cannot detect mutations from Asian mtDNA 
because it is based on the revised Cambridge reference sequence [467], which belongs to 
the European haplogroup H2 [463]. It may give miscalls and often results need to be 
validated by conventional sequencing. In conclusion, with the increased identification of 
mtDNA mutations, the human MitoChip is a high-throughput tool for mutation detection 
with some limitations. 
7.4 Concluding remarks 
In this work, different mutations in the mtDNA were identified. Some of these mutations 
were novel and others were recurrent. In addition to previous investigations, the 
biochemical and molecular genetic techniques have helped us to better understand the role 
of these mutations in causing the disease in the investigated patients. Also, my 
investigations have revealed that not all pathogenic mtDNA mutations have been identified 
as the number of cases being described continues to increase.  
Interestingly, the identification of the m.12283G>A, within mt-tRNALeu(UCN) with low 
mutation loads, has broadened our knowledge about the behaviour of mt-tRNA mutations, 
challenging the general dogma that mt-tRNA mutations are pathogenic only when they 
have high mutation loads. In addition, this finding has led us to rethink about the way of 
screening pathogenic mtDNA mutations as mutations present at low levels may easily 
escape the established screening methodologies such as direct DNA sequencing. Moreover, 
this finding highlights that mt-RNA with low mutation loads may function by different 
mechanisms than other mt-tRNA mutations with high mutation loads. 
 
The comparison study between conventional sequencing and the MitoChip (V.2.0) 
revealed that the second is a high-throughput especially when investigating large 
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populations but it is still not the ultimate tool to detect all mtDNA mutations because it is 
not able to detect mtDNA insertion and rearrangement mutations. This favors the use of 
conventional sequencing, which is more preferred in diagnostic labs to avoid missing 
simple insertion and small-scale mtDNA mutations. In addition, this shows the need of 
next generation sequencing techniques with ultimate features to overcome disadvantages 
associated with old generation sequencing techniques which will provides a great promise 
in diagnostics. 
 
Finally, more effort is required to increase our knowledge in this field to help us to solve 
unexplained issues related to mitochondrial biology and diseases to contribute effectively 
to mitochondrial DNA disease management. 
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